WO2009016460A2 - Pyrazole compounds and their use as raf inhibitors - Google Patents

Pyrazole compounds and their use as raf inhibitors Download PDF

Info

Publication number
WO2009016460A2
WO2009016460A2 PCT/IB2008/001952 IB2008001952W WO2009016460A2 WO 2009016460 A2 WO2009016460 A2 WO 2009016460A2 IB 2008001952 W IB2008001952 W IB 2008001952W WO 2009016460 A2 WO2009016460 A2 WO 2009016460A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazol
pyrimidin
pyridin
pyrrolo
amino
Prior art date
Application number
PCT/IB2008/001952
Other languages
French (fr)
Other versions
WO2009016460A8 (en
WO2009016460A3 (en
Inventor
Jingrong Jean Cui
Judith Gail Deal
Danlin Gu
Chuangxing Guo
Mary Catherine Johnson
Robert Steven Kania
Susan Elizabeth Kephart
Maria Angelica Linton
Indrawan James Mcapline
Mason Alan Pairish
Cynthia Louise Palmer
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40122511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009016460(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2695114A priority Critical patent/CA2695114A1/en
Priority to BRPI0815042-7A2A priority patent/BRPI0815042A2/en
Priority to EA201000113A priority patent/EA201000113A1/en
Priority to EP08788934A priority patent/EP2183243A2/en
Priority to AP2010005167A priority patent/AP2010005167A0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to CN200880109854A priority patent/CN101815712A/en
Priority to JP2010518763A priority patent/JP4792126B2/en
Priority to AU2008281543A priority patent/AU2008281543A1/en
Publication of WO2009016460A2 publication Critical patent/WO2009016460A2/en
Publication of WO2009016460A3 publication Critical patent/WO2009016460A3/en
Publication of WO2009016460A8 publication Critical patent/WO2009016460A8/en
Priority to TNP2010000052A priority patent/TN2010000052A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention is directed to compounds, their synthesis, and their use as modulators or inhibitors of the Raf enzyme.
  • the compounds of the present invention are useful for modulating (e.g. inhibiting) Raf activity and for treating diseases or conditions mediated by Raf, such as for example, disease states associated with abnormal cell growth such as cancer.
  • Erk pathway is an intracellular signal transduction pathway used by nearly all types of human cells to translate extracellular signals to cellular decisions, including proliferation, differentiation, senescence, or apoptosis (Wellbrock et al., Nat. Rev. MoI. Cell Biol. 11 :875-885 (2004)).
  • Ras GTPase which receives signals from membrane receptors and activates the Raf protein kinases, which activate the Mek protein kinases, which in turn activate the Erk protein kinases.
  • Activated Erk kinases phosphorylate a number of nuclear and cytoplasmic targets to initiate various cellular decisions.
  • Raf The biological importance of Raf in the Erk pathway is underscored by the finding that mutated forms of Raf are associated with certain human malignancies (see e.g. Monia et al., Nature Medicine 2:668-675 (1996); Davies et al., Nature 417:949-954 (2002)).
  • Three distinct genes have been identified in mammals that encode Raf proteins; a-Raf, b-Raf and c-Raf (also known as Raf-1 ) and isoformic variants that result from differential splicing of mRNA are known (Chong et al., EMBO J. 20:3716-3727 (2001 )).
  • the Erk pathway is mutationally activated in a number of human cancers, most often by mutation of the Ras or b-Raf genes. Mutations in Ras and b- Raf genes generally occur in the same tumor types, including cancers of the colon, lung and pancreas and melanoma, but are usually mutually exclusive. This suggests that activation of either Ras or Raf is sufficient for pathway activation and cancer progression.
  • the present invention is a compound of Formula (I)
  • X is N or CR 7 ;
  • R 1 is H, C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -Ci 4 aryl, C 2 -C 9 cycloheteroalkyl, or C 2 -C 9 heteroaryl, wherein each of said CrC 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl is optionally substituted with one or more R 8 ;
  • R 2 is C 2 -C 9 cycloheteroalkyl or C 5 -C 14 heteroaryl, wherein each of said C 2 -C 9 cycloheteroalkyl and C 5 -C 14 heteroaryl is optionally substituted with one or more R 8 ;
  • R 3 is H Or -NR 9 R 10 ;
  • R 4 , R 5 , R 6 , R 7 are each independently H, -NR 9 R 10 , -CN, -C(O)R 9 , -C(O)OR 9 , -NO 2 , -SR 9 , -OR 9 , C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, or C 2 -C 9 heteroaryl wherein each of said C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, or C 2 -Cg heteroaryl is optionally substituted with one or more R 8 ; each R 8
  • R 9 and R 10 are each independently H, C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl,
  • C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl is optionally substituted with at least one R 11 ; or R 9 and R 10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered ring optionally substituted with one or more R 11 ; each R 11 is independently fluorine, chlorine, bromine, -OH, cyano, C 1 -C 6 alkyl, C 1 -C 11 heteroalkyl, C 3 -C 8 cycloalkyl, -0-(C 3 -C 8 cycloalkyl), -S-(C 3 -C 8 cycloalkyl), C 6 -C 14 aryl, -0-(C 6 -C 14 aryl), -S-(C 6 -C 14 aryl), C 2 -C 9 cyclohe
  • X is N. In another aspect of this embodiment, X is CR 7 .
  • R 4 is H.
  • R 5 is H.
  • R 6 is H. I still a further aspect of this embodiment, R 4 , R 5 , and R 6 are H.
  • R 1 is C 1 -C 6 alkyl optionally substituted with one or more R 8 . In a further aspect of this embodiment, R 1 is C 1 -C 6 alkyl substituted with at least one R 8 .
  • R 1 is selected from methyl, isopropyl, (3-methyloxetan-3-yl)methyl, 2,2-difluoroethyl, and acetonitrile.
  • R 3 is -NR 9 R 10 .
  • R 2 is selected from the group consisting of
  • the invention is a compound of Formula (Ia) having the following structure:
  • R 1 is C 1 -C 6 alkyl optionally substituted with one or more R 8 ;
  • R 2 is C 2 -C 9 cycloheteroalkyl or C 5 -C 14 heteroaryl, wherein each of said C 3 -C 12 cycloheteroalkyl and C 2 -C 9 heteroaryl is optionally substituted with one or more R 8 ;
  • R 3 is H Or -NR 9 R 10 ;
  • each R 8 is independently -OH, fluorine, chlorine, bromine, cyano, -NR 9 R 10 , -C(O)N(R 9 R 10 ), C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, C 2 -C 9 heteroaryl, or -(CH 2 ) n C(O)R 9 ' wherein each of said C 3 -C 8 cycloalkyl, C 6
  • R 9 and R 10 are each independently H, C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl,
  • each of said C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl are optionally substituted with at least one R 11 ; or R 9 and R 10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered ring optionally substituted with one or more R 11 ; each R 11 is independently fluorine, chlorine, bromine, -OH, cyano, C 1 -C 6 alkyl, C 1 -C 11 heteroalkyl,
  • R 1 is selected from methyl, isopropyl, (3-methyloxetan-3- yl)methyl, 2,2-difluoroethyl, and acetonitrile.
  • R 3 is -NR 9 R 10 .
  • R 2 is selected from the group consisting of
  • the present invention is a compound of Formula (II)
  • X is N or CR 7 ;
  • R 1 is H, C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, or C 2 -C 9 heteroaryl, wherein each of said C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl is optionally substituted with one or more R 8 ;
  • R 2 is C 2 -C 9 cycloheteroalkyl or C 2 -Cg heteroaryl, wherein each of said C 2 -C 9 cycloheteroalkyl and C 5 -C 14 heteroaryl is optionally substituted with one or more R 8 ; or optionally where R 2 is C 2 -C 9 heteroaryl, the hydrogen atoms on any 2 adjacent ring atoms may combine to form a 5-7 membered cycloalkyl optionally substituted by one or more R 8 , a 5-7 membered cycloheteroalkyl optionally substituted by one or more R 8 , or a 5-7 membered heteroaryl optionally substituted by one or more R 8 ;
  • R 3 is H or -NR 9 R 10 ; or where X is CR 7 , R 3 may combine with R 7 to form a 5-7 membered heteroaryl optionally substituted by one or more R 8 , 5-7 membered cycloheteroalkyl optionally substituted by one or more R 8 , phenyl optionally substituted by one or more R 8 , or 5-7 membered cycloalkyl optionally substituted by one or more R 8 ;
  • R 4 , R 5 , R 6 , R 7 are each independently H, -NR 11 R 12 , -CN, -C(O)R 11 , -C(O)OR 11 , -NO 2 , -SR 11 , -
  • R 9 and R 10 are each independently H, -C(O)N(R 13 R 14 ), -C(O)R 13 , -C(O)OR 13 , C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, or C 2 -C 9 heteroaryl, wherein each of said C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl is optionally substituted with at least one R 11 ; or R 9 and R 10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered
  • X is N, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, X is CR 7 , or a pharmaceutically acceptable salt thereof. In a further aspect, R 4 is H, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R 5 is H, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R 6 is H, or a pharmaceutically acceptable salt thereof. In still a further aspect of this embodiment, R 4 , R 5 , and R 6 are H, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R 1 is C 1 -C 6 alkyl optionally substituted with one or more R 8 , or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R 1 is C 1 -C 6 alkyl substituted with at least one R 8 , or a pharmaceutically acceptable salt thereof.
  • R 1 is selected from methyl, ethyl, isopropyl, cyclopropyl, 2,2- difluoroethyl, cyanomethyl, difluorocyclobutanyl, (3-methyloxetan-3-yl)methyl, 1 ,1-dimethyl-2- hydroxyethyl, 1 -methyl- 1-cyanoethyl, difluoromethyl, tert-butyl, 3-hydroxypropan-2-yl, piperidinyl, N-acetyl- piperidinyl, H, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 4-cyanophenyl, cis-fluorocyclobutanyl, trans- fluorocyclobutanyl, oxetanyl, and N-methyl-piperidinyl, or a pharmaceutically acceptable salt thereof.
  • R 1 is selected from methyl, isopropyl, (3-methyloxetan-3- yl)methyl, 2,2-difluoroethyl, and acetonitrile, or a pharmaceutically acceptable salt thereof.
  • R 3 is -NR 9 R 10 , or a pharmaceutically acceptable salt thereof.
  • R 2 is selected from the group consisting of
  • R is -NR R . In another aspect of this embodiment, R is NH 2 , H,
  • the invention is a compound of Formula (Ha) having the following structure:
  • R 1 is C 1 -C 6 alkyl optionally substituted with one or more R 8 ;
  • R 2 is C 2 -C 9 cycloheteroalkyl or C 5 -C 14 heteroaryl, wherein each of said C 3 -C 12 cycloheteroalkyl and C 2 -C 9 heteroaryl is optionally substituted with one or more R 8 ;
  • R 3 is H or -NR 9 R 10 ; each R 8 is independently -OR 11 , fluorine, chlorine, bromine, oxo, cyano, -NR 13 R 14 , -C(O)N(R 13 R 14 ), -C(O)R 13 , -C(O)OR 13 , -NO 2 , C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, C 2 -C 9 heteroaryl, or -(CH 2 ) n C(O)R 9 , wherein each of said C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl is optionally substituted with one or more R
  • R 9 and R 10 are each independently H, -C(O)N(R 13 R 14 ), -C(O)R 13 , -C(O)OR 13 , C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, or C 2 -C 9 heteroaryl, wherein each of said C 1 -C 6 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, C 2 -C 9 cycloheteroalkyl, and C 2 -C 9 heteroaryl is optionally substituted with at least one R 11 ; or R 9 and R 10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered
  • R 1 is selected from methyl, ethyl, isopropyl, cyclopropyl, 2,2- difluoroethyl, cyanomethyl, difluorocyclobutanyl, (3-methyloxetan-3-yl)methyl, 1 ,1-dimethyl-2- hydroxyethyl, 1 -methyl- 1-cyanoethyl, difluoromethyl, tert-butyl, 3-hydroxypropan-2-yl, piperidinyl, N-acetyl- piperidinyl, H, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 4-cyanophenyl, cis-fluorocyclobutanyl, trans- fluorocyclobutanyl, oxetanyl, and N-methyl-piperidinyl, or a pharmaceutically acceptable salt thereof.
  • R 2 is selected from the group consisting of
  • R is -NR R . In another aspect of this embodiment, R is
  • the present invention is a compound selected from the group consisting of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3
  • the present invention is a compound selected from the group consisting of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro
  • the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(3-(2,3-dimethyl-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is selected from 4-[3-(6-amino-5-methoxypyridin-3-yl)-1- isopropyl-1 H-pyrazol-4-yl]-N-cyclopropylpyrimidin-2-amine, (2S)-1-( ⁇ 4-[3-(3-chloro-1H-pyrrolo[2,3- b]pyridin-5-yl)-1-(3,3-difluorocyclobutyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propan-2-ol, (2S)-1-( ⁇ 4-[3-(6- amino-5-methylpyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propan-2-ol, 3-( ⁇ 4- [3-(3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5
  • the compound is selected from 3-( ⁇ 4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3- (1-methyl-1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, (2S)-1-[(4- ⁇ 3- [6-amino-5-(difluoromethoxy)-pyridin-3-yl]-1-isopropyl-1 H-pyrazol-4-yl ⁇ pyrimidin-2-yl)amino]propan-2-ol, A- [1-(difluoromethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1- ( ⁇ 4-[3-(6-amino-5-methoxypyridin-3-yl)-1-(d
  • the compound is selected from (2S)-1-( ⁇ 4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-ethyl-1H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propan-2-ol, 4-[1-isopropyl-3-(3-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)- 1-piperidin-4-yl-1 H-pyrazol-4-yl]pyrimidin-2-amine, 3-chloro-5-(1-piperidin-4-yl-4-pyrimidin-4-yl-1 H- pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine, 4-[1-tert
  • the compound is selected from N-(2,2-difluoroethyl)-4-(1-(2,2- difluoroethyl)-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-amine, 3-(4-(1-(2,2- difluoroethyl)-3-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin-2- ylamino)propanenitrile, (S)-1-(4-(1-(2,2-difluoroethyl)-3-((R)-3-methyl-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 3-
  • the compound is selected from 3-( ⁇ 4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3- (5-methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, 3-( ⁇ 4-[1-(2,2-difluoroethyl)-3- (1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, 3-( ⁇ 4-[3-(5-amino-6- methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, (2S)-1-(4- (1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b
  • the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2- difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
  • the compound is 3-( ⁇ 4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(5- methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, or a pharmaceutically acceptable salt thereof.
  • the compound is 3-( ⁇ 4-[1-(2,2-difluoroethyl)-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, or a pharmaceutically acceptable salt thereof
  • the compound is 3-( ⁇ 4-[3-(5-amino-6-methoxypyrazin-2- yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile, or a pharmaceutically acceptable salt thereof
  • the compound is 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1- (2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-propan
  • the present invention also relates to a pharmaceutical composition, comprising at least one compound as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention also relates to a method of treating abnormal cell growth, or any Raf- mediated disease or condition, in a mammal in need thereof, comprising the step of administering to said mammal a therapeutically effective amount of at least one compound as described herein, or a pharmaceutically acceptable salt thereof.
  • the abnormal cell growth is cancerous.
  • the abnormal cell growth in non-cancerous.
  • the present invention further relates to a method of inhibiting Raf enzymatic activity, comprising contacting a Raf enzyme with a Raf-inhibiting amount of at least one compound as described herein, or a pharmaceutically acceptable salt thereof.
  • the present invention further relates to the use of any of the compounds as described herein, or a salt or solvate thereof, in the manufacture of a medicament for the treatment of abnormal cell growth in a mammal.
  • the present invention further relates to methods of making the compounds as described herein using the methods as shown in the specific examples herein and in the general synthetic methods A, B, C, D, E, F, G, H and I as described herein.
  • the present invention further relates to any of the compounds described above, or salts or solvates thereof, for use as a medicament.
  • the present invention further relates to the use of any of the compounds described above, or salts or solvates thereof, for the manufacture of a medicament for the treatment of abnormal cell growth.
  • halo and/or halogen refer to fluorine, chlorine, bromine or iodine.
  • oxo refers to an oxygen covalently attached to a carbon atom on an alkyl, cycloalkyl, or cycloheteroalkyl by a double bond such that the carbon is in the sp 2 hydridization state and the resultant functional group is a ketone.
  • C 1 -C 6 alkyl refers to a saturated aliphatic hydrocarbon radical including straight chain and branched chain groups of 1 to 6 carbon atoms.
  • Examples of (C 1 to C 6 ) alkyl groups include methyl, ethyl, propyl, 2-propyl, ⁇ -butyl, /so-butyl, fert-butyl, pentyl, and the like.
  • C 2 -C 8 alkenyl means an alkyl moiety comprising 2 to 8 carbons having at least one carbon-carbon double bond.
  • the carbon-carbon double bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound.
  • Such groups include both the E and Z isomers of said alkenyl moiety. Examples of such groups include, but are not limited to, ethenyl, propenyl, butenyl, allyl, and pentenyl.
  • C 2 -C 8 alkynyl means an alkyl moiety comprising from 2 to 8 carbon atoms and having at least one carbon-carbon triple bond.
  • the carbon-carbon triple bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound. Examples of such groups include, but are not limited to, ethyne, propyne, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 1- hexyne, 2-hexyne, and 3-hexyne.
  • C 1 -C 6 alkoxy means an O-alkyl group wherein said alkyl group contains from 1 to 6 carbon atoms and is straight, branched, or cyclic.
  • “CrC 6 alkoxy” is used interchangeably herein with "-0-C 1 -C 6 alkyl”. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butoxy, iso-butoxy, tert-butoxy, cyclopentyloxy, and cyclohexyloxy.
  • C 1 -C 11 heteroalkyl refers to a straight- or branched-chain alkyl group having a total of from 2 to 12 atoms in the chain, including from 1 to 11 carbon atoms, and one or more atoms of which is a heteroatom selected from S, O, and N, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms.
  • the S atoms in said chains may be optionally oxidized with one or two oxygen atoms, to afford sulfides and sulfones, respectively.
  • the C 1 -C 11 heteroalkyl groups in the compounds of the present invention can contain an oxo group at any carbon or heteroatom that will result in a stable compound.
  • Exemplary C 1 -C 11 heteroalkyl groups include, but are not limited to, alcohols, alkyl ethers, primary, secondary, and tertiary alkyl amines, amides, ketones, esters, sulfides, and sulfones.
  • C 6 -C 14 aryl means a group derived from an aromatic hydrocarbon containing from 6 to 14 carbon atoms that can be, for example, monocyclic, bicyclic or tricyclic. Examples of such groups include, but are not limited to, phenyl or naphthyl.
  • Ph and phenyl
  • benzyl as used herein, means a -CH 2 C 6 H 5 group.
  • C 6 -C 14 aryloxy means an O-aryl group wherein said aryl group is a group derived from an aromatic hydrocarbon containing from 6 to 14 carbon atoms that can be, for example, monocyclic, bicyclic or tricyclic. Alternatively, “C 6 -C 14 aryloxy” is used interchangeably herein with
  • -0-C 6 -C 14 aryl examples include, but are not limited to phenolyl or naphtholyl.
  • -S-C 6 -C 14 aryl as used herein, means an S-aryl group wherein said aryl group is a group derived from an aromatic hydrocarbon containing from 6 to 14 carbon atoms that can be, for example, monocyclic, bicyclic or tricyclic.
  • C 2 -C 9 heteroaryl as used herein, means an aromatic heterocyclic group having a total of from 5 to
  • heterocyclic groups include benzo-fused ring systems.
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • the C 4 to Cg heteroaryl groups may be C-attached or N-attached where such is possible.
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
  • C 2 -C 9 cycloheteroalkyl as used herein, means a non-aromatic, monocyclic, bicyclic, tricyclic, spirocyclic, or tetracyclic group having a total of from 4 to 13 atoms in its ring system, and containing from 2 to 9 carbon atoms and from 1 to 4 heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms.
  • such C 2 to C 9 cycloheteroalkyl groups may contain an oxo substituent at any available atom that will result in a stable compound.
  • such a group may contain an oxo atom at an available carbon or nitrogen atom. Such a group may contain more than one oxo substituent if chemically feasible.
  • a C 2 to C 9 cycloheteroalkyl group contains a sulfur atom, said sulfur atom may be oxidized with one or two oxygen atoms to afford either a sulfoxide or sulfone.
  • An example of a 4 membered cycloheteroalkyl group is azetidinyl (derived from azetidine).
  • An example of a 5 membered cycloheteroalkyl group is pyrrolidinyl.
  • An example of a 6 membered cycloheteroalkyl group is piperidinyl.
  • An example of a 9 membered cycloheteroalkyl group is indolinyl.
  • An example of a 10 membered cycloheteroalkyl group is 4H-quinolizinyl.
  • C 2 to C 9 cycloheteroalkyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H- pyranyl, dioxanyl, 1 ,3-dioxolany
  • C 3 -C 8 cycloalkyl group means a saturated, monocyclic, fused, spirocyclic, or polycyclic ring structure having a total of from 3 to 8 carbon ring atoms.
  • groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, and adamantyl.
  • cyano refers to a -C ⁇ N group.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. It is to be understood that in the compounds of the present invention when a group is said to be “unsubstituted,” or is “substituted” with fewer groups than would fill the valencies of all the atoms in the compound, the remaining valencies on such a group are filled by hydrogen.
  • a C 6 aryl group also called “phenyl” herein
  • phenyl is substituted with one additional substituent
  • one of ordinary skill in the art would understand that such a group has 4 open positions left on carbon atoms of the C 6 aryl ring (6 initial positions, minus one to which the remainder of the compound of the present invention is bonded, minus an additional substituent, to leave 4). In such cases, the remaining 4 carbon atoms are each bound to one hydrogen atom to fill their valencies.
  • a C 6 aryl group in the present compounds is said to be "disubstituted," one of ordinary skill in the art would understand it to mean that the C 6 aryl has 3 carbon atoms remaining that are unsubstituted. Those three unsubstituted carbon atoms are each bound to one hydrogen atom to fill their valencies.
  • solvate is used to describe a molecular complex between compounds of the present invention and solvent molecules.
  • examples of solvates include, but are not limited to, compounds of the invention in combination water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof.
  • DMSO dimethylsulfoxide
  • hydrate can be used when said solvent is water. It is specifically contemplated that in the present invention one solvent molecule can be associated with one molecule of the compounds of the present invention, such as a hydrate. Furthermore, it is specifically contemplated that in the present invention, more than one solvent molecule may be associated with one molecule of the compounds of the present invention, such as a dihydrate.
  • solvates of the present invention are contemplated as solvates of compounds of the present invention that retain the biological effectiveness of the non-hydrate form of the compounds.
  • pharmaceutically acceptable salt means a salt of a compound of the present invention that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable.
  • pharmaceutically acceptable formulation means a combination of a compound of the invention, or a salt or solvate thereof, and a carrier, diluent, and/or excipient(s) that are compatible with a compound of the present invention, and is not deleterious to the recipient thereof.
  • Pharmaceutical formulations can be prepared by procedures known to those of ordinary skill in the art.
  • the compounds of the present invention can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, and the like.
  • excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as povidone, sodium starch glycolate, sodium carboxymethylcellulose, agar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols.
  • fillers and extenders such as starch, sugars, mannitol, and silicic derivatives
  • binding agents such
  • Final pharmaceutical forms may be pills, tablets, powders, lozenges, saches, cachets, or sterile packaged powders, and the like, depending on the type of excipient used. Additionally, it is specifically contemplated that pharmaceutically acceptable formulations of the present invention can contain more than one active ingredient. For example, such formulations may contain more than one compound according to the present invention. Alternatively, such formulations may contain one or more compounds of the present invention and one or more additional agents that reduce abnormal cell growth.
  • the term "Raf-inhibiting amount” as used herein, refers to the amount of a compound of the present invention, or a salt or solvate thereof, required to inhibit the enzymatic activity of Raf in vivo, such as in a mammal, or in vitro. The amount of such compounds required to cause such inhibition can be determined without undue experimentation using methods described herein and those known to those of ordinary skill in the art.
  • inhibiting Raf enzyme activity means decreasing the activity or functioning of the Raf enzyme either in vitro or in vivo, such as in a mammal, such as a human, by contacting the enzyme with a compound of the present invention.
  • Raf as used herein means a-Raf, b-Raf, c-Raf, or mutants thereof, or any of the known Raf isoformic splice variants.
  • a therapeutically effective amount means an amount of a compound of the present invention, or a salt or solvate thereof, that, when administered to a mammal in need of such treatment, is sufficient to effect treatment, as defined herein.
  • a therapeutically effective amount of a compound of the present invention, or a salt or solvate thereof is a quantity sufficient to modulate or inhibit the activity of the Raf enzyme such that a disease condition that is mediated by activity of the Raf enzyme is reduced or alleviated.
  • treat with reference to abnormal cell growth, or to any Raf mediated disease or condition, in a mammal, particularly a human, include: (i) preventing the disease or condition from occurring in a subject which may be predisposed to the condition, such that the treatment constitutes prophylactic treatment for the pathologic condition; (ii) modulating or inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) relieving and/or alleviating the disease or condition or the symptoms resulting from the disease or condition, e.g., relieving an inflammatory response without addressing the underlying disease or condition.
  • abnormal cell growth such as cancer
  • these terms simply mean that the life expectancy of an individual affected with abnormal cell growth will be increased or that one or more of the symptoms of the disease will be reduced.
  • references herein to the inventive compounds include references to salts, solvates, and complexes thereof, including polymorphs, stereoisomers, tautomers, and isotopically labeled versions thereof.
  • compounds of the present invention can be pharmaceutically acceptable salts and/or pharmaceutically acceptable solvates.
  • abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition), including the abnormal growth of normal cells and the growth of abnormal cells. This includes, but is not limited to, the abnormal growth of: tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; any tumors that proliferate by receptor tyrosine kinases; any tumors that proliferate by aberrant serine/threonine kinase activation; benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs; tumors, both benign and malignant, expressing an activated Ras oncogene; tumor cells, both benign and malignant, in which the Ras protein
  • Abnormal cell growth also refers to and includes the abnormal growth of cells, both benign and malignant, resulting from activity of the enzyme farnesyl protein transferase.
  • abnormal cell growth and “hyperproliferative disorder” are used interchangeably in this application.
  • stereoisomers refers to compounds that have identical chemical constitution, but differ with regard to the arrangement of their atoms or groups in space.
  • enantiomers refers to two stereoisomers of a compound that are non-superimposable mirror images of one another.
  • racemic or “racemic mixture,” as used herein, refer to a 1 :1 mixture of enantiomers of a particular compound.
  • diastereomers refers to the relationship between a pair of stereoisomers that comprise two or more asymmetric centers and are not mirror images of one another.
  • the compounds of the present invention are useful for modulating or inhibiting Raf activity. Accordingly, these compounds are useful for the prevention and/or treatment of disease states associated with abnormal cell growth such as cancer, alone or in combination with other anti-cancer agents. s / / s
  • the compounds of the present invention may have asymmetric carbon atoms.
  • the carbon- carbon bonds of the compounds of the present invention may be depicted herein using a solid line
  • a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g. specific enantiomers, racemic mixtures, etc.) at that carbon atom are included.
  • the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
  • the compounds of the present invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof.
  • the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
  • Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate using, for example, chiral high pressure liquid chromatography (HPLC).
  • racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
  • a suitable optically active compound for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art.
  • Chiral compounds of the invention may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
  • Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art. See, e.g. "Stereochemistry of Organic Compounds" by E L Eliel (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
  • a compound of the invention contains an alkenyl or alkenylene group
  • geometric cisltrans (or Z/E) isomers are possible.
  • the compound contains, for example, a keto or oxime group or an aromatic moiety
  • tautomeric isomerism ('tautomerism') can occur.
  • Examples of tautomerism include keto and enol tautomers.
  • a single compound may exhibit more than one type of isomerism. Included within the scope of the invention are all stereoisomers, geometric isomers and tautomeric forms of the inventive compounds, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof.
  • Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.
  • the compounds of the present invention may be administered as prodrugs.
  • certain derivatives of compounds of Formula (I) which may have little or no pharmacological activity themselves can, when administered to a mammal, be converted into a compound of Formula (I) having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as "prodrugs”.
  • Prodrugs can, for example, be produced by replacing appropriate functionalities present in the compound of Formula (I) with certain moieties known to those skilled in the art. See, e.g. "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and "Bioreversible Carriers in Drug Design", Pergamon Press, 1987 (ed.
  • prodrugs include: an ester moiety in the place of a carboxylic acid functional group; an ether moiety or an amide moiety in place of an alcohol functional group; and an amide moiety in place of a primary or secondary amino functional group.
  • replacement groups are known to those of skill in the art. See, e.g. "Design of Prodrugs” by H Bundgaard (Elsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety. It is also possible that certain compounds of Formula (I) may themselves act as prodrugs of other compounds of Formula (I).
  • Salts of the present invention can be prepared according to methods known to those of skill in the art.
  • Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methyl benzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1 ,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, he
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially equivalent amount of the selected mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained.
  • the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution.
  • Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention.
  • Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc.
  • salts can be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
  • the desired salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
  • an inorganic acid such as hydrochloric acid, hydrobro
  • the desired salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
  • an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
  • suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
  • the invention also includes isotopically-labeled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 CI, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulfur, such as 35 S.
  • Certain isotopically-labeled compounds of the invention are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, 3 H, and carbon-14, 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • Substitution with heavier isotopes such as deuterium, 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Topography
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
  • compositions of the invention comprise a therapeutically effective amount of at least one compound of the present invention and an inert, pharmaceutically acceptable carrier or diluent.
  • a pharmaceutical composition of the invention is administered in a suitable formulation prepared by combining a therapeutically effective amount (i.e., a Raf modulating, regulating, or inhibiting amount effective to achieve therapeutic efficacy) of at least one compound of the present invention (as an active ingredient) with one or more pharmaceutically suitable carriers, which may be selected, for example, from diluents, excipients and auxiliaries that facilitate processing of the active compounds into the final pharmaceutical preparations.
  • a therapeutically effective amount i.e., a Raf modulating, regulating, or inhibiting amount effective to achieve therapeutic efficacy
  • one compound of the present invention as an active ingredient
  • pharmaceutically suitable carriers which may be selected, for example, from diluents, excipients and auxiliaries that facilitate processing of the active compounds into the final pharmaceutical preparations.
  • the pharmaceutical carriers employed may be either solid or liquid.
  • Exemplary solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • Exemplary liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the inventive compositions may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Further additives or excipients may be added to achieve the desired formulation properties.
  • a bioavailability enhancer such as Labrasol, Gelucire or the like, or formulator, such as CMC (carboxy-methylcellulose), PG (propyleneglycol), or PEG (polyethyleneglycol), may be added.
  • CMC carboxy-methylcellulose
  • PG propyleneglycol
  • PEG polyethyleneglycol
  • Gelucire ® a semi-solid vehicle that protects active ingredients from light, moisture and oxidation, may be added, e.g., when preparing a capsule formulation.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or formed into a troche or lozenge.
  • the amount of solid carrier may vary, but generally will be from about 25 mg to about 1 g.
  • the preparation may be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or non-aqueous liquid suspension.
  • a semi-solid carrier is used, the preparation may be in the form of hard and soft gelatin capsule formulations.
  • the inventive compositions are prepared in unit-dosage form appropriate for the mode of administration, e.g. parenteral or oral administration.
  • a salt of a compound of the present invention may be dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3 M solution of succinic acid or citric acid.
  • the agent may be dissolved in a suitable co-solvent or combinations of co-solvents.
  • suitable co-solvents include alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0 to 60% of the total volume.
  • a compound of the present invention is dissolved in DMSO and diluted with water.
  • the composition may also be in the form of a solution of a salt form of the active ingredient in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
  • the agents of the compounds of the present invention may be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
  • Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • disintegrating agents may be added, such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings may be used, which may optionally contain gum arabic, polyvinyl pyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • a suitable vehicle e.g. sterile pyrogen-free water
  • the compounds of the present invention may also be formulated as a depot preparation.
  • Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • a pharmaceutical carrier for hydrophobic compounds is a co- solvent system comprising benzyl alcohol, a non-polar surfactant, a water-miscible organic polymer, and an aqueous phase.
  • the co-solvent system may be a VPD co-solvent system.
  • VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the non-polar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • the VPD co-solvent system (VPD: 5W) contains VPD diluted 1 :1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration.
  • the proportions of a co- solvent system may be suitably varied without destroying its solubility and toxicity characteristics.
  • co-solvent components may be varied: for example, other low-toxicity non- polar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
  • hydrophobic pharmaceutical compounds may be employed.
  • Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity due to the toxic nature of DMSO.
  • the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.
  • additional strategies for protein stabilization may be employed.
  • the pharmaceutical compositions also may comprise suitable solid- or gel-phase carriers or excipients.
  • These carriers and excipients may provide marked improvement in the bioavailability of poorly soluble drugs.
  • Examples of such carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • additives or excipients such as Gelucire®, Capryol®, Labrafil®, Labrasol®, Lauroglycol®, Plurol®, Peceol® Transcutol® and the like may be used.
  • the pharmaceutical composition may be incorporated into a skin patch for delivery of the drug directly onto the skin.
  • an exemplary daily dose generally employed will be from about 0.001 to about 1000 mg/kg of body weight, with courses of treatment repeated at appropriate intervals.
  • the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount of about 10 mg to about
  • 2000 mg or from about 10 mg to about 1500 mg, or from about 10 mg to about 1000 mg, or from about
  • 10 mg to about 750 mg or from about 10 mg to about 500 mg, or from about 25 mg to about 500 mg, or from about 50 to about 500 mg, or from about 100 mg to about 500mg.
  • the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount from about 0.5 w/w% to about 95 w/w%, or from about 1 w/w% to about 95 w/w%, or from about 1 w/w% to about 75 w/w%, or from about 5 w/w% to about 75 w/w%, or from about 10 w/w% to about 75 w/w%, or from about 10 w/w% to about 50 w/w%.
  • the compounds of the present invention may be administered to a mammal suffering from abnormal cell growth, such as a human, either alone or as part of a pharmaceutically acceptable formulation, once a day, twice a day, three times a day, or four times a day, or even more frequently.
  • a mammal suffering from abnormal cell growth such as a human
  • a pharmaceutically acceptable formulation once a day, twice a day, three times a day, or four times a day, or even more frequently.
  • This invention also relates to a method for the treatment of abnormal cell growth in a mammal, including a human, comprising administering to said mammal an amount of a compound of the Formula (I), as defined above, or a salt or solvate thereof, that is effective in treating abnormal cell growth.
  • the abnormal cell growth is cancer, including, but not limited to, mesothelioma, hepatobilliary (hepatic and billiary duct), a primary or secondary CNS tumor, a primary or secondary brain tumor, lung cancer (NSCLC and SCLC), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of
  • the cancer is selected from lung cancer (NSCLC and SCLC), cancer of the head or neck, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, breast cancer, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, non hodgkins's lymphoma, spinal axis tumors, or a combination of one or more of the foregoing cancers.
  • lung cancer NSCLC and SCLC
  • SCLC central nervous system
  • the cancer is selected from lung cancer (NSCLC and SCLC), ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, or a combination of one or more of the foregoing cancers.
  • the cancer is selected from lung cancer (NSCLC and SCLC), ovarian cancer, colon cancer, rectal cancer, or a combination of one or more of the foregoing cancers.
  • said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.
  • This invention also relates to a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of the present invention, or a salt or solvate thereof, that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
  • an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
  • the anti-tumor agent used in conjunction with a compound of the present invention and pharmaceutical compositions described herein is an anti- angiogenesis agent, kinase inhibitor, pan kinase inhibitor or growth factor inhibitor.
  • Preferred pan kinase inhibitors include SutentTM (sunitinib), described in U.S. Patent No. 6,573,293 (Pfizer, Inc, NY, USA).
  • Anti-angiogenesis agents include but are not limited to the following agents, such as EGF inhibitors, EGFR inhibitors, VEGF inhibitors, VEGFR inhibitors, TIE2 inhibitors, IGF1 R inhibitors, COX-II (cyclooxygenase II) inhibitors, MMP-2 (matrix-metalloprotienase 2) inhibitors, and MMP-9 (matrix- metalloprotienase 9) inhibitors.
  • Preferred VEGF inhibitors include for example, Avastin (bevacizumab), an anti-VEGF monoclonal antibody of Genentech, Inc. of South San Francisco, California.
  • VEGF inhibitors include CP-547,632 (Pfizer Inc., NY, USA), AG13736 (Pfizer Inc.), ZD-6474 (AstraZeneca), AEE788 (Novartis), AZD-2171 , VEGF Trap (Regeneron/Aventis), Vatalanib (also known as PTK-787, ZK-222584: Novartis & Schering AG), Macugen (pegaptanib octasodium, NX-1838, EYE-001 , Pfizer Inc./Gilead/Eyetech), IM862 (Cytran Inc. of Kirkland, Washington, USA); and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California) and combinations thereof.
  • VEGF inhibitors useful in the practice of the present invention are described in US Patent No. 6,534,524 and 6,235,764, both of which are incorporated in their entirety for all purposes. Additional VEGF inhibitors are described in, for example in WO 99/24440, in WO 95/21613, WO 99/61422, U.S. Patent 5,834,504, WO 98/50356, U.S. Patent 5,883,113 U.S. Patent 5,886,020, U.S. Patent 5,792,783, U.S.
  • Other anti-angiogenic compounds include acitretin, fenretinide, thalidomide, zoledronic acid, angiostatin, aplidine, cilengtide, combretastatin A-4, endostatin, halofuginone, rebimastat, removab, Revlimid, squalamine, ukrain, Vitaxin and combinations thereof.
  • antiproliferative agents that may be used in combination with the compounds of the present invention include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr, including the compounds disclosed and claimed in the following: U.S. Patent 6,080,769; U.S. Patent 6,194,438; U.S. Patent 6,258,824; U.S. Patent 6,586447; U.S. Patent 6,071 ,935; U.S. Patent 6,495,564; and U.S. Patent 6,150,377; U.S. Patent 6,596,735; U.S. Patent 6,479,513; WO 01/40217; U.S. 2003-0166675.
  • Each of the foregoing patents and patent applications is herein incorporated by reference in their entirety.
  • PDGRr inhibitors include but are not limited to those disclosed in international patent application publication numbers WO01/40217 and WO2004/020431 , the contents of which are incorporated in their entirety for all purposes.
  • Preferred PDGFr inhibitors include Pfizer's CP-673,451 and CP-868,596 and its salts.
  • Preferred GARF inhibitors include Pfizer's AG-2037 (pelitrexol and its salts).
  • GARF inhibitors useful in the practice of the present invention are disclosed in US Patent No. 5,608,082 which is incorporated in its entirety for all purposes.
  • COX-II inhibitors which can be used in conjunction with a compound of Formula (I) and pharmaceutical compositions disclosed herein include CELEBREXTM (celecoxib), parecoxib, deracoxib, ABT-963, MK-663 (etoricoxib), COX-189 (Lumiracoxib), BMS 347070, RS 57067, NS-398, Bextra (valdecoxib), paracoxib, Vioxx (rofecoxib), SD-8381 , 4-Methyl-2-(3,4-dimethylphenyl)-1- (4-sulfamoyl-phenyl)-1 H-pyrrole, 2-(4-Ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)-1 H-pyrrole, T-614, JTE-522, S-2474, SVT-2016, CT-3, SC-58125 and Arcoxia (etoricoxib).
  • COX-II CELEBREXTM
  • the anti-tumor agent is celecoxib (U.S. Patent No. 5,466,823), valdecoxib (U.S. Patent No. 5,633,272), parecoxib (U.S. Patent No. 5,932,598), deracoxib (U.S. Patent No. 5,521 ,207), SD-8381 (U.S. Patent No. 6,034,256, Example 175), ABT-963 (WO 2002/24719), rofecoxib (CAS No. 162011-90-7), MK-663 (or etoricoxib) as disclosed in WO 1998/03484, COX-189 (Lumiracoxib) as disclosed in WO 1999/11605, BMS-347070 (U.S.
  • Patent 6,180,651 NS-398 (CAS 123653-11-2), RS 57067 (CAS 17932-91-3), 4-Methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoyl-phenyl)-1 H- pyrrole, 2-(4-Ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)-1 H-pyrrole, or meloxicam.
  • NSAIDs non-steroidal anti- inflammatory drugs
  • Preferred COX-I inhibitors include ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, ibuprofen, and resulting in lower levels of prostaglandins, include but are not limited to the following, Salsalate (Amigesic), Diflunisal (Dolobid), lbuprofen (Motrin), Ketoprofen (Orudis), Nabumetone (Relafen), Piroxicam (Feldene), Naproxen (Aleve, Naprosyn), Diclofenac (Voltaren), lndomethacin (Indocin), Sulindac (Clinoril), Tolmetin (Tolectin),
  • Targeted agents used in combination with a compound of the present invention and pharmaceutical compositions disclosed herein include EGFr inhibitors such as lressa (gefitinib, AstraZeneca), Tarceva (erlotinib or OSI-774, OSI Pharmaceuticals Inc.), Erbitux (cetuximab, lmclone Pharmaceuticals, Inc.), EMD-7200 (Merck AG), ABX-EGF (Amgen Inc. and Abgenix Inc.), HR3 (Cuban Government), IgA antibodies (University of Er Weg-Nuremberg), TP-38 (IVAX), EGFR fusion protein, EGF- vaccine, anti-EGFr immunoliposomes (Hermes Biosciences Inc.) and combinations thereof.
  • EGFr inhibitors such as lressa (gefitinib, AstraZeneca), Tarceva (erlotinib or OSI-774, OSI Pharmaceuticals Inc.), Erbitux (cetuximab, lmclone Pharmaceuticals,
  • Preferred EGFr inhibitors include lressa, Erbitux, Tarceva and combinations thereof.
  • Other anti-tumor agents include those selected from pan erb receptor inhibitors or ErbB2 receptor inhibitors, such as CP-724,714 (Pfizer, Inc.), CI-1033 (canertinib, Pfizer, Inc.), Herceptin (trastuzumab, Genentech Inc.), Omitarg (2C4, pertuzumab, Genentech Inc.), TAK-165 (Takeda), GW-572016 (lonafamib, GlaxoSmithKline), GW-282974 (GlaxoSmithKline), EKB-569 (Wyeth), PKI-166 (Novartis), dHER2 (HER2 Vaccine, Corixa and GlaxoSmithKline), APC8024 (HER2 Vaccine, Dendreon), anti- HER2/neu bispecific antibody (Decof Cancer Center), B7.her2.lgG3 (A
  • Preferred erb selective anti-tumor agents include Herceptin, TAK-165, CP-724,714, ABX-EGF, HER3 and combinations thereof.
  • Preferred pan erbb receptor inhibitors include GW572016, CI-1033, EKB-569, and Omitarg and combinations thereof.
  • Additional erbB2 inhibitors include those disclosed in WO 98/02434, WO 99/35146, WO 99/35132, WO 98/02437, WO 97/13760, WO 95/19970, U.S. Patent 5,587,458, and U.S. Patent 5,877,305, each of which is herein incorporated by reference in its entirety.
  • ErbB2 receptor inhibitors useful in the present invention are also disclosed in U.S. Patents 6,465,449, and 6,284,764, and in WO 2001/98277 each of which are herein incorporated by reference in their entirety.
  • anti-tumor agents may be selected from the following agents, BAY-43-9006 (Onyx Pharmaceuticals Inc.), Genasense (augmerosen, Genta), Panitumumab (Abgenix/Amgen), Zevalin (Schering), Bexxar (Corixa/GlaxoSmithKline), Abarelix, Alimta, EPO 906 (Novartis), discodermolide (XAA- 296), ABT-510 (Abbott), Neovastat (Aeterna), enzastaurin (EIi Lilly), Combrestatin A4P (Oxigene), ZD-6126 (AstraZeneca), flavopiridol (Aventis), CYC-202 (Cyclacel), AVE-8062 (Aventis), DMXAA (Roche/Antisoma), Thymitaq (Eximias), Temodar (temozolomide, Schering Plough) and Revilimd (Celegene) and combinations thereof.
  • anti-tumor agents may be selected from the following agents, CyPat (cyproterone acetate), Histerelin (histrelin acetate), Plenaixis (abarelix depot), Atrasentan (ABT-627), Satraplatin (JM-216), thalomid (Thalidomide), Theratope, Temilifene (DPPE), ABI-007 (paclitaxel), Evista (raloxifene), Atamestane (Biomed-777), Xyotax (polyglutamate paclitaxel), Targetin (bexarotine) and combinations thereof.
  • CyPat cyproterone acetate
  • Histerelin histrelin acetate
  • Plenaixis abarelix depot
  • ABT-627 Atrasentan
  • JM-216 thalomid (Thalidomide)
  • Theratope Temilifene (DPPE), ABI-007 (paclitaxel), Evista (raloxi
  • anti-tumor agents may be selected from the following agents, Trizaone (tirapazamine), Aposyn (exisulind), Nevastat (AE-941 ), Ceplene (histamine dihydrochloride), Orathecin (rubitecan), Virulizin, Gastrimmune (G17DT), DX-8951f (exatecan mesylate), Onconase (ranpirnase), BEC2 (mitumoab), Xcytrin (motexafin gadolinium) and combinations thereof.
  • Further anti-tumor agents may be selected from the following agents, CeaVac (CEA), NeuTrexin (trimetresate glucuronate) and combinations thereof.
  • Additional anti-tumor agents may be selected from the following agents, OvaRex (oregovomab), Osidem (IDM-1 ), and combinations thereof. Additional anti-tumor agents may be selected from the following agents, Advexin (ING 201), Tirazone (tirapazamine), and combinations thereof. Additional anti-tumor agents may be selected from the following agents, RSR13 (efaproxiral), Cotara (1311 chTNT 1/b), NBI-3001 (IL-4) and combinations thereof. Additional anti-tumor agents may be selected from the following agents, Canvaxin, GMK vaccine, PEG lnteron A, Taxoprexin (DHA/paciltaxel), and combinations thereof.
  • anti-tumor agents include Pfizer's MEK1/2 inhibitor PD325901 , Array Biopharm's MEK inhibitor ARRY-142886, Bristol Myers' CDK2 inhibitor BMS-387,032, Pfizer's CDK inhibitor PD0332991 and AstraZeneca's AXD-5438, and combinations thereof.
  • mTOR inhibitors may also be utilized such as CCI-779 (Wyeth) and rapamycin derivatives RAD001 (Novartis) and AP-23573 (Ariad), HDAC inhibitors, SAHA (Merck Inc./Aton Pharmaceuticals) and combinations thereof.
  • Additional anti-tumor agents include aurora 2 inhibitor VX-680 (Vertex), and Chk1/2 inhibitor XL844 (Exilixis).
  • cytotoxic agents e.g., one or more selected from the group consisting of epirubicin (Ellence), docetaxel (Taxotere), paclitaxel, Zinecard (dexrazoxane), rituximab (Rituxan) imatinib mesylate (Gleevec), and combinations thereof, may be used in combination with a compound of the present invention and pharmaceutical compositions disclosed herein.
  • the invention also contemplates the use of the compounds of the present invention together with hormonal therapy, including but not limited to, exemestane (Aromasin, Pfizer Inc.), leuprorelin (Lupron or Leuplin, TAP/Abbott/Takeda), anastrozole (Arimidex, Astrazeneca), gosrelin (Zoladex, AstraZeneca), doxercalciferol, fadrozole, formestane, tamoxifen citrate (tamoxifen, Nolvadex, AstraZeneca), Casodex (AstraZeneca), Abarelix (Praecis), Trelstar, and combinations thereof.
  • exemestane Amasin, Pfizer Inc.
  • leuprorelin Louprorelin
  • anastrozole Arimidex, Astrazeneca
  • gosrelin Zoladex, AstraZeneca
  • doxercalciferol
  • the invention also relates to the use of the compounds of the present invention together with hormonal therapy agents such as anti-estrogens including, but not limited to fulvestrant, toremifene, raloxifene, lasofoxifene, letrozole (Femara, Novartis), anti-androgens such as bicalutamide, flutamide, mifepristone, nilutamide, CasodexTM(4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'- (trifluoromethyl) propionanilide, bicalutamide) and combinations thereof.
  • hormonal therapy agents such as anti-estrogens including, but not limited to fulvestrant, toremifene, raloxifene, lasofoxifene, letrozole (Femara, Novartis), anti-androgens such as bicalutamide, flutamide, mifepri
  • the invention provides a compound of the present invention alone or in combination with one or more supportive care products, e.g., a product selected from the group consisting of Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or combinations thereof.
  • supportive care products e.g., a product selected from the group consisting of Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or combinations thereof.
  • Particularly preferred cytotoxic agents include Camptosar, Erbitux, Iressa, Gleevec, Taxotere and combinations thereof.
  • the following topoisomerase I inhibitors may be utilized as anti-tumor agents: camptothecin; irinotecan HCI (Camptosar); edotecarin; orathecin (Supergen); exatecan (Daiichi); BN-80915 (Roche); and combinations thereof.
  • Particularly preferred toposimerase Il inhibitors include epirubicin (Ellence).
  • Alkylating agents include, but are not limited to, nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, AMD-473, altretamine, AP-5280, apaziquone, brostallicin, bendamustine, carmustine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, mafosfamide, and mitolactol; platinum- coordinated alkylating compounds include but are not limited to, cisplatin, Paraplatin (carboplatin), eptaplatin, lobaplatin, nedaplatin, Eloxatin (oxaliplatin, Sanofi) or satrplatin and combinations thereof.
  • alkylating agents include Eloxatin (oxaliplatin).
  • Antimetabolites include but are not limited to, methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil (5-FU) alone or in combination with leucovorin, tegafur, UFT, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1 , Alimta (premetrexed disodium, LY231514, MTA), Gemzar (gemcitabine, EIi Lilly), fludarabin, 5-azacitidine, capecitabine, cladribine, clofarabine, decitabine, eflornithine, ethynylcytidine, cytosine arabinoside, hydroxyurea, TS-1 , melphalan, nelarabine, nolatrexed,
  • Antibiotics include intercalating antibiotics and include, but are not limited to: aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, bleomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, galarubicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, valrubicin, zinostatin and combinations thereof.
  • Plant derived anti-tumor substances include for example those selected from mitotic inhibitors, for example vinblastine, docetaxel (Taxotere), paclitaxel and combinations thereof.
  • Cytotoxic topoisomerase inhibiting agents include one or more agents selected from the group consisting of aclarubicn, amonafide, belotecan, camptothecin, 10-hydroxycamptothecin, 9- aminocamptothecin, diflomotecan, irinotecan HCI (Camptosar), edotecarin, epirubicin (Ellence), etoposide, exatecan, gimatecan, lurtotecan, mitoxantrone, pirarubicin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan, and combinations thereof.
  • Preferred cytotoxic topoisomerase inhibiting agents include one or more agents selected from the group consisting of camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, irinotecan HCI (Camptosar), edotecarin, epirubicin (Ellence), etoposide, SN-38, topotecan, and combinations thereof.
  • Interferons include interferon alpha, interferon alpha-2a, interferon, alpha-2b, interferon beta, interferon gamma-1a, interferon gamma-1b (Actimmune), or interferon gamma-n1 and combinations thereof.
  • agents include filgrastim, lentinan, sizofilan, TheraCys, ubenimex, WF-10, aldesleukin, alemtuzumab, BAM-002, dacarbazine, daclizumab, denileukin, gemtuzumab ozogamicin, ibritumomab, imiquimod, lenograstim, lentinan, melanoma vaccine (Corixa), molgramostim, OncoVAX-CL, sargramostim, tasonermin, tecleukin, thymalasin, tositumomab, Virulizin, 2-100, epratuzumab, mitumomab, oregovomab, pemtumomab (Y- muHMFGI ), Provenge (Dendreon) and combinations thereof.
  • Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of tissue cells to direct them to have antitumor activity.
  • agents include krestin, lentinan, sizofiran, picibanil, ubenimex and combinations thereof.
  • Other anticancer agents that can be used in combination with a compound of the present invention include alitretinoin, ampligen, atrasentan bexarotene, bortezomib.
  • Bosentan calcitriol, exisulind, finasteride.fotemustine, ibandronic acid, miltefosine, mitoxantrone, l-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pegaspargase, pentostatin, tazarotne, Telcyta (TLK-286, Telik Inc.), Velcade (bortemazib, Millenium), tretinoin, and combinations thereof.
  • Platinum-coordinated compounds include but are not limited to, cisplatin, carboplatin, nedaplatin, oxaliplatin, and combinations thereof.
  • Camptothecin derivatives include but are not limited to camptothecin, 10-hydroxycamptothecin, 9- aminocamptothecin, irinotecan, SN-38, edotecarin, topotecan and combinations thereof.
  • Other antitumor agents include mitoxantrone, l-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, tretinoin and combinations thereof.
  • CTLA4 cytotoxic lymphocyte antigen 4
  • CTLA4 compounds disclosed in U.S. Patent 6,682,736
  • anti-proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors.
  • CTLA4 antibodies that can be used in combination with compounds of the present invention include those disclosed in U.S. Patents 6,682,736 and 6,682,736 both of which are herein incorporated by reference in their entirety.
  • Gene therapy agents may also be employed as anti-tumor agents such as TNFerade (GeneVec), which express TNFalpha in response to radiotherapy.
  • statins may be used in combination with a compound of the present invention and pharmaceutical compositions thereof.
  • Statins HMG-CoA reducatase inhibitors
  • Atorvastatin LipitorTM, Pfizer Inc.
  • Pravastatin Pravastatin
  • Lovastatin MevacorTM, Merck Inc.
  • Simvastatin ZaocorTM, Merck Inc.
  • Fluvastatin LescolTM, Novartis
  • Cerivastatin BoycolTM, Bayer
  • Rosuvastatin CrestorTM, AstraZeneca
  • Lovostatin and Niacin Niacin
  • statin is selected from the group consisting of Atovorstatin and Lovastatin, derivatives and combinations thereof.
  • Other agents useful as anti-tumor agents include Caduet.
  • reactive intermediate compounds of the general structure represented by A and B are prepared according to Method A.
  • Reaction of thiol (1) with a methylating agent in the presence of an appropriate base provides a thio-methyl ether of the formula 2.
  • Treatment of 2 with oxalyl chloride leads to formation of an aldehyde represented by formula 3.
  • Aldehyde 3 can be further transformed to an isoxazole represented by the formula 4 by treatment with hydroxylamine.
  • Isoxazole 4 can be cleaved to aldehyde 5 by treatment with an appropriate base.
  • Isoxazole 5 can be further transformed to a pyrazoline of the type in formula 6 by reaction with hydrazine.
  • Pyrazole 6 can be converted to A by a 2 step sequence involving reaction with NaNO 2 followed by reaction with iodide.
  • A can be converted to B by reaction of the amine with dihydropyran.
  • compounds of the general structure represented by 11 are prepared according to Method B.
  • Reactive intermediate A can be prepared using Method A.
  • the introduction of R 1 in 7 can be accomplished by alkylation of A under conditions appropriate to couple a reactive agent (e.g. R 1 -l, R 1 -Br, R 1 -CI, R 1 -OMs, R 1 -OTs, or the like) therewith.
  • the sulfur in 7 can be oxidized to sulfones 8 by an appropriate oxidizing agent, such as oxone.
  • Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur by an amine to yield 9. Suzuki coupling of 9 with a suitable boronic acid (or boronic ester) in the presence of an appropriate catalyst, such as a palladium catalyst, produces intermediates 10.
  • Reactive intermediate B can be prepared using Method A. Suzuki coupling of B with a suitable boronic acid (or boronic ester) in the presence of an appropriate catalyst, such as a palladium catalyst, produces intermediates 12.
  • the THP protected amine can be revealed by deprotection using various methods to produce amine 13.
  • Methods for removing a THP from an amine are known to those skilled in the art (e.g. see T. Greene and P. Wuts, "Protective Groups in Organic Synthesis", 3 rd Edition 1999, John Wiley & Sons).
  • the introduction of R 1 in 14 can be accomplished by alkylation of 13 under conditions appropriate to couple a reactive agent (e.g.
  • the sulfur in 14 can be oxidized to 15a and/or 15b by treatment with an appropriate oxidizing agent, such as ozone.
  • an appropriate oxidizing agent such as ozone.
  • Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur with an amine to yield 10.
  • compounds 10 require deprotection of any remaining protecting groups, such deprotection can be accomplished by various methods to produce compounds 11.
  • Reactive intermediate A can be prepared using Method A.
  • the introduction of R 1 in 7 can be accomplished by alkylation of A under conditions appropriate to couple a reactive agent (e.g. R 1 -l, R 1 -Br, R 1 -CI, R 1 -OMs, R 1 -OTs, or the like) therewith.
  • Suzuki coupling of 7 with a suitable boronic acid (or boronic ester) in the presence of an appropriate catalyst, such as a palladium catalyst produces intermediates 16.
  • the sulfur in 16 can be oxidized to 17a and/or 17b by treatment with an appropriate oxidizing agent, such as ozone.
  • Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur with an amine to yield 10.
  • compounds 10 require deprotection of any remaining protecting groups, such deprotection can be accomplished by various methods to produce compounds 11.
  • Reactive intermediate A can be prepared using Method A.
  • the introduction of R 1 in 7 can be accomplished by alkylation of A under conditions appropriate to couple a reactive agent (e.g. R 1 -l, R 1 -Br, R 1 -Cl, R 1 -OMs, R 1 -OTs, or the like) therewith.
  • a reactive agent e.g. R 1 -l, R 1 -Br, R 1 -Cl, R 1 -OMs, R 1 -OTs, or the like
  • the sulfur in 7 can be oxidized to sulfones 8 by an appropriate oxidizing agent, such as oxone.
  • Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur by an amine to yield 9.
  • isoxazole 22 is accomplished via the Vilsmeier reaction on 4-methylpyrimidine or picoline followed by condensation with hydroxylamine. Ring-opening of the isoxazole with an appropriate base, such as aqueous sodium hydroxide, is followed by condensation with hydrazine to afford aminopyrazole 24.
  • a Sandmeyer reaction converts the amino group to an iodopyrazole (25) and, prior to the Suzuki coupling reaction, the pyrazole NH is either alkylated with a preferred R 3 group or protected with a protecting group to afford 26.
  • a Suzuki coupling reaction of 26 with a suitable boronic acid or boronic ester completes the synthesis of compounds represented by 27. Deprotection and/or chlorination can be accomplished if necessary as previously described to afford 28 or 29 respectively.
  • Compound 31 can be prepared from 5-bromo-1 H-pyrrolo[2,3-b]pyridine 30 by reaction with carbon monoxide in the presence of an appropriate catalyst followed by protection of the pyrrole nitrogen if needed.
  • Compound 31 can be condensed with 2-methyl-6-(methylthio)pyridine by reaction in the presence of an appropriate base, such as LIHMDS, to provide 32.
  • the imine in compound 33 can be installed by reaction of 32 with DMF-DMA to give 33.
  • Compound 33 can be cyclized to form pyrazole 34 by reaction with hydrazine.
  • the pyrazole NH is either alkylated with a preferred R 1 group or protected with a protecting group to afford 35.
  • Compound 41 can be protected at the pyrrole nitrogen, if necessary, to provide compound 42.
  • a coupling reaction in the presence of an appropriate tin reagent and an appropriate catalyst can provide a compound of the type 43.
  • Compound 43 can then be converted into ketone 44 by heating with an appropriate acid, followed by condensation with DMF-DMA to form enone 45.
  • Compound 45 can be cyclized to form pyrazole 46 by reaction with hydrazine.
  • the pyrazole NH is either alkylated with a preferred R 1 group or protected with a protecting group to afford 47.
  • a Suzuki coupling reaction of 49 with a suitable boronic acid or boronic ester completes the synthesis of compounds represented by 50. Deprotection and/or chlorination can be accomplished if necessary as previously described to afford compounds of the type 51.
  • a halide of the type 52 can be reacted with an anhydride 53 to form compound 54.
  • Compound 54 can be coupled, via Stille coupling, to an appropriate intermediate 55 to provide products of the type 56.
  • intermediate 55 can be prepared by reacting a compound of the type 9 with an appropriate tin reagent.
  • Examples B-1 to 1-1 provide detailed synthetic steps for preparing several specific compounds of the present invention.
  • Table 1 shows analytical data for compounds that were prepared using the methods described herein.
  • Table 2 and Table 3 show the biochemical and cellular data for the compounds of Examples B-1 to I-2. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations.
  • Et2 ⁇ diethyl ether
  • DMF ⁇ /, ⁇ /-dimethylformamide
  • THF tetrahydrofuran
  • DHP dihydropyran
  • DCM diichloro-methane
  • DMA dimethyl acetal
  • DBU 1,8- Diazabicyclo[5.4.0]undec-7-ene
  • LiHMDS or LHMDS lithium hexamethyldisilazide
  • TBME terf-butyl methyl ether
  • LDA Lithium Diisopropylamide
  • DMSO dimethylsulfoxide
  • MeOH methanol
  • EtOH ethanol
  • EtOAc ethyl acetate
  • THF tetrahydrofuran
  • Ac acetyl
  • Me methyl
  • Ph phenyl
  • boronic acids and esters are either commercially available, known in the literature or may be prepared according to the following methods.
  • One of skill in the art would readily appreciate that the following are merely set forth as exemplary boronic acid and boronic ester intermediates, and that these exemplary intermediates can be modified according to known methods to provide a wide variety of possible boronic acids and borinic esters that could be used to prepare compounds within the scope of the claims.
  • Step 1
  • Example A-1 Preparation of reactive intermediates A and B according to Method A Preparation of 4-methyl-2-(methylthio)pyrimidine (2)
  • Example A-2 Procedure for preparation of 4-(5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)- 2-(methy!thio)pyrimidine (B)
  • Example B-1 Preparation of of (2S)-1-(4-(1-isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol- 4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1 )
  • Example B-2 Preparation of (2S)-1-(4-(1-isopropyl-3-(6-(methylamino)pyridin-3-yl)-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-2)
  • Example B-4 Preparation of (2S)-1-(4-(1 -isopropyl-3-(5-methyl-6-(methylamino)pyridin-3-y I)-IH- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-4)
  • Example B-6 Preparation of (2S)-1-(4-(3-(2,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-6)
  • Example B-7 Preparation of (2S)-1-(4-(1-isopropyl-3-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-7)
  • Example B-8 Preparation of (2S)-1-(4-(1-isopropyl-3-(2-methylimidazo[1,2-a]pyrimidin-6-yl)-1H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-8)
  • reaction mixture was allowed to cool to room temperature. Then cone. HCI (200 mL) was added to the mixture. The resulting mixture was heated to 80°C and refluxed overnight. TLC (petroleum ether/EtOAc 5:1 ) indicated the reaction was complete. The reaction mixture was allowed to cool to room temperature, poured into water (1 L) and extracted with EtOAc (1 L x 3).
  • Example B-33 Preparation of 3-( ⁇ 4-[1-(2,2-difluoroethyl)-3-(1H-pyrrolo[2,3-/)]pyridin-5-yl)-1AY- pyrazol-4-yl]pyrimidin-2-yl ⁇ amino)propanenitrile
  • the mixture was then heated in a microwave reactor at 8O 0 C for 2.5 hours.
  • the reaction was degassed and fresh catalyst (20 mg) was added.
  • the mixture was heated in the microwave at 8O 0 C for 4 more hours.
  • the resulting dark mixture was partitioned between ethyl acetate and brine.
  • the aqueous layer was extracted twice with ethyl acetate.
  • the combined organics were washed with brine, dried over Magnesium sulfate and reduced to minimum volume.
  • a microwave reaction vessel was charged with sulfone B-49-3 (6 g, 14.3 mmol, in five batches), 3- aminopropanenitrile (3.0 g, 42.9 mmol) and CsF (2.39 g, 15.7 mmol) in DMSO (60 mL). The resulting solution was subjected to microwave irradiation at 12O 0 C for 30 minutes. The reaction mixture was cooled to room temperature. The mixture was partitioned between EtOAc (600 mL) and brine (100 mL x 3). The layers were separated and the aqueous layer extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo.
  • the reaction mixture was partitioned between 25 mL ethyl acetate and 10 mL deionized water. The aqueous layer was back-extracted with 15 mL ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, concentrated, and purified by silica gel chromatography, eluting with 0-20% [ethanol + 5% cone, ammonium hydroxide] in ethyl acetate. The product was lyophilized to give B-49 (128.4 mg, 84%) as a pale pink solid.
  • the aqueous layer was back-extracted with 25 mL ethyl acetate.
  • the combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to dryness.
  • the residue was dissolved in dichloromethane (27 mL), trifluoroacetic acid (3mL) was added, and the mixture stirred at room temperature for 6.5 hr. Then the solvent was evaporated, and the residue partitioned between ethyl acetate (50 mL) and saturated aqueous sodium bicarbonate solution (25 mL).
  • the organic layer was dried over magnesium sulfate, filtered, and concentrated to a brown tar.
  • the crude product was purified by silica gel chromatography, eluting with 0-20% [ethanol + 5% cone, ammonium hydroxide] in ethyl acetate, affording B-78-5 (325.7 mg, 56%) as a light brown foam.
  • Example B-79 Preparation of 3- ⁇ 4-[3-(5-Amino-6-methoxy-pyrazin-2-yl)-1-(2,2-difluoro-ethyl)-1H- pyrazol-4-yl]-pyrimidin-2-ylamino ⁇ -propionitrile
  • the resulting mixture was deoxygenated with a nitrogen bubbler for 5 min and then 1 ,1'-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex (15 mg, 0.019 mmol) was added. The mixture was then heated in an 8O 0 C oil bath for 20 hours. LCMS indicated the iodide had been completely consumed. The mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organics were dried over magnesium sulfate and reduced to minimum volume.
  • Example C-1 Preparation of [4-[2-((S)-2-Hydroxy-propylamino)-pyrimidin-4-yl]-3-(1H-pyrrolo[2,3- b]pyridin-5-yl)-pyrazol-1-yl]-acetonitrile
  • the palladium catalyst was added and nitrogen bubbling continued for a few minutes before the bubbler was removed.
  • the mixture was heated at 85 0 C for 18hr.
  • LCMS shows complete conversion to product.
  • the mixture was dropped into saturated aqueous NaCI and the resulting solids collected by filtration and rinsed with water. The solids were dissolved in methanol/dichloromethane (1 :9), dried over MgSO 4 and reduced to minimum volume.
  • Example D-1 Preparation of (2S)-1-(4-(1-isopropyl-3-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol
  • reaction mixture was quenched with a solution of 10% citric acid in THF (100 mL) at -65 0 C.
  • the resulting mixture was warmed up to room temperature, poured into water (100 mL) and extracted with EtOAc (200 mL). The organic layer was separated and washed with saturated aqueous NaCI (100 mL ⁇ 2), dried over Na 2 SO 4 and concentrated in vacuo to yield compound D-1-2 (25 g, 85%) as a yellow solid.
  • Example D-2 Preparation of (2S)-1 -(4-(1 -isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H- pyrazol-4-yi)pyrimidin-2-ylamino)propan-2-ol D-2-1 D-2-2 D-2-3
  • Example F-1 Preparation of 3-chloro-5-(1-isopropyl-4-(pyrimidin-4-yl)-1 H-pyrazol-3-yl)-1H- pyrrolo[2,3-b]pyridine
  • F-1-2 F-1-3 Compound F-1-2 was sprinkled to a solution of NaOH (8.06 g, 0.201 mol) in the mixture water/ethanol (30 mL/30 mL) under stirring. The mixture spontaneously heated to 7O 0 C, a brownish-red solution formed, and a light precipitate formed. On densification, water was added. After spontaneous heating ceased, the mixture was stirred at room temperature for 1 h. Ethanol was added, and the solution was rotary evaporated. This operation was repeated twice, and the residue was washed on a filter with ethyl acetate and ether to give compound F-1-3 as beige crystals (yield 100%, 34 g).
  • Example G-1 Preparation of (2S)-1-(4-(3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1- (tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol
  • n-BuLi 2.5 M, 93 mL, 0.233 mol
  • i-Pr2NH 32.5 mL, 0.233 mol
  • dry THF 420 mL
  • a solution of 4- methyl-2-(methylthio)pyrimidine 22.33 g, 0.16 mol
  • dry THF 110 mL
  • G-1-10 G-1 The crude azaindole G-1-10 (400 mg, 0.98 mmol), N-chlorosuccinimide (NCS, 130.83 mg, 0.98 mmol) in DMF (50 mL) under N 2 atmosphere was heated to 4O 0 C and stirred overnight. LC-MS showed the starting material was completely consumption. The resultant mixture was then diluted with EtOAc (500 mL). The organic layer was separated and washed with water and saturated aqueous NaCI for several times, dried over anhydrous Na 2 SO 4 , evap. to give the crude product (380 mg). The crude product was purified by prep. HPLC to afford the product G-1 (170 mg, 39.53%) as green solid.
  • Example H-1 4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -isopropyl-1 H-pyrazol-4-yl)pyridin-2- amine
  • Heating at 8O 0 C was continued for an additional 18 hours at which time 150mg more of 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine and 25mg more 1 ,1'-bis(diphenylphospino)ferrocene palladium (II) chloride were added. After degassing, the reaction was sealed and placed in microwave for 60 min at 8O 0 C. The mixture was filtered and the solids rinsed with water and MeOH. The filtrate was partitioned between ethyl acetate and saturated aqueous NaCI. The aqueous layer was extracted with ethyl acetate (2x).
  • the resulting mixture was sealed in a 20 mL microwave reaction vial and heated in an oil bath at 9O 0 C for 18 hrs then at 110 0 C for 2 hrs. The mixture was removed from the oil bath and allowed to cool to room temperature. The mixture was loaded directly onto silica gel and purified using a gradient of 0-35% ethyl acetate in dichloromethane as eluent to give 1.26g (58%) of 1-1-3 as an oil.
  • the mixture was sealed in a microwave vial and heated in an oil bath at 100C for 18 hrs. This mixture was then heated in the microwave at 17O 0 C for 20 minutes to themolyze the tert-butoxycarbonyl groups.
  • the mixture was partitioned between ethyl acetate and saturated aqueous NaCI. Some dark insoluble solids did not go into either phase and were removed by filtration. The layers were separated and the aqueous layer was extracted twice with ethyl acetate. The combined organics were washed once each with water and saturated aqueous NaCI, dried over Magnesium sulfate and reduced to minimum volume.
  • Step i
  • Raf kinase activity is measured in vitro by determining transfer of radiolabeled 32-P phosphate from ATP to the specific Raf substrate Mek1.
  • Full-length wild type b-Raf is expressed in recombinant form and purified from bacterial or insect cells.
  • Recombinant Mek1 is purified from E. coli bacterial cells.
  • the full-length wild type Mek1 is used as the b-Raf substrate.
  • G2 the full-length K97R Mek1 mutant is used as the b- Raf substrate.
  • In vitro kinase assays are performed in solution containing the following; 50 mM Hepes (pH 7.4), 5 nM b-Raf, 0.8 ⁇ M Mek1 , 10 mM MgCI2, 25 ⁇ M ATP, 0.002% (v/v) Tween-20, 5 ⁇ g/mL leupeptin, 1.2 mM DTT, 2% (v/v) DMSO, 0.2-1.0 ⁇ Ci [ ⁇ - 32 P]ATP per well.
  • the assays are performed in wells of a 96 well polypropylene round bottom plate, each well containing 43.5 ⁇ L assay mix and 1.5 ⁇ L inhibitor compound or DMSO vehicle. 15 ⁇ L of b-Raf mix is added and the plate is shaken on a plate shaker and preincubated for 10 minutes at ambient temperature. The reaction is started by addition of 15 ⁇ L ATP mix and shaking. The reaction is terminated after 40 minutes by addition of 25 ⁇ L 0.5 M EDTA (pH 7.4).
  • Silent Screen filter plate (Nalge/Nunc: 256081 ). The wells are filtered and washed five times with 0.85% phosphoric acid. The filter is placed in a tray with about 50 mL 0.85% phosphoric acid and gently rotated for 10 minutes on an orbital shaker. The procedure is repeated once with fresh 0.85% phosphoric acid.
  • Raf kinase activity is calculated from the specific activity of [32-P] ATP, 32-P incorporation into Mek1 , and the concentration of b-Raf.
  • Example K Raf Cellular Assay Compounds of the present invention were evaluated for potency against b-Raf using a cellular assay as follows.
  • the activity of Raf kinases in cells is determined by measuring the level of phosphorylation of Mek1/2 at serine 217/221 , the site phosphorylated by Raf kinases in vivo.
  • Mek1/2 Ser phosphorylation is measured using anti-phospho-Mek1/2 antibodies (Cell Signaling #9121) in an ELISA format. Healthy growing human melanoma A2058 cells (harboring a b-Raf mutation) are used for the assay.
  • A2058 cells are grown in 10% FBS DMEM medium.
  • the cells When the cells are near 85%+ confluence, the cells are rinsed with PBS once and trypsinized with trypsin/EDTA for 3 minutes. The cells are resuspended in 10% FBS DMEM and are centrifuged down at 1000 rpm for 5 minutes. The cells are resuspended in 10% FBS DMEM and counted on a cell counter. The cells are seeded at 50,000 cells/well in a volume of 100 ⁇ L/well in 10% FBS DMEM in a 96 well flat-bottom plate. The negative control wells receive only 100 ⁇ L of 10% FBS DMEM medium without cells. The plate is incubated overnight in a cell culture incubator with 5% CO 2 at 37 0 C.
  • testing compounds are prepared in 10% FBS DMEM medium and serially diluted at 1 :3 for 11 test concentrations. Each concentration of the compounds is tested in duplicate.
  • the compound solutions are added at 25 ⁇ L/well to the corresponding wells in the cell plate, and 25 ⁇ L/well of the vehicle (0.5% DMSO in 10% FBS DMEM) is added to the negative control wells (no cells) and the positive control wells (cells without compounds).
  • the plate is incubated for 1 hour in a cell culture incubator with 5% CO 2 at 37 0 C. After 1 hour of incubation, the medium is removed, 100 ⁇ L/well of cell lysis buffer is added into the cell plate, and the plate is shaken for 15 minutes at room temperature.
  • the cell lysates are transferred to an ELISA plate (pre-coated with anti-Mek1 anti-body, Cell Signaling #2352), and the plate is incubated with gentle shaking for 2 hours at room temperature. After 2 hours, the contents of the wells are aspirated and the wells are washed 4 times with wash buffer. 100 ⁇ L of phospho-Mek1/2 detection antibody (Cell Signaling #9121 ) is added into each well and the plate is incubated with gentle shaking for 1 hour at room temperature. After 1 hour, the wells are aspirated and washed 4 times with wash buffer.
  • phospho-Mek1/2 detection antibody Cell Signaling #9121

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

Description

PYRAZOLE COMPOUNDS
This application claims the benefit of U. S. Provisional Application No. 60/953,235 filed August 1 , 2007, and U. S. Provisional Application No. 61/080,054 filed July 11 , 2008, the contents of which are hereby incorporated by reference in their entireties.
Field of the Invention
The present invention is directed to compounds, their synthesis, and their use as modulators or inhibitors of the Raf enzyme. The compounds of the present invention are useful for modulating (e.g. inhibiting) Raf activity and for treating diseases or conditions mediated by Raf, such as for example, disease states associated with abnormal cell growth such as cancer.
Background
The "Erk pathway" is an intracellular signal transduction pathway used by nearly all types of human cells to translate extracellular signals to cellular decisions, including proliferation, differentiation, senescence, or apoptosis (Wellbrock et al., Nat. Rev. MoI. Cell Biol. 11 :875-885 (2004)). One of the invariant components of this pathway is the Ras GTPase, which receives signals from membrane receptors and activates the Raf protein kinases, which activate the Mek protein kinases, which in turn activate the Erk protein kinases. Activated Erk kinases phosphorylate a number of nuclear and cytoplasmic targets to initiate various cellular decisions. The biological importance of Raf in the Erk pathway is underscored by the finding that mutated forms of Raf are associated with certain human malignancies (see e.g. Monia et al., Nature Medicine 2:668-675 (1996); Davies et al., Nature 417:949-954 (2002)). Three distinct genes have been identified in mammals that encode Raf proteins; a-Raf, b-Raf and c-Raf (also known as Raf-1 ) and isoformic variants that result from differential splicing of mRNA are known (Chong et al., EMBO J. 20:3716-3727 (2001 )). The Erk pathway is mutationally activated in a number of human cancers, most often by mutation of the Ras or b-Raf genes. Mutations in Ras and b- Raf genes generally occur in the same tumor types, including cancers of the colon, lung and pancreas and melanoma, but are usually mutually exclusive. This suggests that activation of either Ras or Raf is sufficient for pathway activation and cancer progression.
Since tumor cells frequently become dependent, or 'addicted' to one or two key signaling pathways for their survival (see, e.g. Jonkers et al., Cancer Cell. 6:535-538 (2004)), the Erk pathway represents a highly attractive target for drug intervention to treat cancer. Protein kinases in general are considered desirable targets for drug therapy, as evidenced by recent successes in targeting growth factor receptor and intracellular tyrosine kinases. Inhibitors of Mek have shown promise in clinical trials, however, there is ample evidence to indicate Mek-independent Raf signaling that may also contribute to cancer progression (Wellbrock et al, Nat. Rev. MoI. Cell Biol. 11 :875-885 (2004)). Therefore, targeting Raf kinases promises an alternative and complementary approach to treating tumors in which Ras or Raf genes are mutated. Summary In one embodiment, the present invention is a compound of Formula (I)
Figure imgf000003_0001
(I) wherein:
X is N or CR7;
R1 is H, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-Ci4 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said CrC6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R8;
R2 is C2-C9 cycloheteroalkyl or C5-C14 heteroaryl, wherein each of said C2-C9 cycloheteroalkyl and C5-C14 heteroaryl is optionally substituted with one or more R8; R3 is H Or -NR9R10;
R4, R5, R6, R7 are each independently H, -NR9R10, -CN, -C(O)R9, -C(O)OR9, -NO2, -SR9, -OR9, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-Cg heteroaryl is optionally substituted with one or more R8; each R8 is independently -OH, fluorine, chlorine, bromine, cyano, -NR9R10, -C(O)N(R9R10), -C(O)R9, -C(O)OR9, -NO2, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, C2-C9 heteroaryl, or -(CH2)nC(O)R9, wherein each of said C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R11;
R9 and R10 are each independently H, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl,
C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl,
C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with at least one R11; or R9 and R10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered ring optionally substituted with one or more R11; each R11 is independently fluorine, chlorine, bromine, -OH, cyano, C1-C6 alkyl, C1-C11 heteroalkyl, C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more group selected from fluorine, chlorine, bromine, -OH, cyano, and C1-C6 alkyl; n is O, 1 , 2, 3, or 4; or a pharmaceutically acceptable salt thereof. In one aspect of this embodiment, X is N. In another aspect of this embodiment, X is CR7. In a further aspect, R4 is H. In a further aspect of this embodiment, R5 is H. In a further aspect of this embodiment, R6 is H. I still a further aspect of this embodiment, R4, R5, and R6 are H. In a further aspect of this embodiment, R1 is C1-C6 alkyl optionally substituted with one or more R8. In a further aspect of this embodiment, R1 is C1-C6 alkyl substituted with at least one R8. In a further aspect of this embodiment, R1 is selected from methyl, isopropyl, (3-methyloxetan-3-yl)methyl, 2,2-difluoroethyl, and acetonitrile. In another aspect of this embodiment, R3 is -NR9R10.
In another aspect of this embodiment, R2 is selected from the group consisting of
Figure imgf000004_0001
Figure imgf000004_0002
Figure imgf000004_0003
Figure imgf000004_0004
Figure imgf000004_0005
Figure imgf000005_0001
In a further embodiment, the invention is a compound of Formula (Ia) having the following structure:
Figure imgf000005_0002
wherein: R1 is C1-C6 alkyl optionally substituted with one or more R8;
R2 is C2-C9 cycloheteroalkyl or C5-C14 heteroaryl, wherein each of said C3-C12 cycloheteroalkyl and C2-C9 heteroaryl is optionally substituted with one or more R8; R3 is H Or -NR9R10; each R8 is independently -OH, fluorine, chlorine, bromine, cyano, -NR9R10, -C(O)N(R9R10), C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, C2-C9 heteroaryl, or -(CH2)nC(O)R9' wherein each of said C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R11;
R9 and R10 are each independently H, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl,
C6-C14 aryl, C3-C9 cycloheteroalkyl, or C5-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl are optionally substituted with at least one R11; or R9 and R10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered ring optionally substituted with one or more R11; each R11 is independently fluorine, chlorine, bromine, -OH, cyano, C1-C6 alkyl, C1-C11 heteroalkyl,
C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S- (C3-C8 cycloalkyl), C6-Ci4 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more group selected from fluorine, chlorine, bromine, -OH, cyano, and C1-C6 alkyl; or a pharmaceutically acceptable salt thereof.
In one aspect of this embodiment, R1 is selected from methyl, isopropyl, (3-methyloxetan-3- yl)methyl, 2,2-difluoroethyl, and acetonitrile. In another aspect of this embodiment, R3 is -NR9R10.
In another aspect of this embodiment, R2 is selected from the group consisting of
Figure imgf000006_0001
In another embodiment, the present invention is a compound of Formula (II)
Figure imgf000007_0001
(II) wherein:
X is N or CR7; R1 is H, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R8;
R2 is C2-C9 cycloheteroalkyl or C2-Cg heteroaryl, wherein each of said C2-C9 cycloheteroalkyl and C5-C14 heteroaryl is optionally substituted with one or more R8; or optionally where R2 is C2-C9 heteroaryl, the hydrogen atoms on any 2 adjacent ring atoms may combine to form a 5-7 membered cycloalkyl optionally substituted by one or more R8, a 5-7 membered cycloheteroalkyl optionally substituted by one or more R8, or a 5-7 membered heteroaryl optionally substituted by one or more R8;
R3 is H or -NR9R10; or where X is CR7, R3 may combine with R7 to form a 5-7 membered heteroaryl optionally substituted by one or more R8, 5-7 membered cycloheteroalkyl optionally substituted by one or more R8, phenyl optionally substituted by one or more R8, or 5-7 membered cycloalkyl optionally substituted by one or more R8;
R4, R5, R6, R7 are each independently H, -NR11R12, -CN, -C(O)R11, -C(O)OR11, -NO2, -SR11, -
S(O)2R11, -OR11, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl is optionally substituted with one or more R8; each R8 is independently -OR11, fluorine, chlorine, bromine, oxo, cyano, -NR13R14,
-C(O)N(R13R14), -C(O)R13, -C(O)OR13, -NO2, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, C2-C9 heteroaryl, or -(CH2)nC(O)R11, wherein each of said C3-C8 cycloalkyl, C6-C14 aryl, C2-Cg cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R11;
R9 and R10 are each independently H, -C(O)N(R13R14), -C(O)R13, -C(O)OR13, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with at least one R11; or R9 and R10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered cycloheteroalkyl ring optionally substituted with one or more R11; each R11 and R12 is independently fluorine, chlorine, bromine, -OH, -C(O)R13, -C(O)OR13, -SR13, - S(O)2R13, -OR13, -NR13R14, -C(O)N(R13R14), cyano, C1-C6 alkyl, C1-Cn heteroalkyl, C3-C8 cycloalkyl, -O- (C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more R13; each R13 and R14 is independently H, oxo, C1-C6 alkyl, C1-C11 heteroalkyl, C3-C8 cycloalkyl, -O- (C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more group selected from fluorine, chlorine, bromine, -OH, cyano, and C1-C6 alkyl; n is O, 1 , 2, 3, or 4; or a pharmaceutically acceptable salt thereof. In one aspect of this embodiment, X is N, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, X is CR7, or a pharmaceutically acceptable salt thereof. In a further aspect, R4 is H, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R5 is H, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R6 is H, or a pharmaceutically acceptable salt thereof. In still a further aspect of this embodiment, R4, R5, and R6 are H, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R1 is C1-C6 alkyl optionally substituted with one or more R8, or a pharmaceutically acceptable salt thereof. In a further aspect of this embodiment, R1 is C1-C6 alkyl substituted with at least one R8, or a pharmaceutically acceptable salt thereof.
In one aspect of this embodiment, R1 is selected from methyl, ethyl, isopropyl, cyclopropyl, 2,2- difluoroethyl, cyanomethyl, difluorocyclobutanyl, (3-methyloxetan-3-yl)methyl, 1 ,1-dimethyl-2- hydroxyethyl, 1 -methyl- 1-cyanoethyl, difluoromethyl, tert-butyl, 3-hydroxypropan-2-yl, piperidinyl, N-acetyl- piperidinyl, H, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 4-cyanophenyl, cis-fluorocyclobutanyl, trans- fluorocyclobutanyl, oxetanyl, and N-methyl-piperidinyl, or a pharmaceutically acceptable salt thereof.
In a further aspect of this embodiment, R1 is selected from methyl, isopropyl, (3-methyloxetan-3- yl)methyl, 2,2-difluoroethyl, and acetonitrile, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, R3 is -NR9R10, or a pharmaceutically acceptable salt thereof.
In another aspect of this embodiment, R2 is selected from the group consisting of
Figure imgf000009_0001
Figure imgf000010_0001
and
Figure imgf000010_0002
or a pharmaceutically acceptable salt thereof.
In another aspect of this embodiment, R is -NR R . In another aspect of this embodiment, R is NH2, H,
Figure imgf000011_0001
Figure imgf000012_0001
or a pharmaceutically acceptable salt thereof.
In a further embodiment, the invention is a compound of Formula (Ha) having the following structure:
Figure imgf000012_0002
wherein:
R1 is C1-C6 alkyl optionally substituted with one or more R8;
R2 is C2-C9 cycloheteroalkyl or C5-C14 heteroaryl, wherein each of said C3-C12 cycloheteroalkyl and C2-C9 heteroaryl is optionally substituted with one or more R8;
R3 is H or -NR9R10; each R8 is independently -OR11, fluorine, chlorine, bromine, oxo, cyano, -NR13R14, -C(O)N(R13R14), -C(O)R13, -C(O)OR13, -NO2, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, C2-C9 heteroaryl, or -(CH2)nC(O)R9, wherein each of said C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R11;
R9 and R10 are each independently H, -C(O)N(R13R14), -C(O)R13, -C(O)OR13, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with at least one R11; or R9 and R10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered cycloheteroalkyl ring optionally substituted with one or more R11; each R11 and R12 is independently fluorine, chlorine, bromine, -OH, -C(O)R13, -C(O)OR13, -SR13, - S(O)2R13, -OR13, -NR13R14, -C(O)N(R13R14), cyano, C1-C6 alkyl, C1-C11 heteroalkyl, C3-C8 cycloalkyl, -O- (C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-Cg heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more R13; each R13 and R14 is independently H, oxo, C1-C6 alkyl, C1-C11 heteroalkyl, C3-C8 cycloalkyl, -O- (C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more group selected from fluorine, chlorine, bromine, -OH, cyano, and C1-C6 alkyl; or a pharmaceutically acceptable salt thereof.
In one aspect of this embodiment, R1 is selected from methyl, ethyl, isopropyl, cyclopropyl, 2,2- difluoroethyl, cyanomethyl, difluorocyclobutanyl, (3-methyloxetan-3-yl)methyl, 1 ,1-dimethyl-2- hydroxyethyl, 1 -methyl- 1-cyanoethyl, difluoromethyl, tert-butyl, 3-hydroxypropan-2-yl, piperidinyl, N-acetyl- piperidinyl, H, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 4-cyanophenyl, cis-fluorocyclobutanyl, trans- fluorocyclobutanyl, oxetanyl, and N-methyl-piperidinyl, or a pharmaceutically acceptable salt thereof.
In another aspect of this embodiment, R2 is selected from the group consisting of
Figure imgf000013_0001
Figure imgf000014_0001
or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, R is -NR R . In another aspect of this embodiment, R is
NH2, H,
Figure imgf000015_0001
Figure imgf000016_0001
or a pharmaceutically acceptable salt thereof.
In a further embodiment, the present invention is a compound selected from the group consisting of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin- 5-yl)-1 H-pyrazol-4-yl]-N-[2-(1 H-pyrazol-1-yl)ethyl]pyrimidin-2-amine, (2S)-1-(4-(1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, N-(2-fluoroethyl)-4-[1- isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1-(4-(3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-methyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 2-({4-[1-isopropyl-3- (1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethanol, 4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N-[2-(1 H-pyrazol-4-yl)ethyl]pyrimidin-2-amine, (2S)-1-(4-(3- (2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, [4- [2-((S)-2-Hydroxy-propylamino)-pyrimidin-4-yl]-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1-yl]-acetonitrile, 1-[2-({4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethyl]pyridin- 2(1 H)-one, (2R)-2-({4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-1-ol, N-[(1-ethyl-1 H-pyrazol-4-yl)methyl]-4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)- 1 H-pyrazol-4-yl]pyrimidin-2-amine, N-[(2,5-dimethyl-1 ,3-oxazol-4-yl)methyl]-4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5- yl)-1 H-pyrazol-4-yl]-N-(tetrahydrofuran-3-ylmethyl)pyrimidin-2-amine, 4-(1-isopropyl-3-(1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)-N-(pyridin-2-ylmethyl)pyrimidin-2-amine, (2S)-1-(4-(1-isopropyl-3-(1 H- pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N-(2-methoxyethyl)pyrimidin-2-amine, 1-ethyl-4-[({4-[1- isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)methyl]pyrrolidin-2-one, (2S)-1-(4-(1-isopropyl-3-(5-methyl-6-(methylamino)pyridin-3-yl)-1H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(2-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-methyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(2-methylimidazo[1 ,2-a]pyrimidin-6- yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(6-(methylamino)pyridin-3- yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethylimidazo[1 ,2-a]pyrimidin-6- yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-(2,2-difluoroethyl)-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1 -(4-(3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4- (3-(3-chloro-2-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(1-((3-methyloxetan-3-yl)methyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 5-(4-(2-((S)-2-hydroxypropylamino)pyrimidin-4-yl)-1- isopropyl-1 H-pyrazol-3-yl)-3,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-2(3H)-one, (2S)-1-(4-(3-(3,3-dimethyl-2,3- dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-methyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol and (2S)- 1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-((3-methyloxetan-3-yl)methyl)-1 H-pyrazol-4-yl)pyrimidin- 2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the present invention is a compound selected from the group consisting of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- (2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol and (2S)-1 -(4-(1 -isopropyl-3-(3-methyl- 1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol; or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(2,3-dimethyl-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
In a further embodiment, the compound is selected from 4-[3-(6-amino-5-methoxypyridin-3-yl)-1- isopropyl-1 H-pyrazol-4-yl]-N-cyclopropylpyrimidin-2-amine, (2S)-1-({4-[3-(3-chloro-1H-pyrrolo[2,3- b]pyridin-5-yl)-1-(3,3-difluorocyclobutyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3-(6- amino-5-methylpyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 3-({4- [3-(3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[1-(2,2-difluoroethyl)-3-(3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2-hydroxy- 1 ,1-dimethylethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2-hydroxy-1 ,1- dimethylethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[3-(3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)- 1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, N-{5-[4-{2-[(2- cyanoethyl)amino]pyrimidin-4-yl}-1-(2,2-difluoroethyl)-1 H-pyrazol-3-yl]-4-methylpyridin-2-yl}acetamide, N- [1-(cyclopropyl-sulfonyl)piperidin-4-yl]-4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol- 4-yl]pyrimidin-2-amine, 3-({4-[1-(2,2-difluoroethyl)-3-(6-methylpyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, (2S)-1-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-4-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propan-2-ol, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-tert-butyl-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-isopropyl-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1 -(2,2-difluoroethyl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2- difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 2-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-4-(2-{[(2S)-2-hydroxypropyl]amino}pyrimidin-4-yl)-1 H-pyrazol-1-yl]-2-methylpropanenitrile, (2S)-1-({4- [1-(2,2-difluoroethyl)-3-(1-methyl-1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-2-ol, 3-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, and 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(1-methyl-1 H- pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof.
In a further embodiment, the compound is selected from 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3- (1-methyl-1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, (2S)-1-[(4-{3- [6-amino-5-(difluoromethoxy)-pyridin-3-yl]-1-isopropyl-1 H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-ol, A- [1-(difluoromethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1- ({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-(difluoromethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2- ol, (2S)-1-({4-[3-(2-aminopyrimidin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4- [3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(difluoromethyl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 3-({4-[1- (difluoromethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)- propanenitrile, 2-amino-5-[4-(2-{[(2S)-2-hydroxypropyl]-amino}pyrimidin-4-yl)-1-isopropyl-1 H-pyrazol-3- yl]pyridin-3-ol, 3-({4-[1-(2,2-difluoroethyl)-3-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[3-(6-amino-5-methylpyridin-3-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 2-[4-{2-[(2,2-difluoroethyl)amino]pyrimidin-4-yl}-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-1-yl]-2-methylpropan-1-ol, 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3- (5-methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 3-({4-[1-isopropyl-3-(3- methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5- acetyl-6-aminopyridin-3-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-{[4-(1- isopropyl-3-pyridin-3-yl-1 H-pyrazol-4-yl)pyrimidin-2-yl]amino}-propanenitrile, 4-[3-(6-amino-5- methoxypyridin-3-yl)-1-tert-butyl-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)pyrimidin-2-amine, (2R)-2-[4-(2- aminopyrimidin-4-yl)-3-(3-chloro-1 H-pyrrolot2,3-b]pyridin-5-yl)-1 H-pyrazol-1-yl]propan-1-ol, 4-[3-(6-amino- 5-methoxypyridin-3-yl)-1 -cyclopropyl-1 H-pyrazol-4-yl]pyrimidin-2-amine, 3-({4-[3-(6-amino-5- methoxypyridin-3-yl)-1 -cyclopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 2-[4-(2- aminopyrimidin-4-yl)-3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-1-yl]-2-methylpropan-1-ol, 4-[3- (6-amino-5-methoxypyridin-3-yl)-1-cyclopropyl-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)pyrimidin-2-amine, and 4-[3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is selected from (2S)-1-({4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-ethyl-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[1-isopropyl-3-(3-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)- 1-piperidin-4-yl-1 H-pyrazol-4-yl]pyrimidin-2-amine, 3-chloro-5-(1-piperidin-4-yl-4-pyrimidin-4-yl-1 H- pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine, 4-[1-tert-butyl-3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl]pyrimidin-2-amine, (2S)-1-({4-[1-tert-butyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[1-(1-acetylpiperidin-4-yl)-3-(3-chloro-1H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)-pyrimidin-2-amine, 4-[3-(6-amino-5-methoxypyridin-3- yl)-1H-pyrazol-4-yl]-N-(2,2-difluoroethyl)-pyrimidin-2-amine, 3-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1- (tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 4-[3-(6-amino-5- methoxypyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-N-(2,2-difluoroethyl)-pyrimidin-2-amine, 3-({4-[1 -tert-butyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[1-tert-butyl-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-[(4-{3-(5-methoxypyridin-3-yl)-1-[(3R)-tetrahydrofuran-3-yl]-1 H- pyrazol-4-yl}pyrimidin-2-yl)amino]propanenitrile, 3-({4-[1-tert-butyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 3-[(4-{3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-[(3R)- tetrahydrofuran-3-yl]-1 H-pyrazol-4-yl}pyrimidin-2-yl)amino]propanenitrile, (2S)-1-({4-[3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-piperidin-4-yl-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)pyrimidin- 2-amine, 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)- propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 4-[3-(6-amino-5-methoxypyridin-3-yl)-4-{2-[(2-hydroxyethyl)-amino]pyrimidin-4-yl}- 1 H-pyrazol-1-yl]-benzonitrile, 4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N- (6-methoxypyridin-3-yl)pyrimidin-2-amine, 3-(4-(3-(6-amino-5-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, 3-(4-(3-(6-amino-5-methoxypyridin-3-yl)-1 -(2,2- difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, (S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-((1s,3s)-3-fluorocyclobutyl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (S)-1-(4-(3- (6-amino-5-methoxypyridin-3-yl)-1-((1r,3r)-3-fluorocyclobutyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan- 2-ol, (S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-((1 r,3r)-3-fluorocyclobutyl)-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-(2,2-difluoroethyl)-3-(3-methyl-2,3-dihydro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 3-(4-(1-(2,2-difluoroethyl)-3-(2,3-dihydro- 1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, and 1-(4-(1-(2,2- difluoroethyl)-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-2- methylpropan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is selected from N-(2,2-difluoroethyl)-4-(1-(2,2- difluoroethyl)-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-amine, 3-(4-(1-(2,2- difluoroethyl)-3-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin-2- ylamino)propanenitrile, (S)-1-(4-(1-(2,2-difluoroethyl)-3-((R)-3-methyl-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 3-(4-(1-(2,2-difluoroethyl)-3-(3-methyl-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, 3-(4-(1-(1-hydroxy-2- methylpropan-2-yl)-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propanenitrile, 3-(4-(1-(2,2-difluoroethyl)-3-(2-oxo-2,3-dihydro-1 H-pyrrolo[2,3-b]pyriclin-5-yl)-1 l-l- pyrazol-4-yl)-pyrimidin-2-ylamino)propanenitrile, (2S)-1 -({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 - (2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1 -({4-[3-(3-chloro-2-methyl-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-[(4-{3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-[(3-methyloxetan-3-yl)nnethyl]-1 H-pyrazol-4-yl}pyrimidin-2- yl)amino]propan-2-ol, (2S)-1-({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-oxetan-3-yl-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[1-(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[1-(2,2-difluoroethyl)-3-(3-fluoro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[1-(2,2- difluoroethyl)-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2- ol, 5-[1-(2,2-difluoroethyl)-4-(2-{[(2S)-2-hydroxypropyl]amino}pyrimidin-4-yl)-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine-3-carbonitrile, (2S)-1-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)- 1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 2-({4-[1-(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethanol, 2-({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5- yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethanol, 4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[1 -(2,2-difIuoroethyl)-3-(3-methyl- 1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1-({4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-(1-methylpiperidin-4-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3- (3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -(3-methoxypropyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan- 2-ol, (2S)-1-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-2-ol, (2S)-1-({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(1-methylpiperidin-4-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, N-(2,2-difluoroethyl)-4-[1-(1-methylpiperidin-4-yl)-3-(3- methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-(1-methylpiperidin-4-yl)-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)pyrimidin-2-amine, 4-[3-(6- amino-5-methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 3-(4-(1-(2,2-difluoroethyl)-3-(1- cyanoethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, 3-({4-[3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)-propanenitrile, 2-[4-(2-amino-pyrimidin-4-yl)-3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-1-yl]-2-methylpropan-1-ol, 3-chloro-5-(1-isopropyl-4-pyrimidin-4-yl-1H-pyrazol-3-yl)-1 H- pyrrolo[2,3-b]pyridine, 3-chloro-5-[1-(1-methylpiperidin-4-yl)-4-pyrimidin-4-yl-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine, 5-(1-tert-butyl-4-pyrimidin-4-yl-1 H-pyrazol-3-yl)-3-methoxypyridin-2-amine, (2S)-1- (4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(tetrahydrofuran-3-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, 3-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-methyl-1 l-l-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, N-(2,2-difluoroethyl)-4-[1 -(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[1-(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1H-pyrazol-4-yl]-N-(tetrahydrofuran-3-yl)pyrimidin-2-amine, 2-[3-(3-chloro-1H-pyrrolo[2,3- b]pyridin-5-yl)-4-{2-[(2-hydroxyethyl)amino]pyrimidin-4-yl}-1 H-pyrazol-1-yl]-2-methylpropanenitrile, 2-[4-(2- aminopyrimidin-4-yl)-3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-1 -yl]-2-methylpropanenitrile, 3- (4-(3-(6-amino-5-methylpyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylannino)- propanenitrile, 4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyridin-2-amine, 4- (1 -isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyridin-2-amine, 4-(1 -isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[2,3-b]pyridine, 3-chloro-5-(1-isopropyl-4-(1 H- pyrrolo[2,3-b]pyridin-4-yl)-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine, (2S)-1 -({4-[3-(5-amino-6- methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3- (7-chloro-5H-pyrrolo[2,3-b]pyrazin-2-yl)-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol , or a pharmaceutically acceptable salt thereof.
In a further embodiment, the compound is selected from 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3- (5-methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2,2-difluoroethyl)-3- (1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6- methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, (2S)-1-(4- (1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol and 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)- propanenitrile, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is selected from 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-
(5-methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2,2-difluoroethyl)-3- (1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6- methoxypyrazin-2-yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, and 3-(4-(3- (5-acetyl-6-aminopyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, or a pharmaceutically acceptable salt thereof.
In a further embodiment, the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2- difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(5- methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is 3-({4-[1-(2,2-difluoroethyl)-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof In a further embodiment, the compound is 3-({4-[3-(5-amino-6-methoxypyrazin-2- yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof In a further embodiment, the compound is 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1- (2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is selected from any group of 10 compounds found in Table 1 , or a pharmaceutically acceptable salt thereof.
In a further embodiment is any of the aspects described above in combination with any of the other aspects described above which is not inconsistent therewith. The present invention also relates to a pharmaceutical composition, comprising at least one compound as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
The present invention also relates to a method of treating abnormal cell growth, or any Raf- mediated disease or condition, in a mammal in need thereof, comprising the step of administering to said mammal a therapeutically effective amount of at least one compound as described herein, or a pharmaceutically acceptable salt thereof. For example, in one embodiment the abnormal cell growth is cancerous. In a further embodiment, the abnormal cell growth in non-cancerous.
The present invention further relates to a method of inhibiting Raf enzymatic activity, comprising contacting a Raf enzyme with a Raf-inhibiting amount of at least one compound as described herein, or a pharmaceutically acceptable salt thereof.
The present invention further relates to the use of any of the compounds as described herein, or a salt or solvate thereof, in the manufacture of a medicament for the treatment of abnormal cell growth in a mammal.
The present invention further relates to methods of making the compounds as described herein using the methods as shown in the specific examples herein and in the general synthetic methods A, B, C, D, E, F, G, H and I as described herein.
The present invention further relates to any of the compounds described above, or salts or solvates thereof, for use as a medicament. The present invention further relates to the use of any of the compounds described above, or salts or solvates thereof, for the manufacture of a medicament for the treatment of abnormal cell growth.
Detailed Description
As used herein, the terms "comprising" and "including" are used in their open, non-limiting sense. The terms "halo" and/or "halogen" refer to fluorine, chlorine, bromine or iodine.
The term "oxo" as used herein refers to an oxygen covalently attached to a carbon atom on an alkyl, cycloalkyl, or cycloheteroalkyl by a double bond such that the carbon is in the sp2 hydridization state and the resultant functional group is a ketone.
The term "C1-C6 alkyl" refers to a saturated aliphatic hydrocarbon radical including straight chain and branched chain groups of 1 to 6 carbon atoms. Examples of (C1 to C6) alkyl groups include methyl, ethyl, propyl, 2-propyl, π-butyl, /so-butyl, fert-butyl, pentyl, and the like.
The term "C2-C8 alkenyl", as used herein, means an alkyl moiety comprising 2 to 8 carbons having at least one carbon-carbon double bond. The carbon-carbon double bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound. Such groups include both the E and Z isomers of said alkenyl moiety. Examples of such groups include, but are not limited to, ethenyl, propenyl, butenyl, allyl, and pentenyl. The term "allyl," as used herein, means a -CH2CH=CH2 group. The term, "C(R)=C(R)," as used herein, represents a carbon-carbon double bond in which each carbon is substituted by an R group.
As used herein, the term "C2-C8 alkynyl" means an alkyl moiety comprising from 2 to 8 carbon atoms and having at least one carbon-carbon triple bond. The carbon-carbon triple bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound. Examples of such groups include, but are not limited to, ethyne, propyne, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 1- hexyne, 2-hexyne, and 3-hexyne.
The term "C1-C6 alkoxy", as used herein, means an O-alkyl group wherein said alkyl group contains from 1 to 6 carbon atoms and is straight, branched, or cyclic. Alternatively, "CrC6 alkoxy" is used interchangeably herein with "-0-C1-C6 alkyl". Examples of such groups include, but are not limited to, methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butoxy, iso-butoxy, tert-butoxy, cyclopentyloxy, and cyclohexyloxy.
The term "C1-C11 heteroalkyl" refers to a straight- or branched-chain alkyl group having a total of from 2 to 12 atoms in the chain, including from 1 to 11 carbon atoms, and one or more atoms of which is a heteroatom selected from S, O, and N, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The S atoms in said chains may be optionally oxidized with one or two oxygen atoms, to afford sulfides and sulfones, respectively. Furthermore, the C1-C11 heteroalkyl groups in the compounds of the present invention can contain an oxo group at any carbon or heteroatom that will result in a stable compound. Exemplary C1-C11 heteroalkyl groups include, but are not limited to, alcohols, alkyl ethers, primary, secondary, and tertiary alkyl amines, amides, ketones, esters, sulfides, and sulfones.
The term "C6-C14 aryl", as used herein, means a group derived from an aromatic hydrocarbon containing from 6 to 14 carbon atoms that can be, for example, monocyclic, bicyclic or tricyclic. Examples of such groups include, but are not limited to, phenyl or naphthyl. The terms "Ph" and "phenyl," as used herein, means a -C6H5 group. The term "benzyl," as used herein, means a -CH2C6H5 group.
The term "C6-C14 aryloxy", as used herein, means an O-aryl group wherein said aryl group is a group derived from an aromatic hydrocarbon containing from 6 to 14 carbon atoms that can be, for example, monocyclic, bicyclic or tricyclic. Alternatively, "C6-C14 aryloxy" is used interchangeably herein with
"-0-C6-C14 aryl". Examples of such groups include, but are not limited to phenolyl or naphtholyl. The term "-S-C6-C14 aryl", as used herein, means an S-aryl group wherein said aryl group is a group derived from an aromatic hydrocarbon containing from 6 to 14 carbon atoms that can be, for example, monocyclic, bicyclic or tricyclic.
"C2-C9 heteroaryl", as used herein, means an aromatic heterocyclic group having a total of from 5 to
10 atoms in its ring, and containing from 2 to 9 carbon atoms and from one to four heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms. The heterocyclic groups include benzo-fused ring systems.
Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, 1H-pyrrolo[2,3- b]pyridinyl, 1 H-pyrazolo[3,4-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1 ,2-a]pyrimidinyl and furopyridinyl. The C4 to Cg heteroaryl groups may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
"C2-C9 cycloheteroalkyl", as used herein, means a non-aromatic, monocyclic, bicyclic, tricyclic, spirocyclic, or tetracyclic group having a total of from 4 to 13 atoms in its ring system, and containing from 2 to 9 carbon atoms and from 1 to 4 heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms. Furthermore, such C2 to C9 cycloheteroalkyl groups may contain an oxo substituent at any available atom that will result in a stable compound. For example, such a group may contain an oxo atom at an available carbon or nitrogen atom. Such a group may contain more than one oxo substituent if chemically feasible. In addition, it is to be understood that when such a C2 to C9 cycloheteroalkyl group contains a sulfur atom, said sulfur atom may be oxidized with one or two oxygen atoms to afford either a sulfoxide or sulfone. An example of a 4 membered cycloheteroalkyl group is azetidinyl (derived from azetidine). An example of a 5 membered cycloheteroalkyl group is pyrrolidinyl. An example of a 6 membered cycloheteroalkyl group is piperidinyl. An example of a 9 membered cycloheteroalkyl group is indolinyl. An example of a 10 membered cycloheteroalkyl group is 4H-quinolizinyl. Further examples of such C2 to C9 cycloheteroalkyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H- pyranyl, dioxanyl, 1 ,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3- azabicyclo[4.1.0]heptanyl, 3H-indolyl quinolizinyl, 3-oxopiperazinyl, 4-methylpiperazinyl, 4- ethylpiperazinyl, 1-oxo-2,8,diazaspiro[4.5]dec-8-yl, 1 H-pyrrolo[2,3-b]pyridin-2(3H)-one, 2,3-dihydro-1 H- pyrrolo[2,3-b]pyridinyl and 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidinyl.
The term "C3-C8 cycloalkyl group" means a saturated, monocyclic, fused, spirocyclic, or polycyclic ring structure having a total of from 3 to 8 carbon ring atoms. Examples of such groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, and adamantyl. The term "cyano" refers to a -C≡N group.
The term "substituted," means that the specified group or moiety bears one or more substituents. The term "unsubstituted," means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents. It is to be understood that in the compounds of the present invention when a group is said to be "unsubstituted," or is "substituted" with fewer groups than would fill the valencies of all the atoms in the compound, the remaining valencies on such a group are filled by hydrogen. For example, if a C6 aryl group, also called "phenyl" herein, is substituted with one additional substituent, one of ordinary skill in the art would understand that such a group has 4 open positions left on carbon atoms of the C6 aryl ring (6 initial positions, minus one to which the remainder of the compound of the present invention is bonded, minus an additional substituent, to leave 4). In such cases, the remaining 4 carbon atoms are each bound to one hydrogen atom to fill their valencies. Similarly, if a C6 aryl group in the present compounds is said to be "disubstituted," one of ordinary skill in the art would understand it to mean that the C6 aryl has 3 carbon atoms remaining that are unsubstituted. Those three unsubstituted carbon atoms are each bound to one hydrogen atom to fill their valencies.
The term "solvate," is used to describe a molecular complex between compounds of the present invention and solvent molecules. Examples of solvates include, but are not limited to, compounds of the invention in combination water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. The term "hydrate" can be used when said solvent is water. It is specifically contemplated that in the present invention one solvent molecule can be associated with one molecule of the compounds of the present invention, such as a hydrate. Furthermore, it is specifically contemplated that in the present invention, more than one solvent molecule may be associated with one molecule of the compounds of the present invention, such as a dihydrate. Additionally, it is specifically contemplated that in the present invention less than one solvent molecule may be associated with one molecule of the compounds of the present invention, such as a hemihydrate. Furthermore, solvates of the present invention are contemplated as solvates of compounds of the present invention that retain the biological effectiveness of the non-hydrate form of the compounds.
The term "pharmaceutically acceptable salt," as used herein, means a salt of a compound of the present invention that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable.
The term "pharmaceutically acceptable formulation," as used herein, means a combination of a compound of the invention, or a salt or solvate thereof, and a carrier, diluent, and/or excipient(s) that are compatible with a compound of the present invention, and is not deleterious to the recipient thereof. Pharmaceutical formulations can be prepared by procedures known to those of ordinary skill in the art. For example, the compounds of the present invention can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as povidone, sodium starch glycolate, sodium carboxymethylcellulose, agar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols. Final pharmaceutical forms may be pills, tablets, powders, lozenges, saches, cachets, or sterile packaged powders, and the like, depending on the type of excipient used. Additionally, it is specifically contemplated that pharmaceutically acceptable formulations of the present invention can contain more than one active ingredient. For example, such formulations may contain more than one compound according to the present invention. Alternatively, such formulations may contain one or more compounds of the present invention and one or more additional agents that reduce abnormal cell growth. The term "Raf-inhibiting amount" as used herein, refers to the amount of a compound of the present invention, or a salt or solvate thereof, required to inhibit the enzymatic activity of Raf in vivo, such as in a mammal, or in vitro. The amount of such compounds required to cause such inhibition can be determined without undue experimentation using methods described herein and those known to those of ordinary skill in the art.
The term "inhibiting Raf enzyme activity," as used herein, means decreasing the activity or functioning of the Raf enzyme either in vitro or in vivo, such as in a mammal, such as a human, by contacting the enzyme with a compound of the present invention.
The term "Raf as used herein means a-Raf, b-Raf, c-Raf, or mutants thereof, or any of the known Raf isoformic splice variants.
The term "therapeutically effective amount," as used herein, means an amount of a compound of the present invention, or a salt or solvate thereof, that, when administered to a mammal in need of such treatment, is sufficient to effect treatment, as defined herein. Thus, a therapeutically effective amount of a compound of the present invention, or a salt or solvate thereof, is a quantity sufficient to modulate or inhibit the activity of the Raf enzyme such that a disease condition that is mediated by activity of the Raf enzyme is reduced or alleviated.
The terms "treat", "treating", and "treatment" with reference to abnormal cell growth, or to any Raf mediated disease or condition, in a mammal, particularly a human, include: (i) preventing the disease or condition from occurring in a subject which may be predisposed to the condition, such that the treatment constitutes prophylactic treatment for the pathologic condition; (ii) modulating or inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) relieving and/or alleviating the disease or condition or the symptoms resulting from the disease or condition, e.g., relieving an inflammatory response without addressing the underlying disease or condition. With regard to abnormal cell growth, such as cancer, these terms simply mean that the life expectancy of an individual affected with abnormal cell growth will be increased or that one or more of the symptoms of the disease will be reduced.
Unless indicated otherwise, all references herein to the inventive compounds include references to salts, solvates, and complexes thereof, including polymorphs, stereoisomers, tautomers, and isotopically labeled versions thereof. For example, compounds of the present invention can be pharmaceutically acceptable salts and/or pharmaceutically acceptable solvates.
"Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition), including the abnormal growth of normal cells and the growth of abnormal cells. This includes, but is not limited to, the abnormal growth of: tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; any tumors that proliferate by receptor tyrosine kinases; any tumors that proliferate by aberrant serine/threonine kinase activation; benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs; tumors, both benign and malignant, expressing an activated Ras oncogene; tumor cells, both benign and malignant, in which the Ras protein is activated as a result of oncogenic mutation in another gene; benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs. Examples of such benign proliferative diseases are psoriasis, benign prostatic hypertrophy, human papilloma virus (HPV), and restinosis.
"Abnormal cell growth" also refers to and includes the abnormal growth of cells, both benign and malignant, resulting from activity of the enzyme farnesyl protein transferase. The terms "abnormal cell growth" and "hyperproliferative disorder" are used interchangeably in this application.
The term "stereoisomers" refers to compounds that have identical chemical constitution, but differ with regard to the arrangement of their atoms or groups in space. In particular, the term "enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another. The terms "racemic" or "racemic mixture," as used herein, refer to a 1 :1 mixture of enantiomers of a particular compound. The term "diastereomers", on the other hand, refers to the relationship between a pair of stereoisomers that comprise two or more asymmetric centers and are not mirror images of one another.
The compounds of the present invention are useful for modulating or inhibiting Raf activity. Accordingly, these compounds are useful for the prevention and/or treatment of disease states associated with abnormal cell growth such as cancer, alone or in combination with other anti-cancer agents. s / / s
In accordance with a convention used in the art, the symbol '' is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure. In accordance with another convention, in some structural formulae herein the
carbon atoms and their bound hydrogen atoms are not explicitly depicted, e.g.,
Figure imgf000027_0001
Figure imgf000027_0002
represents an ethyl group, and '' represents a cyclopentyl group, etc.
The compounds of the present invention may have asymmetric carbon atoms. The carbon- carbon bonds of the compounds of the present invention may be depicted herein using a solid line
( ), a solid wedge ( ~^^m ), or a dotted wedge ( "" ). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g. specific enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the compounds of the present invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture. Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art. See, e.g. "Stereochemistry of Organic Compounds" by E L Eliel (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
Where a compound of the invention contains an alkenyl or alkenylene group, geometric cisltrans (or Z/E) isomers are possible. Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') can occur. Examples of tautomerism include keto and enol tautomers. A single compound may exhibit more than one type of isomerism. Included within the scope of the invention are all stereoisomers, geometric isomers and tautomeric forms of the inventive compounds, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.
The compounds of the present invention may be administered as prodrugs. Thus certain derivatives of compounds of Formula (I), which may have little or no pharmacological activity themselves can, when administered to a mammal, be converted into a compound of Formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as "prodrugs". Prodrugs can, for example, be produced by replacing appropriate functionalities present in the compound of Formula (I) with certain moieties known to those skilled in the art. See, e.g. "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and "Bioreversible Carriers in Drug Design", Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are incorporated herein by reference in their entireties. Some examples of such prodrugs include: an ester moiety in the place of a carboxylic acid functional group; an ether moiety or an amide moiety in place of an alcohol functional group; and an amide moiety in place of a primary or secondary amino functional group. Further examples of replacement groups are known to those of skill in the art. See, e.g. "Design of Prodrugs" by H Bundgaard (Elsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety. It is also possible that certain compounds of Formula (I) may themselves act as prodrugs of other compounds of Formula (I).
Salts of the present invention can be prepared according to methods known to those of skill in the art. Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methyl benzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1 ,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, hexyne-1 ,6-dioate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate, methane- sulfonate, methylsulfate, monohydrogenphosphate, mucate, napsylate, naphthalene-1 -sulfonate, naphthalene-2-sulfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, phenylbutyrate, phenylpropionate, phthalate, phospate/diphosphate, polygalacturonate, propanesulfonate, propionate, propiolate, pyrophosphate, pyrosulfate, salicylate, stearate, subacetate, suberate, succinate, sulfate, sulfonate, sulfite, tannate, tartrate, teoclate, tosylate, triethiodode, and valerate salts.
The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially equivalent amount of the selected mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution. Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
If the inventive compound is a base, the desired salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystal or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulas.
The invention also includes isotopically-labeled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36CI, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulfur, such as 35S. Certain isotopically-labeled compounds of the invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, 3H, and carbon-14, 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
The compounds of the present invention may be formulated into pharmaceutical compositions as described below in any pharmaceutical form recognizable to the skilled artisan as being suitable. Pharmaceutical compositions of the invention comprise a therapeutically effective amount of at least one compound of the present invention and an inert, pharmaceutically acceptable carrier or diluent.
To treat or prevent diseases or conditions mediated by Raf, a pharmaceutical composition of the invention is administered in a suitable formulation prepared by combining a therapeutically effective amount (i.e., a Raf modulating, regulating, or inhibiting amount effective to achieve therapeutic efficacy) of at least one compound of the present invention (as an active ingredient) with one or more pharmaceutically suitable carriers, which may be selected, for example, from diluents, excipients and auxiliaries that facilitate processing of the active compounds into the final pharmaceutical preparations.
The pharmaceutical carriers employed may be either solid or liquid. Exemplary solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the inventive compositions may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Further additives or excipients may be added to achieve the desired formulation properties. For example, a bioavailability enhancer, such as Labrasol, Gelucire or the like, or formulator, such as CMC (carboxy-methylcellulose), PG (propyleneglycol), or PEG (polyethyleneglycol), may be added. Gelucire®, a semi-solid vehicle that protects active ingredients from light, moisture and oxidation, may be added, e.g., when preparing a capsule formulation.
If a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or formed into a troche or lozenge. The amount of solid carrier may vary, but generally will be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or non-aqueous liquid suspension. If a semi-solid carrier is used, the preparation may be in the form of hard and soft gelatin capsule formulations. The inventive compositions are prepared in unit-dosage form appropriate for the mode of administration, e.g. parenteral or oral administration. To obtain a stable water-soluble dose form, a salt of a compound of the present invention may be dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3 M solution of succinic acid or citric acid. If a soluble salt form is not available, the agent may be dissolved in a suitable co-solvent or combinations of co-solvents. Examples of suitable co-solvents include alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0 to 60% of the total volume. In an exemplary embodiment, a compound of the present invention is dissolved in DMSO and diluted with water. The composition may also be in the form of a solution of a salt form of the active ingredient in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
Proper formulation is dependent upon the route of administration selected. For injection, the agents of the compounds of the present invention may be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinyl pyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration intranasally or by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator and the like may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
In addition to the formulations described above, the compounds of the present invention may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. A pharmaceutical carrier for hydrophobic compounds is a co- solvent system comprising benzyl alcohol, a non-polar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be a VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the non-polar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD: 5W) contains VPD diluted 1 :1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. The proportions of a co- solvent system may be suitably varied without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity non- polar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity due to the toxic nature of DMSO. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
The pharmaceutical compositions also may comprise suitable solid- or gel-phase carriers or excipients. These carriers and excipients may provide marked improvement in the bioavailability of poorly soluble drugs. Examples of such carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Furthermore, additives or excipients such as Gelucire®, Capryol®, Labrafil®, Labrasol®, Lauroglycol®, Plurol®, Peceol® Transcutol® and the like may be used.
Further, the pharmaceutical composition may be incorporated into a skin patch for delivery of the drug directly onto the skin.
It will be appreciated that the actual dosages of the agents of this invention will vary according to the particular agent being used, the particular composition formulated, the mode of administration, and the particular site, host, and disease being treated. Those skilled in the art using conventional dosage- determination tests in view of the experimental data for a given compound may ascertain optimal dosages for a given set of conditions. For oral administration, an exemplary daily dose generally employed will be from about 0.001 to about 1000 mg/kg of body weight, with courses of treatment repeated at appropriate intervals. Furthermore, the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount of about 10 mg to about
2000 mg, or from about 10 mg to about 1500 mg, or from about 10 mg to about 1000 mg, or from about
10 mg to about 750 mg, or from about 10 mg to about 500 mg, or from about 25 mg to about 500 mg, or from about 50 to about 500 mg, or from about 100 mg to about 500mg.
Additionally, the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount from about 0.5 w/w% to about 95 w/w%, or from about 1 w/w% to about 95 w/w%, or from about 1 w/w% to about 75 w/w%, or from about 5 w/w% to about 75 w/w%, or from about 10 w/w% to about 75 w/w%, or from about 10 w/w% to about 50 w/w%.
The compounds of the present invention, or salts or solvates thereof, may be administered to a mammal suffering from abnormal cell growth, such as a human, either alone or as part of a pharmaceutically acceptable formulation, once a day, twice a day, three times a day, or four times a day, or even more frequently. Those of ordinary skill in the art will understand that with respect to the compounds of the present invention, the particular pharmaceutical formulation, the dosage, and the number of doses given per day to a mammal requiring such treatment, are all choices within the knowledge of one of ordinary skill in the art and can be determined without undue experimentation.
This invention also relates to a method for the treatment of abnormal cell growth in a mammal, including a human, comprising administering to said mammal an amount of a compound of the Formula (I), as defined above, or a salt or solvate thereof, that is effective in treating abnormal cell growth.
In one embodiment of this method, the abnormal cell growth is cancer, including, but not limited to, mesothelioma, hepatobilliary (hepatic and billiary duct), a primary or secondary CNS tumor, a primary or secondary brain tumor, lung cancer (NSCLC and SCLC), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, testicular cancer, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, non hodgkins's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, multiple myeloma, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma, or a combination of one or more of the foregoing cancers.
In one embodiment of the present invention the cancer is selected from lung cancer (NSCLC and SCLC), cancer of the head or neck, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, breast cancer, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, non hodgkins's lymphoma, spinal axis tumors, or a combination of one or more of the foregoing cancers.
In another embodiment of the present invention the cancer is selected from lung cancer (NSCLC and SCLC), ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, or a combination of one or more of the foregoing cancers.
In another embodiment of the present invention the cancer is selected from lung cancer (NSCLC and SCLC), ovarian cancer, colon cancer, rectal cancer, or a combination of one or more of the foregoing cancers.
In another embodiment of said method, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.
This invention also relates to a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of the present invention, or a salt or solvate thereof, that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
In one embodiment of the present invention the anti-tumor agent used in conjunction with a compound of the present invention and pharmaceutical compositions described herein is an anti- angiogenesis agent, kinase inhibitor, pan kinase inhibitor or growth factor inhibitor. Preferred pan kinase inhibitors include Sutent™ (sunitinib), described in U.S. Patent No. 6,573,293 (Pfizer, Inc, NY, USA). Anti-angiogenesis agents, include but are not limited to the following agents, such as EGF inhibitors, EGFR inhibitors, VEGF inhibitors, VEGFR inhibitors, TIE2 inhibitors, IGF1 R inhibitors, COX-II (cyclooxygenase II) inhibitors, MMP-2 (matrix-metalloprotienase 2) inhibitors, and MMP-9 (matrix- metalloprotienase 9) inhibitors. Preferred VEGF inhibitors, include for example, Avastin (bevacizumab), an anti-VEGF monoclonal antibody of Genentech, Inc. of South San Francisco, California. Additional VEGF inhibitors include CP-547,632 (Pfizer Inc., NY, USA), AG13736 (Pfizer Inc.), ZD-6474 (AstraZeneca), AEE788 (Novartis), AZD-2171 , VEGF Trap (Regeneron/Aventis), Vatalanib (also known as PTK-787, ZK-222584: Novartis & Schering AG), Macugen (pegaptanib octasodium, NX-1838, EYE-001 , Pfizer Inc./Gilead/Eyetech), IM862 (Cytran Inc. of Kirkland, Washington, USA); and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California) and combinations thereof.
VEGF inhibitors useful in the practice of the present invention are described in US Patent No. 6,534,524 and 6,235,764, both of which are incorporated in their entirety for all purposes. Additional VEGF inhibitors are described in, for example in WO 99/24440, in WO 95/21613, WO 99/61422, U.S. Patent 5,834,504, WO 98/50356, U.S. Patent 5,883,113 U.S. Patent 5,886,020, U.S. Patent 5,792,783, U.S. Patent 6,653,308, WO 99/10349, WO 97/32856, WO 97/22596, WO 98/54093, WO 98/02438, WO 99/16755, and WO 98/02437, all of which are herein incorporated by reference in their entirety. Other anti-angiogenic compounds include acitretin, fenretinide, thalidomide, zoledronic acid, angiostatin, aplidine, cilengtide, combretastatin A-4, endostatin, halofuginone, rebimastat, removab, Revlimid, squalamine, ukrain, Vitaxin and combinations thereof.
Other antiproliferative agents that may be used in combination with the compounds of the present invention include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr, including the compounds disclosed and claimed in the following: U.S. Patent 6,080,769; U.S. Patent 6,194,438; U.S. Patent 6,258,824; U.S. Patent 6,586447; U.S. Patent 6,071 ,935; U.S. Patent 6,495,564; and U.S. Patent 6,150,377; U.S. Patent 6,596,735; U.S. Patent 6,479,513; WO 01/40217; U.S. 2003-0166675. Each of the foregoing patents and patent applications is herein incorporated by reference in their entirety.
PDGRr inhibitors include but are not limited to those disclosed in international patent application publication numbers WO01/40217 and WO2004/020431 , the contents of which are incorporated in their entirety for all purposes. Preferred PDGFr inhibitors include Pfizer's CP-673,451 and CP-868,596 and its salts. Preferred GARF inhibitors include Pfizer's AG-2037 (pelitrexol and its salts). GARF inhibitors useful in the practice of the present invention are disclosed in US Patent No. 5,608,082 which is incorporated in its entirety for all purposes.
Examples of useful COX-II inhibitors which can be used in conjunction with a compound of Formula (I) and pharmaceutical compositions disclosed herein include CELEBREX™ (celecoxib), parecoxib, deracoxib, ABT-963, MK-663 (etoricoxib), COX-189 (Lumiracoxib), BMS 347070, RS 57067, NS-398, Bextra (valdecoxib), paracoxib, Vioxx (rofecoxib), SD-8381 , 4-Methyl-2-(3,4-dimethylphenyl)-1- (4-sulfamoyl-phenyl)-1 H-pyrrole, 2-(4-Ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)-1 H-pyrrole, T-614, JTE-522, S-2474, SVT-2016, CT-3, SC-58125 and Arcoxia (etoricoxib). Additonally, COX-II inhibitors are disclosed in U.S. Patent Applications US 2005-0148627 and US 2005-0148777, the contents of which are incorporated in their entirety for all purposes.
In a particular embodiment the anti-tumor agent is celecoxib (U.S. Patent No. 5,466,823), valdecoxib (U.S. Patent No. 5,633,272), parecoxib (U.S. Patent No. 5,932,598), deracoxib (U.S. Patent No. 5,521 ,207), SD-8381 (U.S. Patent No. 6,034,256, Example 175), ABT-963 (WO 2002/24719), rofecoxib (CAS No. 162011-90-7), MK-663 (or etoricoxib) as disclosed in WO 1998/03484, COX-189 (Lumiracoxib) as disclosed in WO 1999/11605, BMS-347070 (U.S. Patent 6,180,651 ), NS-398 (CAS 123653-11-2), RS 57067 (CAS 17932-91-3), 4-Methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoyl-phenyl)-1 H- pyrrole, 2-(4-Ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)-1 H-pyrrole, or meloxicam.
Other useful inhibitors as anti-tumor agents used in combination with a compound of the present invention and pharmaceutical compositions disclosed herein include aspirin, and non-steroidal anti- inflammatory drugs (NSAIDs) which inhibit the enzyme that makes prostaglandins (cyclooxygenase I and II), resulting in lower levels of prostaglandins, include but are not limited to the following, Salsalate (Amigesic), Diflunisal (Dolobid), lbuprofen (Motrin), Ketoprofen (Orudis), Nabumetone (Relafen), Piroxicam (Feldene), Naproxen (Aleve, Naprosyn), Diclofenac (Voltaren), lndomethacin (Indocin), Sulindac (Clinoril), Tolmetin (Tolectin), Etodolac (Lodine), Ketorolac (Toradol), Oxaprozin (Daypro) and combinations thereof. Preferred COX-I inhibitors include ibuprofen (Motrin), nuprin, naproxen (Aleve), indomethacin (Indocin), nabumetone (Relafen) and combinations thereof.
Targeted agents used in combination with a compound of the present invention and pharmaceutical compositions disclosed herein include EGFr inhibitors such as lressa (gefitinib, AstraZeneca), Tarceva (erlotinib or OSI-774, OSI Pharmaceuticals Inc.), Erbitux (cetuximab, lmclone Pharmaceuticals, Inc.), EMD-7200 (Merck AG), ABX-EGF (Amgen Inc. and Abgenix Inc.), HR3 (Cuban Government), IgA antibodies (University of Erlangen-Nuremberg), TP-38 (IVAX), EGFR fusion protein, EGF- vaccine, anti-EGFr immunoliposomes (Hermes Biosciences Inc.) and combinations thereof. Preferred EGFr inhibitors include lressa, Erbitux, Tarceva and combinations thereof. Other anti-tumor agents include those selected from pan erb receptor inhibitors or ErbB2 receptor inhibitors, such as CP-724,714 (Pfizer, Inc.), CI-1033 (canertinib, Pfizer, Inc.), Herceptin (trastuzumab, Genentech Inc.), Omitarg (2C4, pertuzumab, Genentech Inc.), TAK-165 (Takeda), GW-572016 (lonafamib, GlaxoSmithKline), GW-282974 (GlaxoSmithKline), EKB-569 (Wyeth), PKI-166 (Novartis), dHER2 (HER2 Vaccine, Corixa and GlaxoSmithKline), APC8024 (HER2 Vaccine, Dendreon), anti- HER2/neu bispecific antibody (Decof Cancer Center), B7.her2.lgG3 (Agensys), AS HER2 (Research Institute for Rad Biology & Medicine), trifunctional bispecific antibodies (University of Munich) and mAB AR-209 (Aronex Pharmaceuticals Inc) and mAB 2B-1 (Chiron) and combinations thereof.
Preferred erb selective anti-tumor agents include Herceptin, TAK-165, CP-724,714, ABX-EGF, HER3 and combinations thereof. Preferred pan erbb receptor inhibitors include GW572016, CI-1033, EKB-569, and Omitarg and combinations thereof.
Additional erbB2 inhibitors include those disclosed in WO 98/02434, WO 99/35146, WO 99/35132, WO 98/02437, WO 97/13760, WO 95/19970, U.S. Patent 5,587,458, and U.S. Patent 5,877,305, each of which is herein incorporated by reference in its entirety. ErbB2 receptor inhibitors useful in the present invention are also disclosed in U.S. Patents 6,465,449, and 6,284,764, and in WO 2001/98277 each of which are herein incorporated by reference in their entirety.
Additionally, other anti-tumor agents may be selected from the following agents, BAY-43-9006 (Onyx Pharmaceuticals Inc.), Genasense (augmerosen, Genta), Panitumumab (Abgenix/Amgen), Zevalin (Schering), Bexxar (Corixa/GlaxoSmithKline), Abarelix, Alimta, EPO 906 (Novartis), discodermolide (XAA- 296), ABT-510 (Abbott), Neovastat (Aeterna), enzastaurin (EIi Lilly), Combrestatin A4P (Oxigene), ZD-6126 (AstraZeneca), flavopiridol (Aventis), CYC-202 (Cyclacel), AVE-8062 (Aventis), DMXAA (Roche/Antisoma), Thymitaq (Eximias), Temodar (temozolomide, Schering Plough) and Revilimd (Celegene) and combinations thereof.
Other anti-tumor agents may be selected from the following agents, CyPat (cyproterone acetate), Histerelin (histrelin acetate), Plenaixis (abarelix depot), Atrasentan (ABT-627), Satraplatin (JM-216), thalomid (Thalidomide), Theratope, Temilifene (DPPE), ABI-007 (paclitaxel), Evista (raloxifene), Atamestane (Biomed-777), Xyotax (polyglutamate paclitaxel), Targetin (bexarotine) and combinations thereof.
Additionally, other anti-tumor agents may be selected from the following agents, Trizaone (tirapazamine), Aposyn (exisulind), Nevastat (AE-941 ), Ceplene (histamine dihydrochloride), Orathecin (rubitecan), Virulizin, Gastrimmune (G17DT), DX-8951f (exatecan mesylate), Onconase (ranpirnase), BEC2 (mitumoab), Xcytrin (motexafin gadolinium) and combinations thereof. Further anti-tumor agents may be selected from the following agents, CeaVac (CEA), NeuTrexin (trimetresate glucuronate) and combinations thereof. Additional anti-tumor agents may be selected from the following agents, OvaRex (oregovomab), Osidem (IDM-1 ), and combinations thereof. Additional anti-tumor agents may be selected from the following agents, Advexin (ING 201), Tirazone (tirapazamine), and combinations thereof. Additional anti-tumor agents may be selected from the following agents, RSR13 (efaproxiral), Cotara (1311 chTNT 1/b), NBI-3001 (IL-4) and combinations thereof. Additional anti-tumor agents may be selected from the following agents, Canvaxin, GMK vaccine, PEG lnteron A, Taxoprexin (DHA/paciltaxel), and combinations thereof.
Other anti-tumor agents include Pfizer's MEK1/2 inhibitor PD325901 , Array Biopharm's MEK inhibitor ARRY-142886, Bristol Myers' CDK2 inhibitor BMS-387,032, Pfizer's CDK inhibitor PD0332991 and AstraZeneca's AXD-5438, and combinations thereof.
Additionally, mTOR inhibitors may also be utilized such as CCI-779 (Wyeth) and rapamycin derivatives RAD001 (Novartis) and AP-23573 (Ariad), HDAC inhibitors, SAHA (Merck Inc./Aton Pharmaceuticals) and combinations thereof. Additional anti-tumor agents include aurora 2 inhibitor VX-680 (Vertex), and Chk1/2 inhibitor XL844 (Exilixis).
The following cytotoxic agents, e.g., one or more selected from the group consisting of epirubicin (Ellence), docetaxel (Taxotere), paclitaxel, Zinecard (dexrazoxane), rituximab (Rituxan) imatinib mesylate (Gleevec), and combinations thereof, may be used in combination with a compound of the present invention and pharmaceutical compositions disclosed herein. The invention also contemplates the use of the compounds of the present invention together with hormonal therapy, including but not limited to, exemestane (Aromasin, Pfizer Inc.), leuprorelin (Lupron or Leuplin, TAP/Abbott/Takeda), anastrozole (Arimidex, Astrazeneca), gosrelin (Zoladex, AstraZeneca), doxercalciferol, fadrozole, formestane, tamoxifen citrate (tamoxifen, Nolvadex, AstraZeneca), Casodex (AstraZeneca), Abarelix (Praecis), Trelstar, and combinations thereof. The invention also relates to the use of the compounds of the present invention together with hormonal therapy agents such as anti-estrogens including, but not limited to fulvestrant, toremifene, raloxifene, lasofoxifene, letrozole (Femara, Novartis), anti-androgens such as bicalutamide, flutamide, mifepristone, nilutamide, Casodex™(4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'- (trifluoromethyl) propionanilide, bicalutamide) and combinations thereof. Further, the invention provides a compound of the present invention alone or in combination with one or more supportive care products, e.g., a product selected from the group consisting of Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or combinations thereof.
Particularly preferred cytotoxic agents include Camptosar, Erbitux, Iressa, Gleevec, Taxotere and combinations thereof. The following topoisomerase I inhibitors may be utilized as anti-tumor agents: camptothecin; irinotecan HCI (Camptosar); edotecarin; orathecin (Supergen); exatecan (Daiichi); BN-80915 (Roche); and combinations thereof. Particularly preferred toposimerase Il inhibitors include epirubicin (Ellence).
Alkylating agents include, but are not limited to, nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, AMD-473, altretamine, AP-5280, apaziquone, brostallicin, bendamustine, carmustine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, mafosfamide, and mitolactol; platinum- coordinated alkylating compounds include but are not limited to, cisplatin, Paraplatin (carboplatin), eptaplatin, lobaplatin, nedaplatin, Eloxatin (oxaliplatin, Sanofi) or satrplatin and combinations thereof. Particularly preferred alkylating agents include Eloxatin (oxaliplatin). Antimetabolites include but are not limited to, methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil (5-FU) alone or in combination with leucovorin, tegafur, UFT, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1 , Alimta (premetrexed disodium, LY231514, MTA), Gemzar (gemcitabine, EIi Lilly), fludarabin, 5-azacitidine, capecitabine, cladribine, clofarabine, decitabine, eflornithine, ethynylcytidine, cytosine arabinoside, hydroxyurea, TS-1 , melphalan, nelarabine, nolatrexed, ocfosfate, disodium premetrexed, pentostatin, pelitrexol, raltitrexed, triapine, trimetrexate, vidarabine, vincristine, vinorelbine; or for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6- ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid and combinations thereof.
Antibiotics include intercalating antibiotics and include, but are not limited to: aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, bleomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, galarubicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, valrubicin, zinostatin and combinations thereof.
Plant derived anti-tumor substances include for example those selected from mitotic inhibitors, for example vinblastine, docetaxel (Taxotere), paclitaxel and combinations thereof. Cytotoxic topoisomerase inhibiting agents include one or more agents selected from the group consisting of aclarubicn, amonafide, belotecan, camptothecin, 10-hydroxycamptothecin, 9- aminocamptothecin, diflomotecan, irinotecan HCI (Camptosar), edotecarin, epirubicin (Ellence), etoposide, exatecan, gimatecan, lurtotecan, mitoxantrone, pirarubicin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan, and combinations thereof. Preferred cytotoxic topoisomerase inhibiting agents include one or more agents selected from the group consisting of camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, irinotecan HCI (Camptosar), edotecarin, epirubicin (Ellence), etoposide, SN-38, topotecan, and combinations thereof.
Immunologicals include interferons and numerous other immune enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon, alpha-2b, interferon beta, interferon gamma-1a, interferon gamma-1b (Actimmune), or interferon gamma-n1 and combinations thereof. Other agents include filgrastim, lentinan, sizofilan, TheraCys, ubenimex, WF-10, aldesleukin, alemtuzumab, BAM-002, dacarbazine, daclizumab, denileukin, gemtuzumab ozogamicin, ibritumomab, imiquimod, lenograstim, lentinan, melanoma vaccine (Corixa), molgramostim, OncoVAX-CL, sargramostim, tasonermin, tecleukin, thymalasin, tositumomab, Virulizin, 2-100, epratuzumab, mitumomab, oregovomab, pemtumomab (Y- muHMFGI ), Provenge (Dendreon) and combinations thereof.
Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of tissue cells to direct them to have antitumor activity. Such agents include krestin, lentinan, sizofiran, picibanil, ubenimex and combinations thereof. Other anticancer agents that can be used in combination with a compound of the present invention include alitretinoin, ampligen, atrasentan bexarotene, bortezomib. Bosentan, calcitriol, exisulind, finasteride.fotemustine, ibandronic acid, miltefosine, mitoxantrone, l-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pegaspargase, pentostatin, tazarotne, Telcyta (TLK-286, Telik Inc.), Velcade (bortemazib, Millenium), tretinoin, and combinations thereof.
Platinum-coordinated compounds include but are not limited to, cisplatin, carboplatin, nedaplatin, oxaliplatin, and combinations thereof.
Camptothecin derivatives include but are not limited to camptothecin, 10-hydroxycamptothecin, 9- aminocamptothecin, irinotecan, SN-38, edotecarin, topotecan and combinations thereof. Other antitumor agents include mitoxantrone, l-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, tretinoin and combinations thereof.
Anti-tumor agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocyte antigen 4) antibodies, and other agents capable of blocking CTLA4 may also be utilized, such as MDX-010 (Medarex) and CTLA4 compounds disclosed in U.S. Patent 6,682,736; and anti-proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors. Additionally, specific CTLA4 antibodies that can be used in combination with compounds of the present invention include those disclosed in U.S. Patents 6,682,736 and 6,682,736 both of which are herein incorporated by reference in their entirety.
Specific IGF1R antibodies that can be used in the combination methods of the present invention include those disclosed in WO 2002/053596, which is herein incorporated by reference in its entirety.
Specific CD40 antibodies that can be used in the present invention include those disclosed in WO 2003/040170 which is herein incorporated by reference in its entirety.
Gene therapy agents may also be employed as anti-tumor agents such as TNFerade (GeneVec), which express TNFalpha in response to radiotherapy. In one embodiment of the present invention statins may be used in combination with a compound of the present invention and pharmaceutical compositions thereof. Statins (HMG-CoA reducatase inhibitors) may be selected from the group consisting of Atorvastatin (Lipitor™, Pfizer Inc.), Pravastatin (Pravachol™, Bristol-Myers Squibb), Lovastatin (Mevacor™, Merck Inc.), Simvastatin (Zocor™, Merck Inc.), Fluvastatin (Lescol™, Novartis), Cerivastatin (Baycol™, Bayer), Rosuvastatin (Crestor™, AstraZeneca), Lovostatin and Niacin (Advicor™, Kos Pharmaceuticals), derivatives and combinations thereof.
In a preferred embodiment the statin is selected from the group consisting of Atovorstatin and Lovastatin, derivatives and combinations thereof. Other agents useful as anti-tumor agents include Caduet.
Methods of Preparation
Compounds of the present invention may be prepared using the reaction routes and synthetic schemes described below, employing the techniques available in the art using starting materials that are readily available. Those of skill in the art will understand that a variety of different reagents and protecting groups can be used to produce compounds of the invention according to the following general schemes. Accordingly, when terms such as "appropriate base", "appropriate catalyst", "appropriate oxidizing agent" and the like are used in the general schemes below, those of skill in the art will be able to recognize various alternatives that may be used.
The preparation of certain embodiments of the present invention is described in detail in the examples that follow the general schemes outlined herein. Those of ordinary skill in the art will recognize that the preparations described may be readily adapted to prepare other embodiments of the present invention. For example, the synthesis of non-exemplified compounds according to the invention may be performed by modifications apparent to those skilled in the art, e.g. by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. Alternatively, other reactions referred to herein or known in the art will be recognized as having adaptability for preparing other compounds of the invention.
In one general synthetic process, reactive intermediate compounds of the general structure represented by A and B are prepared according to Method A.
Method A
Figure imgf000041_0001
NaOH
Figure imgf000041_0002
Reaction of thiol (1) with a methylating agent in the presence of an appropriate base provides a thio-methyl ether of the formula 2. Treatment of 2 with oxalyl chloride leads to formation of an aldehyde represented by formula 3. Aldehyde 3 can be further transformed to an isoxazole represented by the formula 4 by treatment with hydroxylamine. Isoxazole 4 can be cleaved to aldehyde 5 by treatment with an appropriate base. Isoxazole 5 can be further transformed to a pyrazoline of the type in formula 6 by reaction with hydrazine. Pyrazole 6 can be converted to A by a 2 step sequence involving reaction with NaNO2 followed by reaction with iodide. Finally, A can be converted to B by reaction of the amine with dihydropyran. In another general synthetic process, compounds of the general structure represented by 11 are prepared according to Method B.
Method B
Figure imgf000042_0001
deprotection if needed
Figure imgf000042_0002
Figure imgf000042_0003
10 11
Reactive intermediate A can be prepared using Method A. The introduction of R1 in 7 can be accomplished by alkylation of A under conditions appropriate to couple a reactive agent (e.g. R1-l, R1-Br, R1-CI, R1-OMs, R1-OTs, or the like) therewith. The sulfur in 7 can be oxidized to sulfones 8 by an appropriate oxidizing agent, such as oxone. Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur by an amine to yield 9. Suzuki coupling of 9 with a suitable boronic acid (or boronic ester) in the presence of an appropriate catalyst, such as a palladium catalyst, produces intermediates 10. Finally, if compounds 10 require deprotection of any remaining protecting groups, such deprotection can be accomplished by various methods to produce compounds 11. These methods are known to those skilled in the art (e.g. see T. Greene and P. Wuts, "Protective Groups in Organic Synthesis", 3rd Edition 1999, John Wiley & Sons).
In another general synthetic process, compounds of the general structure represented by 10 and 11 cab also be prepared according to Method C.
Method C
Figure imgf000043_0001
Figure imgf000043_0002
Reactive intermediate B can be prepared using Method A. Suzuki coupling of B with a suitable boronic acid (or boronic ester) in the presence of an appropriate catalyst, such as a palladium catalyst, produces intermediates 12. The THP protected amine can be revealed by deprotection using various methods to produce amine 13. Methods for removing a THP from an amine are known to those skilled in the art (e.g. see T. Greene and P. Wuts, "Protective Groups in Organic Synthesis", 3rd Edition 1999, John Wiley & Sons). The introduction of R1 in 14 can be accomplished by alkylation of 13 under conditions appropriate to couple a reactive agent (e.g. R1-l, R1-Br, R1-CI, R1-OMs, R1-OTs, or the like) therewith. The sulfur in 14 can be oxidized to 15a and/or 15b by treatment with an appropriate oxidizing agent, such as ozone. Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur with an amine to yield 10. Finally, if compounds 10 require deprotection of any remaining protecting groups, such deprotection can be accomplished by various methods to produce compounds 11.
In another general synthetic process, compounds of the general structure represented by 20 and 22 are prepared according to Method D. Method D
oxidation
Figure imgf000044_0001
16
Figure imgf000044_0002
Reactive intermediate A can be prepared using Method A. The introduction of R1 in 7 can be accomplished by alkylation of A under conditions appropriate to couple a reactive agent (e.g. R1-l, R1-Br, R1-CI, R1-OMs, R1-OTs, or the like) therewith. Suzuki coupling of 7 with a suitable boronic acid (or boronic ester) in the presence of an appropriate catalyst, such as a palladium catalyst, produces intermediates 16. The sulfur in 16 can be oxidized to 17a and/or 17b by treatment with an appropriate oxidizing agent, such as ozone. Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur with an amine to yield 10. Finally, if compounds 10 require deprotection of any remaining protecting groups, such deprotection can be accomplished by various methods to produce compounds 11.
In another general synthetic process, compounds represented by 20 are prepared according to Method E.
Method E
Figure imgf000044_0003
Reactive intermediate A can be prepared using Method A. The introduction of R1 in 7 can be accomplished by alkylation of A under conditions appropriate to couple a reactive agent (e.g. R1-l, R1-Br, R1 -Cl, R1-OMs, R1-OTs, or the like) therewith. The sulfur in 7 can be oxidized to sulfones 8 by an appropriate oxidizing agent, such as oxone. Introduction of amines on the pyrimidine ring can be accomplished by displacement of the sulfur by an amine to yield 9. Suzuki coupling of 9 with a suitable boronic acid or boronic ester (where R is hydrogen or a suitable nitrogen protecting group) in the presence of an appropriate catalyst, such as a palladium catalyst, produces intermediates 18. If compounds 18 require deprotection of any remaining protecting groups, such deprotection can be accomplished by various methods to produce compounds 19. Finally, compounds 19 can be chlorinated under appropriate chlorinating conditions to provide compounds 20.
In another general synthetic process, compounds represented by 29 can be prepared according to Method F.
Method F
rv CH,
Figure imgf000045_0001
21 22 23
Ots
Figure imgf000045_0002
Figure imgf000045_0003
Chlorination,, if needed
Figure imgf000045_0004
27 28
Figure imgf000045_0005
Preparation of isoxazole 22 is accomplished via the Vilsmeier reaction on 4-methylpyrimidine or picoline followed by condensation with hydroxylamine. Ring-opening of the isoxazole with an appropriate base, such as aqueous sodium hydroxide, is followed by condensation with hydrazine to afford aminopyrazole 24. A Sandmeyer reaction converts the amino group to an iodopyrazole (25) and, prior to the Suzuki coupling reaction, the pyrazole NH is either alkylated with a preferred R3 group or protected with a protecting group to afford 26. A Suzuki coupling reaction of 26 with a suitable boronic acid or boronic ester completes the synthesis of compounds represented by 27. Deprotection and/or chlorination can be accomplished if necessary as previously described to afford 28 or 29 respectively.
In another general synthetic process, compounds represented by 40 can be prepared according to Method G.
Method G
Figure imgf000046_0001
Compound 31 can be prepared from 5-bromo-1 H-pyrrolo[2,3-b]pyridine 30 by reaction with carbon monoxide in the presence of an appropriate catalyst followed by protection of the pyrrole nitrogen if needed. Compound 31 can be condensed with 2-methyl-6-(methylthio)pyridine by reaction in the presence of an appropriate base, such as LIHMDS, to provide 32. The imine in compound 33 can be installed by reaction of 32 with DMF-DMA to give 33. Compound 33 can be cyclized to form pyrazole 34 by reaction with hydrazine. The pyrazole NH is either alkylated with a preferred R1 group or protected with a protecting group to afford 35. If the 1-position on the 1 H-pyrrolo[2,3-b]pyridine group is H, protection with a suitable protecting group, such as besylate, is accomplished by known means to provide 36. Oxone oxidation of the methylthio group provides 37. The SO2Me group can be displaced by heating with a suitable amine to provide 38. Deprotection and/or chlorination can be accomplished if necessary as previously described to afford 39 or 40 respectively.
In another general synthetic process, compounds represented by 51 can be prepared according to Method H.
Method H , HCI
Figure imgf000047_0001
41 42 43
Figure imgf000047_0002
44 45 46
Figure imgf000047_0003
Compound 41 can be protected at the pyrrole nitrogen, if necessary, to provide compound 42. A coupling reaction in the presence of an appropriate tin reagent and an appropriate catalyst can provide a compound of the type 43. Compound 43 can then be converted into ketone 44 by heating with an appropriate acid, followed by condensation with DMF-DMA to form enone 45. Compound 45 can be cyclized to form pyrazole 46 by reaction with hydrazine. The pyrazole NH is either alkylated with a preferred R1 group or protected with a protecting group to afford 47. A Suzuki coupling reaction of 49 with a suitable boronic acid or boronic ester completes the synthesis of compounds represented by 50. Deprotection and/or chlorination can be accomplished if necessary as previously described to afford compounds of the type 51.
In another general synthetic process, compounds represented by 56 can be prepared according to Method I.
Method I
Figure imgf000048_0001
Stille couplιng
Figure imgf000048_0002
Figure imgf000048_0003
54 55 56
A halide of the type 52 can be reacted with an anhydride 53 to form compound 54. Compound 54 can be coupled, via Stille coupling, to an appropriate intermediate 55 to provide products of the type 56. intermediate 55 can be prepared by reacting a compound of the type 9 with an appropriate tin reagent.
Examples
The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. Examples B-1 to 1-1 provide detailed synthetic steps for preparing several specific compounds of the present invention. Table 1 shows analytical data for compounds that were prepared using the methods described herein. Table 2 and Table 3 show the biochemical and cellular data for the compounds of Examples B-1 to I-2. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted or indicated by the structural formula or chemical name, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted or indicated by the structural formula or chemical name, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
Various starting materials and other reagents were purchased from commercial suppliers, such as Aldrich Chemical Company, and used without further purification, unless indicated otherwise. 1H-NMR spectra were recorded on a Bruker instrument operating either at 300 MHz, or 400 MHz and 13C-NMR spectra were recorded operating at 75 MHz. NMR spectra were obtained as CDCI3 solutions (reported in ppm), using chloroform as the reference standard (7.25 ppm and 77.00 ppm) or DMSO-D6 (2.50 ppm and 39.51 ppm) or CD3OD (3.4 ppm and 4.8 ppm and 49.3 ppm), or internal tetramethylsilane (0.00 ppm) when appropriate. Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz). The following abbreviations may be used herein: Et2θ (diethyl ether); DMF (Λ/,Λ/-dimethylformamide); THF (tetrahydrofuran); DHP (dihydropyran), DCM (dichloro-methane); DMA (dimethyl acetal); DBU (1 ,8- Diazabicyclo[5.4.0]undec-7-ene); LiHMDS or LHMDS (lithium hexamethyldisilazide); TBME (terf-butyl methyl ether); LDA (Lithium Diisopropylamide); DMSO (dimethylsulfoxide); MeOH (methanol); EtOH (ethanol); EtOAc (ethyl acetate); THF (tetrahydrofuran); Ac (acetyl); Me (methyl); Et (ethyl); and Ph (phenyl).
Boronic acid and boronic ester intermediates:
All boronic acids and esters are either commercially available, known in the literature or may be prepared according to the following methods. One of skill in the art would readily appreciate that the following are merely set forth as exemplary boronic acid and boronic ester intermediates, and that these exemplary intermediates can be modified according to known methods to provide a wide variety of possible boronic acids and borinic esters that could be used to prepare compounds within the scope of the claims.
Preparation of 1 -(tert-butoxycarbonyl)-3-methyl-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-ylboronic acid (64)
Figure imgf000049_0001
Step i:
Figure imgf000049_0002
57 58
To a stirred suspension of compound 57 (74 g, .0.80 mol) in CCI4 (2 L) was added NBS (296 g, 1.68 mol) portionwise at 2O0C. After addition, the mixture was stirred at room temperature for 24 hours. TLC (EtOAc/Hexane 1 :4) showed the material was consumed completely. The reaction mixture was filtered and the filtrate was concentrated in vacuum to give compound 58 (170 g, 83.7%) as a brown solid.
Step 2:
Figure imgf000050_0001
A mixture of compound 58 (172 g, 0.688 mol) and benzensulfonyl chloride (182.2 g, 1.032 mol) in pyridine (1000 mL) was heated to 850C with stirring for 72 hours. TLC (EtOAc/Hexane 1 :4) showed most of material was consumed. Pyridine was removed in vacuum. The residue was suspended in EtOAc and filtered. The filtrate was concentrated in vacuum and the residue was purified by column chromatography (EtOAc/Petrol ether fromi :40 to 1 :4) to give compound 59 (65 g, 24.2%) as a yellow solid. Step 3:
Figure imgf000050_0002
A mixture of compound 3 (45 g, 0.115 mol), 3-bromopropene (45.7 g, 0.38 mol) and K2CO3 (63.5 g, 0.46 mol) in dry DMF (900 mL) was heated to 110 ? with stirring for 16 h under N2 atmosphere. The mixture was cooled to room temperature, poured into water (1.5 L) and extracted with EtOAc (1 L) three times. The combined organic solvent was washed with water (1 L) three times, brine (1 L), dried over Na2SO4 and concentrated in vacuum. The residue was washed with petrol ether to give compound 60 (39 g, 78.9%) as a yellow solid. Step 4:
Figure imgf000050_0003
A mixture of compound 60 (47.4 g, 0.11 mol), tris(trimethylsilyl)silane (54.7 g, 0.22 mol) and azobisisobutyronitrile (AIBN, 18 g, 0.11 mol) in dry toluene (1000 mL) was heated to 80-830C for 3 hours under N2. TLC (EtOAc/Hexane 1:4) showed the material was consumed completely. The mixture was concentrated in vacuum. The residue was purified by column chromatography (EtOAc/petroleum ether from 1 :100 to 1 :30) to give the product (10 g, 25.8%) as a white solid. Step 5:
Figure imgf000051_0001
To a stirring solution of compound 61 (800 mg, 2.26 mmol) in 10 ml_ of boiling ethanol was added 2.0 mL aqueous solution of sodium hydroxide (127 mg, 2.26 mmol) dropwise. The reaction was sealed then heated in 100 degree oil bath and monitored with LCMS. Reaction stayed homogenous and 5 hours later, LCMS indicated reaction complete. Reaction was concentrated to dryness under high vacuum. The resulting residual was stirred in 100 mL DCM overnight and then filtered. LCMS indicated the solids contained no desired material while the filtrate was concentrated to give compound 62 (458 mg, 94.9%) as an off-white solid. Step 6:
Figure imgf000051_0002
A mix of compound 62 (458 mg, 2.15 mmol), Boc-anhydride (563 mg, 2.58 mmol) and 1 ,1-diisopropyl ethylamine (305 mg, 2.37 mmol) in 50 mL of anhydrous THF was refluxed for 2 hrs under nitrogen. TLC indicated reaction complete. Reaction was concentrated to dryness under reduced pressure. The residual was partitioned between EtOAc (100 mL) and brine (50 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated and then loaded onto a 150 g silica gel column. Elution with 0-5% EtOAc in DCM gave compound 63 (460 mg, 68.4%) as an off-white solid. Step 7:
Figure imgf000051_0003
To a stirring solution of compound 63 (460 mg, 1.47 mmol) and triisopropylborate (691 mg, 3.67 mmol) in 25 mL dry THF at -78 ° C was added Butyl lithium solution (2.5 M in hexanes, 1.47 mL, 3.67 mmol) dropwise under nitrogen. The reaction was stirred at -78 ° C and monitored with LCMS. 2hr later, LCMS indicated reaction complete. Reaction was quenched with 25 mL water and concentrated under reduced pressure to a total volume of about 15 mL. The residual was washed with ether (2X10 mL) and the aqueous later was placed in an ice-water bath. While stirring, 10 N HCI aqueous solution was carefully added dropwise until pH = 7. Filtration and washing with ice-water (3x5 mL) gave compound 64 (208 mg, 51%) as a white solid.
Preparation of 3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-ylboronic acid (67)
Figure imgf000052_0001
65 66 67
To a solution of compound 65 (4 g, 20 mmol) in MeCN (500 mL) and AcOH (100 mL) was added Select-Fluor (10 g, 30 mmol), the resulting mixture was heated at 8O0C overnight. TLC (Petroleum ether/EtOAc 5:1 ) indicated the complete consumption of compound 1. The reaction mixture was concentrated in vacuo, the residue was purified via flash chromatography on silica gel (Petroleum ether/EtOAc 10:1 ) to yield 66 (0.64 g, 13%) as an off-white solid. 1 H NMR: (400 MHz, CDCI3): δ 9.434 (brs, 1 H), 8.311-8.280 (m, 1 H), 8.056-8.023 (m, 1H), 7.191 (s, 1 H), 7.086-7.053 (m, 1 H). To a stirring solution of compound 66 (250 mg, 1.16 mmol) and triisopropylborate (547 mg, 2.91 mmol) in 3 mL dry THF at -780C was added Butyl lithium solution (2.5 M in hexanes, 1.16 mL, 2.91 mmol) dropwise under nitrogen. The reaction was stirred at -780C and monitored with LCMS. 2hr later, LCMS indicated 1 :1 :1 SM:desbromo-SM:desired product. Another 1.16 mL of n-butyl lithium was added. Reaction was stirred under nitrogen at -780C for another hour, quenched with 3 mL water and concentrated under reduced pressure to a total volume of about 3 mL. The residual was washed with ether (2X10 mL) and the aqueous later was placed in an ice-water bath. While stirring, 10 N HCI aqueous solution was carefully added dropwise until pH = 7.A milky suspension was formed and filtration did not produce significant amount of solids. The mixture was concentrated on high vacuum to give compound 67 (200 mg, 95%) as an off-white solid.
Preparation of 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ylboronic acid (69)
HO
Figure imgf000052_0002
68 69
A mixture of compound 68 (1.0 g, 4.7 mmol), bis(pinacolato)diboron (1.79 g, 7.04 mmol), potassium acetate (1.38 g, 14.1 mmol), and catalyst PdCI2(dppf) (68.7 mg, 0.094 mmol) in 20 ml DMF was heated in 100 degree microwave reactor for 60 min. LCMS indicated reaction was 20% complete.
Reaction was heated in 100 degree oil bath overnight, LCMS indicated reaction complete. Reaction was concentrated to dryness under high vacuum. Then the residual was partitioned between EtOAc (50 mL) and brine (30 ml_). The aqueous layer was extracted with EtOAc (3x25 ml_)). The combined organic layers were dried over sodium sulfate and then concentrated to a residual. Flush chromatography on silica gel with 2-5% MeOH in DCM gave an off-white powder as desired product (803 mg, 66%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.35 (s, 12 H) 3.56 (s, 2 H) 7.85 (s, 1 H) 8.54 (s, 1 H).
Preparation of 71
Figure imgf000053_0001
70
71
To a solution of compound 70 (40 g, 99.2 mmol) and (JPrO)3B (59.2 mL, 258 mmol) in 2-methyl- tetrahydro-furan (496 mL) (496 mL) cooled to -6O0C was added n-BuLi (108 mL, 267 mmol). The reaction mixture was stirred at -6O0C for 2 hours. TLC (Petroleum ether: EtOAc = 2:1 ) indicated the reaction was complete. The reaction mixture was quenched by the addition of water (500 mL), and concentrated under reduced pressure. The aqueous solution was acidified with cone. HCI to pH =5. The precipitate was filtered and the filter cake was washed with ice water to get the product (60 g, yield: 82.19%) as a white solid.
Preparation of 6-acetamido-4-methylpyridin-3-ylboronic acid (73)
Figure imgf000053_0002
To a stirred solution of the 2-acetylamino-5-bromo-4-methylpyridine (1.858g, 8.11 mmol) and boron isopropoxide (7.5ml, 32.4mmol) in THF cooled to -780C was added n-butyl lithium (4.1 ml, 41mmol of 10 M soln in hexanes). After 1 hour at -780C, the reaction was quenched with water and warmed to room temperature. THF was removed under reduced pressure. Added 2N HCI until a precipitate developed. Filtered and washed with a minimal amount of water and dried under vacuum. 1 H NMR (400 MHz, DMSO-d6) d ppm 2.07 (s, 3 H) 2.39 (s, 3 H) 7.84 (s, 1 H) 8.09 (s, 2 H) 8.33 (s, 1 H) 10.36 (s, 1 H).
Preparation of 3-Methyl-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 H-pyrazolo[3,4-b]pyridine (79)
Figure imgf000054_0001
74
75 76 77
Figure imgf000054_0002
Step 1 :
Figure imgf000054_0003
74
75
To a stirred solution of diisopropyl-amine (50 g, 0.5 mol) in dry THF (1000 mL) was added dropwise n- BuLi (200 mL, 0.5 mol) at -780C under N2 atmosphere. After the addition, the resulting mixture was allowed to warm up to O0C, maintained for 10 minutes and cooled to -780C again. A mixture of compound 74 (80 g, 0.455 mol) in THF (1000 mL) was added dropwise to the LDA solution at -780C under N2 atmosphere. After the addition, the reaction mixture was stirred at -780C for 30 minutes. Then formic acid ethyl ester (50 g, 0.68 mol) was added portionwise to the mixture at -780C. After 2 minutes, the resulting mixture was quenched with a solution of 10% citric acid in THF (400 mL) at -780C. The mixture was allowed to warmed up to room temperature and poured into H2O (500 mL), extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4 and concentrated in vacuo to give compound 75 (92 g, 99%) as a yellow solid. Step 2:
Figure imgf000054_0004
75 76
To a solution of compound 75 (92 g, 0.455 mol) in THF (2 L) was added MeMgBr (230 mL, 0.69 mol) portionwise at -780C under N2 atmosphere. After the addition, the reaction mixture was warmed up to room temperature and stirred at room temperature overnight. TLC (petroleum ether/EtOAc 10:1 ) indicated the complete consumption of compound 2. The reaction mixture was quenched with saturated NH4CI (300 mL), extracted with EtOAc (1 L x 3). The combined organic layers were washed with brine (1 L), dried over Na2SO4 and concentrated in vacuo to give crude compound 76, which was purified by column chromatography (silica gel, petroleum ether/EtOAc 10:1 ) to yield pure compound 76 (85 g, 85%) as yellow oil.
Step 3:
Figure imgf000055_0001
76 77
To a mixture of PDC (365 g, 0.97 mol) and CH2CI2 (2000 mL) was added compound 76 (85 g, 0.39 mol) at O0C. After the addition, the reaction mixture was warmed up to room temperature and stirred overnight. TLC (petroleum ether/EtOAc 10:1) indicated the reaction was complete. The resulting mixture was filtered and the filtrate was concentrated in vacuo to give crude compound 77, which was purified by column chromatography (silica gel, petroleum ether/EtOAc 50:1 ) to yield pure compound 77 (56 g, 63%) as a yellow solid. Step 4:
Figure imgf000055_0002
77 78
To a solution of compound 77 (40 g, 0.184 mol) in ethanol (300 mL) was added NH2NH2 (27.6 g, 0.553 mol) at room temperature. After the addition, the reaction mixture was refluxed overnight. TLC (petroleum ether/EtOAc 3:1 ) indicated the complete consumption of compound 77. The reaction mixture was allowed to cool to room temperature, and concentrated in vacuo to give crude product, which was purified by column chromatography (silica gel, petroleum ether/EtOAc from 10:1 to 3:1 ) to yield 78 (30 g, 76%) as a white solid. Step 5:
Figure imgf000055_0003
A suspension of 5-bromo-3-methyl-1 H-pyrazolo[3,4-b]pyridine (1.04 g, 40.987mmol), bis(pinacolato)diboron (1.93 g, 7.45 mmol, 1.5 Eq), potassium acetate (1.66 g, 16.9mmol, 3.04 Eq) and [1 ,1 '-Bis(diphenylphophino)ferrocene]palladium(ll) dichloride dichlroromethane complex (1 :1 )(0.109 g, 0.149 mmol, 0.03 Eq) in 10 mL anhydrous DMSO was degassed by bubbling nitrogen via needle for 20 min. The reaction was then heated in a microwave reactor at 15O0C for 2 hours (high absorption). After this time, the reaction was cooled to room temperature and then poured in H2O (200 ML) and EtOAc (200 mL). The bi-layered mixture was filtered through compacted celite and the filtrate was dried over Na2SO4 and concentrated in vacuo to a dark oil which was purified by biotage column (Si 40 + M); packed with hexanes; eluted with EtOAc/Hexanes (0-30%: 900 mL, 30-30%: 900 ml_, 30-50%; 900 mL, 27 mL fractions) to afford the product as a white solid (1.19 g, 93.6%). 1 H NMR (300 MHz, CHLOROFORM-d) δ ppm 8.88 (d, J=1.51 Hz, 1 H) 8.51 (d, J=1.51 Hz, 1 H) 2.60 (s, 3 H) 1.30 (s, 6 H) 1.25 (s, 6 H); NH not seen in NMR. Preparation of compound 85
Ste
Figure imgf000056_0001
80 81
To a solution of compound 80 (28 g, 0.2 mol) and NaOH (40 g, 1 mol) in dioxane (450 mL) and H2O (150 mL) at 7O0C was bubbled through CF2HCI gas over 20 min and stirred at the same temperature overnight. TLC (Petroleum ether/EtOAc 2:1) indicated the reaction was done. The reaction mixture was extracted with Et2O (3*300 mL) and the combined organic layers were concentrated in vacuo to give crude product, which was purified via column chromatography (petroleum ether/EtOAc 30:1-3:1 ) to afford compound 81 (20 g, 52.6%) as yellow liquid. Step 2:
Figure imgf000056_0002
81
82 To a solution of compound 81 (10 g, 0.0526 mol) in EtOH/H2O (2:1 , 450 mL) was added iron powder (15 g, 0.268 mol), followed by addition of NH4CI (7.5 g, 0.14 mol) in one portion. After addition, the mixture was refluxed overnight. TLC (Petroleum ether/EtOAc 2:1 ) indicated the reaction was complete. EtOH was removed under reduced pressure and the residue was partitioned between saturated aq. NaHCO3 (500 mL) and EtOAc (400 mL). The aqueous layer was extracted with EtOAc (2*300 mL) and the combined organic layers were washed with brine (2*300 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give compound 82 (8.0 g, 95%) as a yellow solid. Step 3:
Figure imgf000057_0001
82 M 83
To a solution of compound 82 (8.0 g, 0.05 mol) in AcOH (100 mL) was added dropwise bromine (8.0 g, 0.05 mol) at room temperature. The mixture was stirred at ambient temperature for 2 h. TLC (Petroleum ether/EtOAc 2:1 ) indicated the reaction was complete. AcOH was removed under reduced pressure and the residue was partitioned between saturated aq. NaHCO3 (200 mL) and EtOAc (200 mL). The aqueous layer was extracted with EtOAc (200 mL) and the combined organic layers were washed with brine (2*300 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give crude product, which was purified via column chromatography (petroleum ether/EtOAc 8:1-4:1 ) to afford the product 83 (10.9 g, 91.2%) as a yellow solid. Step 4:
Figure imgf000057_0002
84
To a solution of compound 83 ( 5.61 g, 23.5 mmol) in acetonitrile (250 mL) was added di-terf- butyl-dicarbonate (15.65 g, 71.71 mmol), 4-(dimethylamino)pyridine (571 mg, 4.67 mmol), and triethyl amine (16.5 mL, 118 mmol). The mixture was stirred at room temperature for 1.5 hours, then concentrated to dryness and purified by silica gel chromatography (eluting with 10-25% ethyl acetate in hexanes gradient) to give compound 84 (9.53 g, 92.4%) as a white solid. Step 5:
Figure imgf000058_0001
84 85
A solution of bromide 84 (3.30 g, 7.51 mmol) and triisopropyl borate (4.4 mL, 19 mmol) in 2- methyl-tetrahydrofuran (38 mL) was cooled to -65°C (bath temperature) in a dry ice/isopropanol bath. A solution of 2.5 M n-butyllithium in hexanes (7.5 mL, 19 mmol) was added dropwise over 3 minutes. After
5 stirring at -650C for 3 hours, deionized water (10 mL) was added, the cooling bath removed, and the solution allowed to warm to room temperature. Volatiles were removed in vacuo, and the aqueous residue extracted with diethyl ether (2 x 20 mL). These extracts were discarded. The aqueous layer was cooled to 00C, acidified with 6N HCI to pH 3, and extracted with diethyl ether (20 mL), followed by ethyl acetate (20 mL). The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to give
IO crude boronic acid 85 as a yellow foam (2.27 g, -60% purity, 75% uncorrected yield). This crude boronic acid was used in Suzuki reactions without further purification.
Example A-1 : Preparation of reactive intermediates A and B according to Method A Preparation of 4-methyl-2-(methylthio)pyrimidine (2)
MeI
Y K2Co3 γ
SH S^
I5 1 2
A mixture of compound 4-methylpyrimidine-2-thiol (500 g, 3.05 mol), iodomethane (611 g, 4.27 mol) and K2CO3 (915 g, 6.71 mol) in THF (4 L) was stirred at room temperature for 18 h. The suspension was filtered and the solid was washed with ether (500 mL *2). The filtrate was concentrated and dried in vacuum to give compound 2 (380 g, 89.2%) as a yellow oil. !0
Preparation of (E)-3-hydroxy-2-(2-(methylthio)pyrimidin-4-yl)acrylaldehyde (3)
Figure imgf000058_0002
2 3
To a solution of DMF (114.9 g, 1.57 mol) in CHCI3 (800 mL) was added dropwise oxalyl chloride
(190.3 g, 1.50 mol) at O0C. After the addition, the resulting mixture was warmed at 3O0C and stirred for 1
!5 h. The mixture was allowed to cool to O0C and 4-methyl-2-(methylthio)pyrimidine (2) (100 g, 0.714 mol) was added to the mixture. The resulting mixture was warmed to 4O0C and stirred for 16 h. The reaction mixture was cooled to room temperature and filtered. The cake was washed with CHCI3 (150 mLχ3) and dried in vacuum to give (E)-3-hydroxy-2-(2-(methylthio)pyrimidin-4-yl)acrylaldehyde (3) (342.0 g, 100%) as a yellow solid.
Preparation of 4-(isoxazol-4-yl)-2-(methylthio)pyrimidine (4)
Figure imgf000059_0001
To a solution of hydroxylamine hydrochloride (60.0 g, 0.86 mol) in water (2 L) was added (E)-3- hydroxy-2-(2-(methylthio)pyrimidin-4-yl)acrylaldehyde (3) (342 g, 0.714 mol) in portions. After the addition, the mixture was heated at 6O0C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature and the solution was adjusted to pH about 4 by addition of 10% aq. NaHCO3. The resulting precipitate was filtered, washed with water (200 ml_χ2) and dried in vacuum to give 4-(isoxazol-4-yl)-2- (methylthio)pyrimidine (4) (112 g, 81.2%) as a yellow solid.
Preparation of 2-(2-(methylthio)pyrimidin-4-yl)-3-oxopropanenitrile (5)
Figure imgf000059_0002
4 5
A mixture of 4-(isoxazol-4-yl)-2-(methylthio)pyrimidine (4) (112.0 g, 0.58 mol) and NaOH (23.2 g) in water/MeOH (350 mL/350 mL) was stirred at 7O0C for 6 h. The reaction mixture was allowed to cool to room temperature and adjusted to pH 3.5 with citric acid. The resulting precipitate was filtered, washed with water (500 ml_χ3) and ethyl ether (500 ml_χ3). Then the precipitate was dried in vacuum to give 2-(2-
(methylthio)pyrimidin-4-yl)-3-oxopropanenitrile (5) (100 g, 89.3%) as a yellow solid.
Preparation of 4-(2-(methylthio)pyrimidin-4-yl)-1 H-pyrazol-5-amine (6)
Figure imgf000059_0003
5 6
A suspension of 2-(2-(methylthio)pyrimidin-4-yl)-3-oxopropanenitrile (5) (100 g, 0.52 mol), NH2NH2 H2O '(85%, 31.2 g, 0.62 mol) and cone. HCI (60 mL) in ethanol (1 L) was stirred at reflux for 5 h. After cooled to room temperature, the mixture was concentrated in vacuum, and the residue was washed with ether (200 ml_χ3) and suspended in H2O (200 mL). The mixture was basified with saturated aq. Na2CO3 to pH 9 and the precipitate was collected. The solid was washed with H2O (100 mL*3) and ether (200 ml_χ3), then dried in vacuum to give 4-(2-(methylthio)pyrimidin-4-yl)-1 H-pyrazol-5-amine (6) (56.8 g, 51.8%) as a yellow solid. 1H NMR (400 MHz, CD3CN): δ 8.295 (d, 1 H), 7.826 (s, 1 H), 7.101 (d, 2H), 5.800 (d, 1 H), 2.586 (s, 3H).
Preparation of 4-(5-iodo-1 H-pyrazol-4-yl)-2-(methylthio)pyrimidine (A)
Figure imgf000060_0001
A solution of NaNO2 (20.0 g, 0.29 mol) in water (150 mL) was poured into a solution of 4-(2- (methylthio)pyrimidin-4-yl)-1 H-pyrazol-5-amine 6 (50.0 g, 0.24 mol) in a mixture of glacial acetic acid (400 mL) and water (100 mL) at -3 0C. The temperature increased to -1 0C. Concentrated H2SO4 (10 mL) was added to the obtained solution, and a solution of potassium iodide (120.0 g, 1.2 mol.) and I2 (123.0 g, 10.48 mol) in water (200 mL) was added dropwise. The obtained solution was heated to 50 0C for 2 h, and the mixture was neutralized with aqueous ammonia. Excess iodine was treated with Na2S2O3. The precipitate was filtered, and the filtrate was extracted with ethyl acetate. The organic layer was evaporated, and the residue was purified by chromatography (THF: EtOAc = 4:1 ) to give 4-(5-iodo-1 H- pyrazol-4-yl)-2-(methylthio)pyrimidine (A) (42.2 g, 54.6%) as a yellow solid. 1H NMR (400 MHz, DMSO): δ 8.55 (d, 1 H), 8.35 (s, 1H), 7.55 (d, 1 H), 2.55 (s, 3H).
Example A-2: Procedure for preparation of 4-(5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)- 2-(methy!thio)pyrimidine (B)
Figure imgf000060_0002
A mixture of compound A (75.0 g, 0.235 mmol), DHP (39.6 g, 0.471 mmol) and TsOH H2O (7.5 g) was stirred at 6O0C for 6 h. The mixture was cooled to room temperature and concentrated. The residue was purified by chromatography (EtOAc: petroleum ether = 1 :15) to give 4-(5-iodo-1-(tetrahydro-2H-pyran-2- yl)-1 H-pyrazol-4-yl)-2-(methylthio)pyrimidine (B) (57.6 g, 60.8%). 1 H NMR (400 MHz, CDCI3): δ 8.495 (d, 1 H), 8.400 (s, 1 H), 7.638 (d, 1 H), 5.398 (m, 1 H), 4.070 (m, 1 H), 3.732 (m, 1 H), 2.796 (s, 3H), 2.110 (m, 3H), 1.900 (m, 3H).
Example B-1 : Preparation of of (2S)-1-(4-(1-isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol- 4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1 )
Figure imgf000061_0001
Figure imgf000061_0002
Preparation of 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)-2-methylthio)pyrimidine (B-1-1)
Figure imgf000061_0003
A B-1-1
A mixture of 4-(5-iodo-1 H-pyrazol-4-yl)-2-(methylthio)pyrimidine (A) (31.8 g, 0.1 mol), 2-iodo-propane (85 g, 50 ml_, 0.5 mol) and K2CO3 (16.5 g, 0.12 mol) in DMF (500 mL) was heated at 40~50°C overnight. When TLC (hexane: EtOAc = 15:1 ) showed the reaction was complete, DMF was evaporated under reduced pressure. The residue was taken up with EtOAc (400 mL). The mixture was washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude product, which was purified via prep. HPLC to give pure 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)-2-(methylthio)pyhmidine B-1-1 (17 g, 47.2%) as a yellow oil.
Preparation of 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidine (B-1 -2)
Figure imgf000062_0001
B-1-1 B-1-2
To a solution of 4-(3-iodo-1-isopropyl-1 H-pyrazol-4-yl)-2-(methylthio)pyrimidine B-1-1 (15.5 g, 43 mmol) in THF (350 mL) and water (350 mL) was added oxone (39.6 g, 64.6 mmol) at 0 - 50C. After the addition, the mixture was stirred at rt overnight. TLC (hexane: EtOAc = 5:1 ) showed the reaction was complete, EtOAc (500 mL) was added. The organic layer was separated, washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give 4-(3-iodo-1-isopropyl-1 H-pyrazol-4-yl)-2-(methylsulfonyl)pyrirnidine B-1- 2 (16 g, 94.9%).
Preparation of (2S)-1 -(4-(3-iodo-1 -isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1 - 3)
Figure imgf000062_0002
A mixture of 4-(3-iodo-1 -isopropyl-1 H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidine B-1-2 (16 g, 40 mmol) and (s)-1-amino-propan-2-ol (9 g, 122 mmol) in THF (160 mL) was heated to reflux overnight. TLC (hexane: EtOAc = 2:1 ) showed the reaction was complete, EtOAc (80 mL) and saturated aqueous NaCI (80 mL) were added to the mixture, and the layers were separated. The organic layer was separated, washed with saturated aqueous NaCI (30 mL), dried over Na2SO4 and concentrated to give (2S)-1-(4-(3- iodo-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1-3) (15 g, 96.9%) as a brown oil.
Preparation of of (2S)-1-(4-(1-isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin- 2-ylamino)propan-2-ol (B-1 )
Figure imgf000063_0001
To a solution of (2S)-1-(4-(3-iodo-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol B-1-3 (0.312 g, 0.8 mmol) in toluene (15 mL) and EtOH (5 mL) were added 1 H-pyrrolo[2,3-b]pyridin-5-ylboronic acid (0.40 g, 1.6 mmol) and 2 N aq. Na2CO3 (1.24 mL), and the resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (0.23 g, 0.2 mmol) was added and the mixture was degassed again. The resulting mixture was heated to reflux and stirred overnight. The organic layer was separated and concentrated, the residue was purified via prep HPLC to afford (2S)-1-(4-(1-isopropyl-3-(1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyhmidin-2-ylamino)propan-2-ol (B-1 ) (0.260 g, 66.19%) as a yellow solid.
Example B-2: Preparation of (2S)-1-(4-(1-isopropyl-3-(6-(methylamino)pyridin-3-yl)-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-2)
H2N N
Figure imgf000063_0002
B-2-1 B-2-2 B-2-3
Figure imgf000063_0003
B-2
Preparation of N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2 -amine B-2-3
Figure imgf000063_0004
B-2-2 B-2-3 To a solution of 5-bromo-N-methylpyridin-2-amine B-2-2 (1 g, 5.37 mmol) in DMF (30 mL) were added KOAc (1.58 g, 16.1 mmol) and bis(pinacolato)diboron (2 g, 8.06 mmol). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J2CI2 (0.5 g, 0.53 mmol) was added and the mixture was degassed again. The reaction was heated to 80-900C and stirred overnight. DMF was removed under reduced pressure. The residue was dissolved with EtOAc (40 mL), washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude N-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyridin-2-amine B-2-3 (2.3 g), which was used directly in next step.
Preparation of (2S)-1-(4-(1-isopropyl-3-(6-(methylamino)pyridin-3-yl)-1H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol (B-2)
Figure imgf000064_0001
B-2
To a solution of (2S)-1-(4-(3-iodo-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (9) (0.65 g, 1.68 mmol) in toluene (20 mL) and EtOH (7 mL) were added N-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)pyridin-2-amine 12 (1.44 g, 3.36 mmol in theory) and 2 N Na2CO3 aq. (2.5 mL). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (0.2 g, 0.168 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. The mixture was cooled. The organic layer was separated and concentrated. The residue was purified by prep. HPLC to afford (2S)-1-(4-(1-isopropyl-3-(6-(methylamino)pyridin-3-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol (B-2) (0.020 g, 3.2%) as a light yellow solid.
Example B-3: Preparation of (2S)-1-(4-(3-(6-amino-5-methylpyridin-3-yl)-1-isopropyl-1H-pyrazoI-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-3)
H2
Figure imgf000064_0002
Preparation of 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (B-3-2)
Figure imgf000065_0001
B-3-1 B-3-2
To a solution of 5-bromo-3-methylpyridin-2-amine B-3-1 (2 g, 11 mmol) in DMF (70 mL) were added KOAc (3.2 g, 33 mmol) and bis(pinacolato)diboron (4.1 g, 16 mmol). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3)2CI2 (1 g, 1.1 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. The mixture was poured into water (100 mL). The mixture was extracted with EtOAc (50 ml_χ3), the organic layer was washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude 3-methyl-5-(4,4,5,5-tetramethyl-1 )3,2- dioxaborolan-2-yl)pyridin-2-amine (B-3-2) (3.5 g), which was used directly in next step.
Preparation of (2S)-1 -(4-(3-(6-amino-5-methylpyridin-3-yl)-1 -isopropyl-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol (B-3)
Figure imgf000065_0002
To a solution of (2S)-1-(4-(3-iodo-1 -isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1-3) (0.52 g, 1.34 mmol) in toluene (21 mL) and EtOH (7 mL) were added 3-methyl-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine (B-3-2) (1 g, 2.68 mmol in theory) and 2 N aq. Na2CO3 (2 mL). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (0.15 g, 0.134 mmol) was added and the mixture was degassed again. The reaction was heated to 80-900C and stirred overnight. The mixture was cooled. The organic layer was separated and concentrated. The residue was purified by prep. HPLC to afford (2S)-1 -(4-(3-(6-amino-5-methylpyridin-3-yl)-1 -isopropyl-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol (B-3) (0.057 g, 11.6%) as a light yellow solid.
Example B-4: Preparation of (2S)-1-(4-(1 -isopropyl-3-(5-methyl-6-(methylamino)pyridin-3-y I)-IH- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-4)
Figure imgf000066_0001
B-4-1 B-4-2 B-4-3
Figure imgf000066_0002
Preparation of 5-bromo-N,3-dimethylpyridin-2-amine (B-4-2)
Figure imgf000066_0003
B-4-1 B-4-2 To a solution of 5-bromo-3-methylpyridin-2-amine (B-4-1) (3.7 g, 0.02 mol) in THF (50 ml_) was added portionwise NaH (0.8 g, 0.02 mol) at 00C. After the addition, the mixture was stirred at room temperature for about 0.5 hr, and cooled to 00C again, lodomethane (2.8 g, 0.02 mol) was added slowly. The resulting mixture was allowed to rise to room temperature and stirred for 1 hr. TLC (EtOAc: Petroleum ether = 1 :4) showed that the reaction was complete. Saturated aqueous NaCI (10 mL) and EtOAc (10 ml.) were added. The organic layer was concentrated and the residue was purified via a silica gel column eluted with EtOAc/Petroleum ether (1 :8) to give 5-bromo-N,3-dimethylpyridin-2-amine (B-4-2) (2.3 g, 57.8%) as a white solid.
Preparation of N,3-dimethyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine (B-4-3)
Figure imgf000066_0004
B-4-2 B-4-3
To a solution of give 5-bromo-N,3-dimethylpyridin-2-amine (B-4-2) (2.3 g, 11.4 mmol) in DMF (70 mL) were added KOAc (3.35 g, 34.2 mmol) and bis(pinacolato)diboron (4.34 g, 17.1 mmol). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J2CI2 (1 g, 1.1 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. The mixture was poured into saturated aqueous NaCI (80 ml_). The mixture was extracted with EtOAc (50 ml_χ3). The organic layer was washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude N,3-dimethyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine (B-4-3) (3.5 g), which was not purified and used directly in next step.
Preparation of (2S)-1 -(4-(1 -isopropyl-3-(5-methyl-6-(methylamino)pyridin-3-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-4)
Figure imgf000067_0001
To a solution of (2S)-1-(4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1-3) (1 g, 2.58 mmol) in toluene (30 mL) and EtOH (10 mL) were added N,3-dimethyl-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine (B-4-3) (2 g, 6.3 mmol in theory) and 2 N aq. Na2CO3 (4 mL). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3)4 (0.3 g, 0.26 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. MS showed the reaction was complete and the mixture was cooled. The organic layer was separated and concentrated. The residue was purified by prep. HPLC to afford (2S)-1-(4-(1-isopropyl-3-(5-methyl-6- (methylamino)pyridin-3-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-4) (0.167 g, 16.98%) as a light yellow solid.
Example B-5: Preparation of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-5)
Figure imgf000068_0001
B-5-1 B-5-2 B-5-3
Figure imgf000068_0002
Preparation of 5-bromo-3-iodopyridin-2-amine (B-5-2)
Figure imgf000068_0003
B-5-1 B-5-2
A mixture of 5-bromopyridin-2-amine (B-5-1) (50 g, 0.29 mol), I2 (59 g, 0.233 mol) and NaIO4 (24.8 g, 0.116 mol) in DMF 600 mL) was stirred at 80-900C overnight. TLC (EtOAc: Petroleum ether = 1 :5) showed that the reaction was complete. The mixture was concentrated under reduced pressure to remove the solvent. The residue was dissolved in EtOAc (500 mL), washed with water (100 mL) and saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated to give crude compound B-5-2, which was purified via a silica gel column eluted with EtOAc/Petroleum ether (12:1 ) to afford pure 5-bromo-3- iodopyridin-2-amine (B-5-2) (35 g, 40.5%) as an orange solid.
Preparation of 5-bromo-3-methyl-2-(trimethylsilyl)-1 H-pyrrolo[2,3-b]pyridine (B-5-3)
Figure imgf000068_0004
B-5-2 B-5-3
To a solution of 5-bromo-3-iodopyridin-2-amine (B-5-2) (30 g, 0.1 mol) in DMF (600 mL) were added KOAc (29.4 g, 0.3 mol) and LiCI (4.25 g, 0.1 mol). After the mixture was degassed under N2 for 3 times, Pd(OAc)2 (2.24 g, 0.01 mol) was added, and the mixture was degassed again. Then trimethyl-prop-1-ynyl- silane (56 g, 0.5 mol) was added. The resulting mixture was heated to 80-1000C for 2 days. TLC (EtOAc: Petroleum ether = 1 :5) showed that the reaction was complete. Excess DMF was removed under reduced pressure. The residue was dissolved in EtOAc (500 mL), washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude product, which was purified via a silica gel column chromatography (100-200) (Petroleum ether, then EtOAc: Petroleum ether = 1 :10) to give 5-bromo-3- methyl-2-(trimethylsilyl)-1 H-pyrrolo[2,3-b]pyridine (B-5-3) (not pure, 5 g, 17.7%) as a brown oil.
Preparation of 5-bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine (B-5-4)
Figure imgf000069_0001
To a solution of 5-bromo-3-methyl-2-(trimethylsilyl)-1 H-pyrrolo[2,3-b]pyridin (B-5-3) (5 g, 17.8 mmol) in THF (50 mL) was added 2 N HCI (20 ml_). The mixture was stirred at reflux overnight. HPLC showed the reaction was complete. After the mixture was concentrated under reduced pressure, the residue was dissolved in aqueous NaHCO3 (20 mL) and extracted with EtOAc (10 mLχ3). The organic layer was washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude product, which was purified via prep. HPLC to give 5-bromo-3-methyl-1 H-pyrrolo[2,3-b]pyridine (B-5-4) (2 g, 53.2%) as a pale solid.
Preparation of 3-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine (B-5-5)
Figure imgf000069_0002
To a solution of 5-bromo-3-methyl-1 H-pyrrolo[2,3-b]pyridine (B-5-4) (0.5 g, 2.37 mmol) in DMF (150 mL) were added KOAc (0.7 g, 7.11 mmol) and bis(pinacolato)diboron (0.72 g, 2.84 mmol). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J2CI2 (0.2 g, 0.237 mmol) was added and the mixture was degassed again. The reaction was heated to 80-900C and stirred overnight. The mixture was poured into water (30 mL), extracted with EtOAc (15 mLχ3). The organic layer was washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude 3-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine (B-5-5) (0.7 g), which was used directly in next step.
Preparation of (2S)-1 -(4-(1 -isopropyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-5)
Figure imgf000070_0001
To a solution of (2S)-1-(4-(3-iodo-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (9) (0.65 g, 1.7 mmol) in toluene (21 mL) and EtOH (7 mL) were added 3-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine 21 (0.7 g, 2.37 mmol in theory) and 2 N aq. Na2CO3 (2.5 mL). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (0.19 g, 0.17 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. The mixture was cooled. The organic layer was separated and concentrated. The residue was purified by prep. HPLC to afford (2S)-1-(4-(1-isopropyl-3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-5) (0.150 mg, 16.2%) as a white solid.
Example B-6: Preparation of (2S)-1-(4-(3-(2,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-6)
Figure imgf000070_0002
B-6-1 B-6-2 B-6-3
Figure imgf000070_0003
Preparation of 5-bromo-3-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (B-6-2)
Figure imgf000070_0004
B-6-1 B-6-2 To a solution of 5-bromo-3-methyl-1 H-pyrrolo[2,3-b]pyridine (B-6-1 ) (1.2 g, 5.68 mmol) in THF (30 mL) was added NaH (0.34 g, 8.5 mmol) under N2 at O0C, 4-bromophenylsulfonyl chloride (1.2 g, 6.8 mmol) was added 30 minutes later. The mixture was stirred at room temperature for 1.5 h. TLC (Petroleum ether: EtOAc = 5:1 ) showed that the reaction was complete. Saturated aqueous NaCI (10 mL) was added, and the mixture was filtered to give 5-bromo-3-methyl-1-(phenylsulfonyl)-1 H-pyrrolo[2,3-b]pyridine (B-6-2) (0.8 g) as a white solid. The organic layer was separated from the filtrate, concentrated to 8 mL, then filtered to give 5-bromo-1-(4-bromophenylsulfonyl)-3-methyl-1 H-pyrrolo[2,3-b]pyridine (0.5 g). Two batches were combined to give 5-bromo-3-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (B-6-2) (1.3 g, 65.2%) as a white solid.
Preparation of 5-bromo-2,3-dimethyl-1 -(phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridine (B-6-3)
Figure imgf000071_0001
B-6-2 B-6-3
To a suspension of 5-bromo-1-(4-bromophenylsulfonyl)-3-methyl-1 H-pyrrolo[2,3-b]pyridine (B-6-2) (0.9 g, 2.56 mmol) in THF (20 mL) was added dropwise LDA (15 mL, 0.2 M in THF) at -40 0C. The mixture was stirred at -10 - -20 0C for 0.5 hour. Methyl iodide (0.55 g 3.84 mmol) was added dropwise at -40 ~ -30 °C.
The reaction was stirred at room temperature overnight. LC-MS showed that the reaction was complete. Saturated aqueous NaCI (10 mL) and EtOAc (10 mL) were added into the mixture. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated to give 5-bromo-2,3-dimethyl-1- (phenylsulfonyl)-1 H-pyrrolo[2,3-b]pyridine (B-6-3) (0.9 g, 96.3%, containing some starting material (B-6-2) as a light yellow solid.
Preparation of 5-bromo-2,3-dimethyl-1H-pyrrolo[2,3-b]pyridine (B-6-4)
Figure imgf000071_0002
B-6-3 β-6-4
To a suspension of 5-bromo-2,3-dimethyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (B-6-3) (0.9 g, 2.5 mmol) in THF (30 mL) and MeOH (30 mL) was added aq. NaOH (20%, 19 mL) at room temperature. The mixture was heated to reflux overnight. TLC (Petroleum ether: EtOAc = 5:1 ) showed the reaction was complete. After the solvent was removed under reduced pressure, water (20 mL) and CH2CI2 (20 mL) were added into the mixture. The organic layer was separated, dried over anhydrous Na2SO4. The mixture was concentrated to give crude mixture which was purified via prep. HPLC to afford 5-bromo-2,3- dimethyl-1 H-pyrrolo[2,3-b]pyridine (B-6-4) (0.4 g, 72.4%) as a white solid.
Preparation of 2,3-dimethyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrrolo[2,3- b]pyridine (B-6-5)
Figure imgf000072_0001
B-6-4 B-6-5
To a solution of 5-bromo-2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridine (B-6-4) (0.4 g, 1.77 mmol) in DMF (30 mL) were added KOAc (0.52 g, 5.3 mmol) and bis(pinacolato)diboron (0.68 g, 2.65 mmol), and the resulting mixture was degassed under N2 for 2 minutes. Then Pd(dppf)2CI2 (40 mg, 0.049 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. The mixture was poured into water (100 mL), extracted with EtOAc (40 mL><3). The organic layer was washed with saturated aqueous NaCI, dried over Na2SO4 and concentrated to give crude 2,3-dimethyl-5- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine (B-6-5) (0.7 g), which was not purified and used directly in next step.
Preparation of (2S)-1 -(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-6)
Figure imgf000072_0002
To a solution of (2S)-1-(4-(3-iodo-1 -isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-1-3) (0.34 g, 0.885 mmol) in toluene (30 mL) and EtOH (10 mL) were added 2,3-dimethyl-5-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (B-6-5) (0.7 g, 1.77 mmol in theory) and 2 N aq. Na2CO3 (1.3 mL). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (68 mg, 0.058 mmol) was added and the mixture was degassed again. The reaction was heated to 80~90°C and stirred overnight. The mixture was cooled. The organic layer was separated and concentrated. The residue was purified by prep. HPLC to afford (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-6) (0.170 mg, 23.6%) as a light yellow solid.
Example B-7: Preparation of (2S)-1-(4-(1-isopropyl-3-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-7)
Figure imgf000073_0001
B-7-4 B-7-5 B-7-6
Figure imgf000073_0002
Preparation of 5-bromo-3-(2-(trimethylsilyl)ethynyl)pyridin-2-amine (B-7-2)
Figure imgf000073_0003
To a solution of 5-bromo-3-iodopyridin-2-amine (B-7-1) (20 g, 66.9 mmol) in Et3N (200 ml_) was added CuI (1.27 g, 6.69 mmol), and the resulting mixture was degassed with N2 for 2 minutes. Then Pd(PPh3J2CI2 (1 4g, 20.1 mmol) was added and the mixture was degassed again. Then ethynyl-trimethyl-silane (7.2 g, 73.6 mmol) was added dropwise into the mixture at O0C. The mixture was stirred at room temperature for 4 hours. TLC (Petroleum ether: EtOAc = 5:1 ) showed that the reaction was complete. The mixture was evaporated under reduced pressure to give crude mixture which was purified via a silica gel column eluted with petroleum ether/EtOAc (20:1 ) to afford 5-bromo-3-(2-(trimethylsilyl)ethynyl)pyridin-2-amine (B-7-2) (1O g, 55.6%) as a white solid.
Preparation of 5-bromo-1H-pyrrolo[2,3-b]pyridine (B-7-3)
Figure imgf000074_0001
To a solution of 5-bromo-3-(2-(trimethylsilyl)ethynyl)pyridin-2-amine (B-7-2) (9.5 g, 35.3 mmol) in f-BuOH (100 mL) was added f-BuOK (10.5 g, 141.3 mmol). The mixture was stirred at 80 °C for 20 hours. TLC
(Petroleum ether: EtOAc = 5:1 ) showed that the reaction was complete. Then the mixture was cooled to room temperature. Concentrated hydrochoric acid (50 mL) was added to the mixture. Then the mixture was heated to reflux for 8 hours. TLC (Petroleum ether: EtOAc = 5:1 ) showed that the reaction was complete. The mixture was cooled to room temperature and poured into water (100 mL). The mixture was filtered through a bed of Celite. The filtrate was diluted with water (100 mL) and made basic by the addition of 50% sodium hydroxide. The mixture was extracted with EtOAc (150 mL*3). The organic layers were washed with water (100 mL) and saturated sodium chloride (100 mL), dried over sodium sulfate and concentrated under reduced pressure to afford 5-bromo-1 H-pyrrolo[2,3-b]pyridine (B-7-3) (6.2 g, 88.6%) as a light yellow solid.
Preparation of 5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (B-7-4)
Figure imgf000074_0002
B-7-3 B-7-4
To a suspension of 5-bromo-1 H-pyrrolo[2,3-b]pyridine (B-7-3) (6.2 g, 0.031 mol) in THF (100 mL) was added NaH (1.51 g, 0.037 mol) under N2. BsCI (3.58 g, 0.035mol) was added 30 minutes later. The mixture was stirred at room temperature overnight. TLC (Petroleum ether: EtOAc = 5:1 ) showed that the reaction was complete. Water (200 mL) and EtOAc (50 mLχ3) were added into the mixture. The organic layer was separated and concentrated to give 5-bromo-1-(phenylsulfonyl)-1 H-pyrrolo[2,3-b]pyridine (B-7- 4) (10 g, 94.3%) as a light yellow solid. 1HNMR (400 MHz, CDCI3): δ 8.465 (s, 1 H), 8.141-8.114 (d, 2H), 7.905 (s, 1 H), 7.679-7.669 (d, 1 H), 7.586-7.529 (m, 1 H), 7.430-7.351 (2, 1 H), 6.458-6.475 (d, 1 H).
Preparation of 5-bromo-1-(4-bromophenylsulfonyl)-2-methyl-1 H-pyrrolo[2,3-b]pyridine (B-7-5)
Figure imgf000075_0001
B-7-4 B-7-5
To a suspension of 5-bromo-1-(phenylsulfonyl)-1 H-pyrrolo[2,3-b]pyridine (B-7-4) (10 g, 0.03 mol) in THF (50 mL) was added dropwise LDA (200 mL, 0.21 M in THF) at -78 0C. The mixture was stirred at -78 °C for one hour. Then MeI (5.2 g 0.038 mol) was added dropwise at -78 0C. The reaction was stirred at -7O0C for
3 hours, and then stirred at room temperature overnight. LC-MS showed the reaction was complete. Water (200 mL) and EtOAc (100 mLχ3) were added into the mixture. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated to give 5-bromo-1-(4-bromophenylsulfonyl)-2-methyl-1 H- pyrrolo[2,3-b]pyridine (B-7-5) (6 g, 57.7%) as a light yellow solid. 1HNMR (400 MHz, CDCI3): δ 8.390- 8.385 (d, 1 H), 8.176-8.145 (d, 2H), 7.828-7.823 (d, 1 H), 7.613-7.576 (t, 1 H), 7.517-7.479 (t, 2H), 6.254 (s, 1 H), 2.748 (s, 3H).
Preparation of 5-bromo-2-methyl-1H-pyrrolo[2,3-b]pyridine (B-7-6)
Br VVΛ_ aq. NaOH "'V^VA kN^N THF ' ^/V
Bs H
B-7-5 B-7-6
To a suspension of 5-bromo-1-(4-bromophenylsulfonyl)-2-methyl-1 H-pyrrolo[2,3-b]pyridine (B-7-5) (4 g, 11.4 mmol) in THF (20 mL) was added aq. NaOH (20 mL) at room temperature. The mixture was heated to reflux overnight. LC-MS showed the reaction was complete. Water (100 mL) and EtOAc (50 mLχ3) were added into the mixture. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated to give crude mixture which was purified via prep. HPLC to afford 5-bromo-2-methyl-1 H- pyrrolo[2,3-b]pyridine (B-7-6) (1.2 g, 50.2%) as a white solid.
Preparation of 2-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine (B-7-7)
Figure imgf000075_0002
B-7-7 To a mixture of 5-bromo-2-methyl-1 H-pyrrolo[2,3-b]pyridine (B-7-6) (0.5 g, 2.4 mmol), bis(pinacolato)diboror) (1.2 g, 4.7 mmol) and KOAc (0.7 g, 7.1 mmol) in DMF (50 mL) was added Pd(dppf)2CI2 (0.05 g, 0.06 mmol). The mixture was degassed under N2 for 2 minutes. Then the mixture was stirred at 8O0C overnight. TLC (CH2CI2: MeOH = 20:1 ) showed that the reaction was complete. Water (50 mL) and EtOAc (50 mL><3) were added into the mixture. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated to give crude 2-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)-1 H-pyrrolo[2,3-b]pyridine (B-7-7) (1.8 g) as a brown solid.
Preparation of (2S)-1 -(4-(1 -isopropyl-3-(2-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-7)
Figure imgf000076_0001
To a suspension of 2-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine (B- 7-7) (1.8 g, 2.3 mmol in the theory) and (2S)-1-(4-(3-iodo-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol (B-1-3) (0.45 g, 1.2mmol) in toluene/EtOH (3:1 , 50 mL) was added aq. Na2CO3 (1.7 mL, 2 M). The mixture was degassed under N2 for 2 minutes, Pd(PPh3J4 (0.05g, 0.042 mmol) was added into the mixture and degassed again. The mixture was stirred at 8O0C for 30 hours. TLC (CH2CI2: MeOH = 20:1 ) showed that the reaction was complete. Water (50 mL) and EtOAc (50 mL*3) were added into the mixture. The organic layer was separated, dried over anhydrous Na2SO4. and concentrated to give crude product which was purified via prep. HPLC to afford (2S)-1-(4-(1-isopropyl-3-(2-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-7) (0.169 g, 18.6%) as a white solid.
Example B-8: Preparation of (2S)-1-(4-(1-isopropyl-3-(2-methylimidazo[1,2-a]pyrimidin-6-yl)-1H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-8)
Figure imgf000077_0001
Preparation of 6-bromo-2-methylimidazo[1,2-a]pyrimidine (B-8-2).
Figure imgf000077_0002
B-8-1 B-8-2
To a solution of 5-bromopyrimidin-2-amine (170.0 g, 0.98 mol) in /-PrOH (2 L) and DMF (500 mL) was added 1-chloropropan-2-one (606 g, 6.53 mol), then the mixture was stirred at 1000C for 16 h. TLC (petroleum ether: ethyl acetate = 1 :2) showed the reaction was complete. The reaction mixture was quenched by Na2CO3 and filtered. The filtrate was concentrated in vacuo and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1 ) to afford compound B-8-2 (10.0 g, 4.8%) as a yellow solid.
Preparation of 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyrimidine (B- 8-3).
Figure imgf000077_0003
To a solution of compound B-8-3 (3.0 g, 14.1 mmol) in DMF (60 mL) were added bis(pinacolato)diboron (3.95 g, 15.5 mmol) and KOAc (4.58 g, 42.4 mmol). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3)2CI2 (0.20 g, 0.23 mmol) was added and the mixture was degassed again. The resulting mixture was heated to 9O0C and stirred overnight. TLC (petroleum ether: ethyl acetate = 1 :2) showed the reaction was complete. The mixture was then cooled and filtered. The filtrate was concentrated to give crude compound B-8-3 (2.5 g) as a brown solid, which was used for the next step without purification. Preparation of (2S)-1 -(4-(1 -isopropyl-3-(2-methylimidazo[1 ,2-a]pyrimidin-6-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-8).
Figure imgf000078_0001
To a solution of compound B-1-3 (2.0 g, 5.16 mmol) in toluene (48 ml_) and EtOH (16 mL) were added crude compound B-8-3 (2.5 g, 9.26 mmol) and 2 N aqueous Na2CO3 (7.5 mL). The resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (0.41 g, 0.36 mmol) was added and the mixture was degassed again. The resulting mixture was heated to 8O0C and stirred overnight. TLC (CH2CL2: MeOH = 20:1 ) showed the reaction was complete, the mixture was cooled. The organic layer was separated and concentrated, and the residue was purified by prep. HPLC to give compound (B-8) (60 mg, 1.6%) as a yellow solid.
Example B-9: Preparation of (2S)-1-(4-(3-(2,3-dimethylimidazo[1,2-a]pyrimidin-6-yl)-1-isopropyl-1H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol PF-04597926. (B-9)
Preparation of 3-bromobutan-2-one (B-9-2).
Figure imgf000078_0002
B-9-1 B-9-2
To a solution of butan-2-one (60Og, 8.3 mol) in AcOH (500 mL) and H2O (2 L) was added dropwise bromine (360 g, 8.5 mol) at 7O0C for 3 h, then the resulting mixture was stirred at room temperature for 14 hrs. TLC (petroleum ether: ethyl acetate = 5:1 ) showed the reaction was complete. Water (1 L) was added, and the organic layer was separated. The aqueous layer was extracted with EtOAc (400 mL*3). The combined organic layers were dried over Na2SO4 and concentrated. The residue was distilled to yield compound B-9-2 (400 g, 70%) as a yellow oil.
Preparation of 6-bromo-2,3-dimethylimidazo[1,2-a]pyrimidine (B-9-4).
Figure imgf000078_0003
To a solution of 5-bromopyrimidin-2-amine (400 g, 2.2 mol) in /-PrOH (2 L) and DMF (500 mL) was added compound B-9-2 (400 g, 2.6 mol), the resulting mixture was stirred at 1000C for 20 hrs. TLC (petroleum ether: ethyl acetate = 1 :1 ) showed the reaction was complete, the reaction mixture was quenched by addition of aqueous Na2CO3 and filtered. The filtrate was concentrated in vacuo and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 1 :1 ) to afford compound B-9-4 (12.0 g, 2.4%) as a yellow solid.
Preparation of 2,3-dimethyl-6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)imidazo[1 ,2-a]pyrimidine (B-9-5).
Figure imgf000079_0001
To a solution of compound B-9-4 (2.0 g, 8.92 mmol) in DMF (60 ml.) were added bis(pinacolato)diboron (2.79 g, 11 mmol) and KOAc (2.74 g, 30 mmol), and the resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J2CI2 (0.20 g, 0.23 mmol) was added and the mixture was degassed again. The resulting mixture was heated to 9O0C and stirred overnight. The mixture was cooled, filtered and the filtrate was concentrated to give crude compound B-9-5 (2.4 g) as a brown solid, which was used for the next step without purification.
Preparation of (2S)-1-(4-(3-(2,3-dimethylimidazo[1,2-a]pyrimidin-6-yl)-1-isopropyl-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-9)
Figure imgf000079_0002
B-9
To a solution of compound B-1-3 (2.0 g, 5.16 mmol) in toluene (48 ml_) and EtOH (16 mL) were added compound B-9-5 (2.4 g) and 2 N aqueous Na2CO3 (7.5 mL), and the resulting mixture was degassed under N2 for 2 minutes. Then Pd(PPh3J4 (0.41 g, 0.36 mmol) was added and the mixture was degassed again. The resulting mixture was heated to 8O0C and stirred overnight. When the mixture was cooled, the organic layer was separated and concentrated. The residue was purified by prep. HPLC to give compound B-9 (220 mg, 1.6%) as a yellow solid.
Example B-10: Preparation of (2S)-1-(4-(1-isopropyl-3-(5-methyl-5H-pyrrolo[3,2-b]pyrazin-2-yl)-1H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-10) cr
Figure imgf000080_0001
Et3N
B-10-1 B-10-2 B-10-3
Figure imgf000080_0002
Preparation of 6-chloropyrazin-2-amine (B-10-2).
Figure imgf000080_0003
B-10-1 B-10-2
A mixture of 2,6-dichloropyrazine (300 g, 2 mol) and 28% aq. NH3 (8 L) was stirred at 14O0C in a sealed system for 14 hours. TLC (petroleum ether/EtOAc 3:1 ) indicated complete consumption of starting material. The reaction mixture was extracted with EtOAc (3 L x 3). The combined organic layers were washed with saturated aqueous NaCI (3 L), dried over Na2SO4 and concentrated in vacuo to give crude compound B-10-2, which was purified by column chromatography (silica gel, petroleum ether/EtOAc 2:1) to yield pure compound B-10-2 (410 g, yield: 59.7%) as a white solid.
Preparation of 3-bromo-6-chloropyrazin-2 -amine (B-10-3).
Figure imgf000080_0004
-10-2 B-10-3 B-10-3b
To a solution of compound B-10-2 (110 g, 0.85 mol) in CHCI3 (1.5 L) was added N-bromo-succinimide (151.3 g, 0.85 mol) portionwise at O0C under N2 atmosphere. After the addition, the reaction mixture was warmed to room temperature and stirred overnight. TLC (petroleum ether/EtOAc 3:1 ) indicated most of compound B-10-2 was consumed. The reaction mixture was washed with saturated Na2CO3 (1 L x 3), H2O (1 L x 3) and saturated aqueous NaCI (1 L) in sequence, dried over Na2SO4 and concentrated in vacuo. The residue was purified via column chromatography (silica gel, EtOAc/hexane 1 :20) to yield pure B-10-3b (35 g) and pure compound B-10-3 (45 g, 28%) as a yellow solid. Preparation of 6-chloro-3-(2-(trimethylsilyl)ethynyl)pyrazin-2 -amine (B-10-4).
Figure imgf000081_0001
B-10-3 B-10-4
To a mixture of compound B-10-3 (70 g, 0.336 mol), CuI (6.3 g, 0.0336 mol) and Pd(PPh3)2CI2 (7 g) in Et3N (1 L) was added ethynyl-trimethyl-silane (35.6 g, 0.352 mol) dropwise at 0 0C under N2 atmosphere.
After the addition, the reaction mixture was warmed to room temperature and stirred for 1.5 hours. TLC (petroleum ether/EtOAc 5:1 ) indicated complete consumption of starting material. The mixture was concentrated in vacuo to give crude compound B-10-4, which was purified by column chromatography (silica gel, petroleum ether/EtOAc 20:1 ) to yield pure compound B-10-4 (36.5 g, yield 42%) as a yellow solid.
Preparation of 3-chloro-5H-pyrrolo[2,3-b]pyrazine (B-10-5).
Figure imgf000081_0002
B-10-4 B-10-5
A solution of compound B-10-4 (32 g, 0.14 mol) and f-BuOK (63.5 g, 0.57 mol) in f-BuOH (1 L) was stirred at 80 0C overnight. TLC (petroleum ether/EtOAc 5:1 ) indicated complete consumption of starting material.
The reaction mixture was allowed to cool to room temperature. Then cone. HCI (200 mL) was added to the mixture. The resulting mixture was heated to 80°C and refluxed overnight. TLC (petroleum ether/EtOAc 5:1 ) indicated the reaction was complete. The reaction mixture was allowed to cool to room temperature, poured into water (1 L) and extracted with EtOAc (1 L x 3). The combined organic layers were washed with 50% Na2CO3 (300 mL), H2O (500 mL) and saturated aqueous NaCI (1 L) in sequence, dried over Na2SO4 and concentrated in vacuo to give crude B-10-5 which was purified by column chromatography (silica gel, petroleum ether/EtOAc 10:1 ) to yield pure B-10-5 (15 g, yield: 63%) as a yellow solid.
Preparation of 3-chloro-5-methyl-5H-pyrrolo[2,3-b]pyrazine (B-10-6).
Figure imgf000081_0003
B-10-5 , B-10-6 A solution was made of 310 mg (1.95 mmol) of compound B-10-5 in 3 ml of anhydrous DMF. This mixture was added to a solution of 125 mg (3.05 mmol) of 60% NaH dispersion in mineral oil in 3 ml of anhydrous DMF. Another 6 ml of DMF was used to rinse the container. Let stir reaction mixture stir for 15 min at room temperature. Added another 150 μl (2.40 mmol) of MeI. Let stir for 2 hr. LCMS shows one peak M+H = 168 with Cl isotope pattern. The reaction mixture was poured into saturated NH4CI solution (100 ml) slowly, then extracted with EtOAc (3 x 50 ml). The organics were combined, dried over MgSO4 and filtered. Silicia gel chromoatography using EtOAc/Hexane gave 257 mg (76% yield) of compound B-10-6 as a yellow solid.
Preparation of 5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-ylboronic acid (B-10-7).
In a flask, dissolved 36 mg (0.128 mmol) of tricyclohexylphosphine and 48 mg (0.052 mmol) of Pd2(dba)3 in 5 ml of anhydrous dioxane. Bubbled in Argon for 10 minutes and let stir at room temperature for another 20 minutes. To this was added 429 mg (1.69 mmol) of bis(pinacolato)diboron. Finally, added a suspension of 257 mg (1.53 mmol) of compound B-10-6 and 226 mg (2.30 mmol) of KOAc in 5 ml of dioxane. Fitted reaction flask with air condensor and heated to 8O0C overnight. After 24 h, poured reaction mixture into saturated aqueous NaCI, extracted with EtOAc (3 x 75 ml) and washed with water. The organics were combined, dried over MgSO4, filtered, and the solvents were removed in vacuo. A gradient column on Biotage was run with CHCI3 to 15%(5% NH4OH in EtOH) in CHCI3 to isolate compound B-10-7 as a brown solid (73 mg, 27% yield).
Preparation of (2S)-1 -(4-(1 -isopropyl-3-(5-methyl-5H-pyrrolo[3,2-b]pyrazin-2-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-10)
Figure imgf000082_0002
In a flask was dissolved 155 mg (0.40 mmol) of compound B-1-3 and 73 mg (0.41 mmol) of boronic acid B-10-7 in 6 ml of anhydrous DMF. To this mixture was added 600 μl of 2.0 M Na2CO3 solution. Argon gas was bubbled into the reaction mixture for 10 minutes. Finally, 17 mg (0.052 mmol) of Pd(CIpPf)2CH2CI2 catalyst was added and the reaction was heated to 8O0C overnight. After 20 h, the reaction mixture was poured into 40 ml of saturated aqueous NaCI and extracted with EtOAc (3 x 50 ml). The organic extracts were combined, dried over magnesium sulfate, filtered, and the solvent removed in vacuo. Compound (B- 10) was isolated by HPLC as a glassy solid in 20% yield (34 mg).
Example B-12: Preparation of (2S)-1-(4-(3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-12)
Figure imgf000083_0001
Preparation of tert-butyl 5-bromo-2 ,3-dihydropyrrolo[2,3-b]pyridine-1-carboxylate (B-12-2)
Figure imgf000083_0002
B-12-2
To a stirred solution of 5-bromo-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridine (500 mg, 2.51 mMoles) and Boc- anhydride (658 mg, 3.01 mMoles) in 10 ml_ of DMF was added diisopropyl ethylamine (357 mg, 2.76 mMoles). The mixture was refluxed for one hour under nitrogen. TLC indicated reaction complete. Reaction was concentrated to dryness (under high vacuum). The residual was partitioned between EtOAc and saturated aqueous NaCI. The organic layer was washed with saturated aqueous NaCI, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a 15 g pre-packed silica gel cartridge. Elution with 0-5% EtOAc in DCM gave tert-butyl 5-bromo-2,3- dihydropyrrolo[2,3-b]pyridine-1-carboxylate (B-12-2) as an off-white solid (725 mg). 1H NMR (400 MHz, CHLOROFORM-d) S ppm 1.56 (s, 9 H) 3.05 (t, J=8.59 Hz, 2 H) 4.03 (t, 2 H) 7.50 (d, J=2.02 Hz, 1 H) 8.26 (d, J=2.02 Hz, 1 H).
Preparation of 1-(tert-butoxycarbonyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ylboronic acid (B-12- 3)
B-12-2 B"1 2-3
To a mixture of tert-butyl 5-bromo-2,3-dihydropyrrolo[2,3-b]pyridine-1-carboxylate (B-12-2) (725 mg, 2.42 mMoles) and bis(pinacolato) diboron (894 mg, 3.52 mMoles) in 20 ml DMF were added potassium acetate (691 mg, 7.04 mMoles) and [1 ,1-Bis(diphenylphosphino)-ferrocene]dichloropalladium (II) dichloromethane (1 :1) complex (34.3 mg, 0.0469 mMoles). The mixture was heated in 1000C microwave reactor for 60 min. LCMS indicated reaction was complete. RXN was filtered and the filtrate was concentrated to dryness under high vacuum. The residual was partitioned between EtOAc and saturated aqueous NaCI. The aqueous layer was extracted with EtOAc (3x40 ml_). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a 25 g silica gel cartridge with 1-4% MeOH in DCM as solvent. The crude product and was used as is in the next step.
Preparation of (2S)-1 -(4-(3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (B-12)
Figure imgf000084_0002
To a solution of 1-(tert-butoxy carbonyl)-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridine-5-ylboronic acid (B-12-3) (546 mg, 2.07 mMoles) and (2S)-1 -(4-(3-iodo-1 -isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (400 mg, 1.03 mMoles) in 10 mL of DMF were added [1 ,1-Bis(diphenylphosphino)- ferrocene]dichloropalladium (II) dichloromethane (1 :1 ) complex (22.7 mg, 0.031 mMoles) and 2N aqueous solution of sodium carbonate (1.55 mL, 3.10 mMoles). The mixture was flushed with nitrogen for 5 min and then heated in microwave for 1 hour at 1000C. LCMS indicated reaction complete. RXN was filtered and the filtrate was concentrated to a residual under high vacuum. The residual was partitioned between EtOAc and water. The organic layer was washed once with saturated aqueous NaCI and dried over sodium sulfate, filtered and concentrated to a residue. The residue was then loaded onto a 25 g silica-gel cartridge. Elution first with 50% EtOAc in DCM and then 2-5% MeOH in 1 :3 MTBE:DCM gave the Boc-protected product as a white solid. Treating it with 4N HCI in dioxane in DCM overnight at room temperature under nitrogen followed by solvent removal gave a brownish residual. This residual was dissolved in DCM, washed with saturated sodium bicarbonate, dried over sodium sulfate, concentrated and then loaded onto a 15 g silica gel cartridge. Elution with 2-5% MeOH in DCM gave (2S)-1-(4-(3-(2,3- dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (B-12) as a white foam (125 mg).
Example B-33: Preparation of 3-({4-[1-(2,2-difluoroethyl)-3-(1H-pyrrolo[2,3-/)]pyridin-5-yl)-1AY- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile
Preparation of 4-(1 -(2,2-difluoroethyl)-3-iodo-1 H-pyrazol-4-yl)-2-(methylthio)pyrimidine (B-33-1 )
Figure imgf000085_0001
A B-33-1
To a solution of Intermediate A (83 g, 0.26 mol) in DMF (600 ml.) were K2CO3 (58 g, 0.417 mol) and 1 ,1-difluoro-2-iodo-ethane (60 g, 0.313 mol). Then the mixture was stirred at room temperature overnight. TLC (CH2CI2: MeOH = 20:1 ) showed the reaction was complete. The mixture was concentrated and the solid was diluted with CH2CI2 (500 ml_). The slurry was filtered and the filtrate was concentrated to give crude product, which was purified via prep. SFC to give compound B-33-1 (41.1 g, 41.3%) as a white solid.
Preparation of 4-(1 -(2,2-difluoroethyl)-3-iodo-1 H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidine and/or 4-(1 -(2,2-difluoroethyl)-3-iodo-1 H-pyrazol-4-yl)-2-(methylsulfinyl)pyrimidine
Figure imgf000085_0002
To a solution of compound B-33-1 (41.1 g, 0.107 mol) in THF (360 mL) was added a solution of Oxone
(81.2 g, 0.132 mol) in H2O (200 mL). Then the mixture was stirred at room temperature overnight. TLC (CH2CI2: MeOH = 10:1 ) showed the reaction was complete. The mixture was concentrated to about one second. The mixture was extracted with CH2CI2 (600 mL). The organic layer was washed with water (100 mL x 2), dried over Na2SO4 and concentrated to give a mixture of sulfone and sulfoxide (7:3 determined by HPLC) (38.6 g, 88.2%) as a yellow solid.
Preparation of 3-(4-(1-(2,2-difluoroethyl)-3-iodo-1H-pyrazol-4-yI)pyrimidin-2-ylamino)propanenitrile (B-33-3)
Figure imgf000086_0001
To a mixture of sulfone and sulfonxide (16 g, 0.039 mol) in THF (250 ml_) was added 3-amino- propionitrile (16 g, 0.23 mol). Then the mixture was stirred at 8O0C for two days. TLC (CH2CI2:Me0H = 10:1 ) showed the reaction was not complete. The mixture was stirred at this temperature for another one day. The mixture was concentrated to dryness. The residue was purified by silica gel chromatography
(CH2CI2:Me0H = 80:1 ) to give B-33-3 (9.8 g, 61.5%) as a white solid.
Preparation of 3-({4-[1 -(2,2-dif luoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile (B-33)
Figure imgf000086_0002
B-33
B-33-3
A mixture of the 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine B-33-4, which was prepared from 5-bromo-1 H-pyrrolo[2,3-b]pyridine according to known literature methods, (145 mg, 0.594 mmol), 3-({4-[1 -(2,2-difluoroethyl)-3-iodo-1 /-/-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile (200mg, 0.495 mmol), and cesium fluoride (1.48 mL of a 1M aqueous solution) in 3 mL of DME was deoxygenated with a nitrogen bubbler for 5 min and then [1 ,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) 1 :1 complex with dichloromethane (41 mg, 0.05 mmol) was added. The mixture was then heated in a microwave reactor at 8O0C for 2.5 hours. The reaction was degassed and fresh catalyst (20 mg) was added. The mixture was heated in the microwave at 8O0C for 4 more hours. The resulting dark mixture was partitioned between ethyl acetate and brine. The aqueous layer was extracted twice with ethyl acetate. The combined organics were washed with brine, dried over Magnesium sulfate and reduced to minimum volume. The residue was purified on silica gel using a gradient of 0-8% methanol (containing 10% ammonium hydroxide) in a mixture of tert-butyl methyl ether and dichloromethane (1 :1 ) to give the desired product as a pale orange solid. This material was triturated twice with tert-butyl methyl ether to give 82 mg (42%) of analytically pure 3-({4-[1-(2,2- difluoroethyl)-3-(1 /-/-pyrrolo[2,3-i»]pyridin-5-yl)-1 /-/-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile as an off white solid. 1H NMR (400 MHz1 ACETONITRILE-Cf3) δ ppm 9.73 (br. s., 1 H), 8.37 (d, J=2.Q2 Hz, 1 H), 8.22 (s, 1 H), 8.10 (d, J=5.31 Hz, 1 H), 8.08 (d, J=1.52 Hz, 1 H), 7.35 - 7.46 (m, 1 H), 6.54 (d, J=3.79 Hz, 1 H), 6.51 (dd, J=3.54, 2.02 Hz, 1 H), 6.30 (tt, J=55.04, 3.82 Hz, 1 H), 5.91 (br. t, J=6.82 Hz, 1 H), 4.62 (td, J=14.65, 3.79 Hz, 2 H), 3.39 (br. s., 2 H), 2.40 (br. s., 2 H).
Example B-49: Preparation of 3-(4-(1-(1-hydroxy-2-methylpropan-2-yl)-3-(5-methoxypyridin-3-yl)- 1H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile
Figure imgf000087_0001
B-49-1 B-49-2
Figure imgf000087_0002
B -49-4 B-49
Preparation of methyl 2-(3-iodo-4-(2-(methylthio)pyrimidin-4-yl)-1H-pyrazol-1-yl)-2- methylpropanoate (B-49-1)
Figure imgf000087_0003
B-49-1
To a mixture compound A (60 g, 0.19 mol) and methyl 2-bromo-2-methylpropanoate (102 g, 0.57 mol) in DMF (400 ml_) was added freshly ground potassium carbonate (65 g, 0.47 mol) in one portion. The reaction mixture was stirred at 8O0C for 18 hours. LC-MS indicated the reaction was complete. The reaction mixture was filtered and the filtrate was partitioned between ethyl acetate (1200 mL) and brine (300 mL). The aqueous layer was extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel chromatography using 5-30% EtOAc in petroleum ether as eluent to give compound B-49-1 (62 g, 78%) as syrup, which solidified on standing.
Preparation of 2-(3-iodo-4-(2-(methylthio)pyrimidin-4-yl)-1 H-pyrazol-1 -yl)-2-methylpropan-1 -ol (B- 49-2)
Figure imgf000089_0001
B-49-1 B-49-2
To a solution of compound B-49-1 (48 g, 0.11 mol) in dry CH2CI2 (1800 mL) at -780C was added dropwise DIBAL solution (256 mL, 1 M) via syringe. The mixture was stirred from -780C to O0C for 1 hour. The reaction mixture was quenched by the addition of of MeOH (80 mL), and then the mixture was diluted with saturated aq. Rochelle salt and CH2CI2. The resulting suspension was stirred vigorously until layers were separated. The aqueous layer was extracted with dichloromethane (2 x 500 mL). The combined organic layers were dried over sodium sulfate and concentrated to 70 g of yellow oil. The oil was purified by chromatography on silica gel using 0-40% ether in DCM as eluent to give compound B-49-2 (20 g, 45%) as a white solid.
Preparation of 2-(3-iodo-4-(2-(methylsulfonyl)pyrimidin-4-yl)-1 H-pyrazol-1 -yl)-2-methylpropan-1 -ol (B-49-3)
Figure imgf000089_0002
A mixture of compound B-49-3 (20 g, 51 mmol) and Oxone (61.5 g, 0.10 mol) in THF (300 mL) and water (300 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between EtOAc (2 L) and brine (600 mL). The aqueous layer was extracted with EtOAc (1 L x 2). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The residue was purified by a short column chromatography using 0-50% ether/DCM as eluent to afford the product B-49-3 (15 g, 74%) as a white solid.
Preparation of 3-(4-(1 -(1 -hydroxy-2-methylpropan-2-yl)-3-iodo-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propanenitrile (B-49-4)
Figure imgf000090_0001
B -49-4
A microwave reaction vessel was charged with sulfone B-49-3 (6 g, 14.3 mmol, in five batches), 3- aminopropanenitrile (3.0 g, 42.9 mmol) and CsF (2.39 g, 15.7 mmol) in DMSO (60 mL). The resulting solution was subjected to microwave irradiation at 12O0C for 30 minutes. The reaction mixture was cooled to room temperature. The mixture was partitioned between EtOAc (600 mL) and brine (100 mL x 3). The layers were separated and the aqueous layer extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by a short column chromatography using 0-50% EtOAc in petroleum ether as eluent and further purified by prep-HPLC to afford product B-49-4 (3.055 g, 55%) as a brown foamlike solid.
Preparation of 3-(4-(1 -(1 -hydroxy-2-methylpropan-2-yl)-3-(5-methoxypyridin-3-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propanenitrile (B-49)
Figure imgf000090_0002
B-49-4 B-49
A solution of iodide B-49-4 (156.2 mg, 0.374 mmol) and 5-methoxypyridine-3-boronic acid (122.1 mg, 0.798 mmol) dissolved in DME (3.7 mL) was degassed by evacuation until the solvent just begins to boil, followed by argon purge, 3 cycles. Added 1.5 mL of 2.0 M aqueous sodium carbonate solution and 25.5 mg [1 ,1 '-bis(diphenylphosphino)ferrocene]palladium(ll) dichloride dichloromethane complex (0.035 mmol) and degassed 3 more cycles. Heated in 80°C oil bath for 3.5 hour, then let cool to room temperature overnight. The reaction mixture was partitioned between 25 mL ethyl acetate and 10 mL deionized water. The aqueous layer was back-extracted with 15 mL ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, concentrated, and purified by silica gel chromatography, eluting with 0-20% [ethanol + 5% cone, ammonium hydroxide] in ethyl acetate. The product was lyophilized to give B-49 (128.4 mg, 84%) as a pale pink solid. Preparation of 3-(4-(3-(5-acetyl-6-aminopyrϊdin-3-yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin- 2-ylamino)propanenitrile (B-78)
Figure imgf000091_0001
B-78-3
Method B
Figure imgf000091_0002
Figure imgf000091_0003
B-78-4 B-33-3 B-78-5
Figure imgf000091_0004
B-78 Preparation of 5-bromo-3-(prop-1-en-2-yl)pyridin-2-amine (B-78-2)
Figure imgf000091_0005
A solution of 2-amino-5-bromo-3-iodopyιϊdine B-78-1 (4.75 g, 15.9 mmol), isopropenylboronic acid pinacol ester (3.28 mL, 2.94 g, 17.5 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]-palladium(ll) dichloride dichloromethane complex (1 :1 ) (295 mg, 0.403 mmol) in dimethylformamide (48 mL) was treated with 24 mL of 2.0 M aqueous sodium carbonate solution. The resulting biphasic mixture was stirred under argon in a 65°C oil bath for 6 hours. After cooling to room temperature, the mixture was diluted with 200 mL ethyl acetate and 75 mL deionized water, then suction-filtered to remove some insoluble black precipitate. After separation, the aqueous layer was back-extracted with 100 mL ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to 5.87 g brown oil. The crude product was purified by silica gel chromatography (eluting with a 10-50% ethyl acetate in hexanes gradient), to give B-78-2 (2.5501 g, 75.3%) as a tan solid.
Preparation of B-78-3
Figure imgf000092_0001
B-78-3
A solution of compound B-78-2 (2.50 g, 11.7 mmol), di-tert-butyldicarbonate (7.75 g, 35.5 mmol), triethylamine (8.3 ml_, 60 mmol), and 4-(dimethylamino)pyridine (391 mg, 3.1 mmol) in acetonitrile (59 mL) was stirred at room temperature for 1 hour. The solvents were removed under reduced pressure, then the residue partitioned between 100 mL ethyl acetate and 25 mL saturated aqueous sodium bicarbonate solution. The aqueous layer was back-extracted with 30 mL ethyl acetate, and the combined organic extracts dried over magnesium sulfate, filtered, and concentrated to 5.38 g orange gel. The crude product was purified by silica gel chromatography (eluting with 0-40% ethyl acetate in hexanes gradient), affording compound B-78-3 (4.22 g, 87%) as a colorless oil.
Preparation of B-78-4
Figure imgf000092_0002
A solution of B-78-3 (4.15 g, 10.0 mmol) and triisopropyl borate (5.8 mL, 4.8 g, 25 mmol) in 2-methyl tetrahydrofuran (67 mL) was cooled to -700C (internal temperature). To this was added 16 mL (25.6 mmol) of 1.6 M n-butyllithium in hexanes solution, dropwise over 4 minutes. After stirring at -70°C for 30 minutes, 25 mL deionized water was added, and the mixture allowed to warm to room temperature.
Volatiles were removed in vacuo, and the aqueous residue extracted with diethyl ether (2 x 30 mL). These extracts were discarded. The aqueous layer was acidified to pH 2 with 6N HCI, and stirred at room temperature overnight, causing a granular white precipitate to form. The precipitate was collected by suction filtration and dried in a 500C vacuum oven for 6 hours, to give boronic acid B-78-4 (2.9348 g,
62.2%) as a white powder.
Preparation of 3-(4-(3-(6-amino-5-(prop-1 -en-2-yl)pyridin-3-yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propanenitrile (B-78-5) Method B
Figure imgf000093_0001
Figure imgf000093_0002
A solution of boronic acid B-78-4 (721.4 mg, 1.88 mmol), iodide B-33-3 (576.0 mg, 1.425 mmol), and [1 ,1 '-bis(diphenylphosphino)ferrocene] palladium(ll)dichloride-dichloromethane compelx (66.5 mg, 0.091 mmol) in DME (14.2 mL) was treated with 2.0 M aqueous sodium carbonate solution (2.4 ml_), and the resulting biphasic mixture heated in an 80°C oilbath for 15 hours. After cooling to room temperature, the mixture was partitioned between ethyl acetate (50 mL) and deionized water (25 mL). The aqueous layer was back-extracted with 25 mL ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to dryness. The residue was dissolved in dichloromethane (27 mL), trifluoroacetic acid (3mL) was added, and the mixture stirred at room temperature for 6.5 hr. Then the solvent was evaporated, and the residue partitioned between ethyl acetate (50 mL) and saturated aqueous sodium bicarbonate solution (25 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated to a brown tar. The crude product was purified by silica gel chromatography, eluting with 0-20% [ethanol + 5% cone, ammonium hydroxide] in ethyl acetate, affording B-78-5 (325.7 mg, 56%) as a light brown foam.
Preparation of 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin- 2-ylamino)propanenitrile (B-78)
Figure imgf000093_0003
B-78-5 B-78
A solution of alkene 6 (227.8 mg, 0.555 mmol) in dichloromethane (28 mL) was cooled to -70°C and treated with ozone for 30 seconds, long enough for solution color to change from brown to bright yellow. The solution was purged with nitrogen for 2 minutes, then quenched with dimethyl sulfide (0.50 ml, 6.8 mmol). The cooling bath was removed, and the mixture stirred at room temperature for 3 hours. The solution was concentrated to dryness, and purified by silica gel chromatography, eluting with 0-20% [EtOH + 5%NH4OH] in ethyl acetate. Ketone B-78 (63.4 mg, 28%) was obtained as a yellow solid. 1 H NMR 1 H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.57 (s, 3 H) 2.60 - 2.71 (m, 2 H) 3.56 - 3.74 (m, 2 H) 4.55 (td, J=13.45, 4.17 Hz, 2 H) 5.54 (t, J=5.05 Hz, 1 H) 6.21 (tt, J=55.29, 4.20 Hz, 1 H) 6.61 (d, J=5.31 Hz, 1 H) 8.03 (s, 1 H) 8.21 (d, J=5.05 Hz, 1 H) 8.23 (d, J=2.02 Hz, 1 H) 8.45 (d, J=2.27 Hz, 1 H).
Example B-79: Preparation of 3-{4-[3-(5-Amino-6-methoxy-pyrazin-2-yl)-1-(2,2-difluoro-ethyl)-1H- pyrazol-4-yl]-pyrimidin-2-ylamino}-propionitrile
Figure imgf000094_0001
Preparation of B-79-2:
Figure imgf000094_0002
To a solution of 5-bromo-3-methoxypyrazin-2-amine (4.50 g, 19.8 mmol) and 4-(dimethylamino)pyridine (1.24g, 10.1 mmol) in 70ml THF was added di-terf-butyldicarbonate (10.4 g, 47.6 mmol) and the reaction mixture was stirred at room temperature for 5.5 hour. The solvents were removed under reduced pressure and the residue was flash chromed on silica gel eluting 3:1 Hexanes/EtOAc to give B-79-2 as a white solid (5.403g, 67%).
Preparation yrazin-2- yl]imidodica
Figure imgf000094_0003
A mixture of the bis(pinacolato)diboron ( 1.12g, 4.4 mmol), di-terf-butyl (5-bromo-3-methoxypyrazin-2- yl)imidodicarbonate B-79-2 (1.62 g, 4 mmol) and potassium acetate (1.2 g, 12 mmol) in toluene (40 mL) was deoxygenated with a nitrogen bubbler for a few minutes before the addition of 1 ,1'- Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex (78 mg, 0.096 mmol). The mixture was then heated in a 50 degree oil bath for 4 days. LCMS indicated that the reaction was complete. The mixture was filtered and the filtrate reduced to minimum volume. The residue B-79-3 was carried straight into the next step without purification, assuming a quantitative yield.
Preparation of 3-{4-[3-(5-Amino-6-methoxy-pyrazin-2-yl)-1 -(2,2-dif luoro-ethyl)-1 H-pyrazol-4-yl]- pyrimidin-2-ylamino}-propionitrile (B-79)
Figure imgf000095_0001
solution of the crude di-te/t-butyl [3-methoxy-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyrazin-2- yφmidodicarbonate B-79-3 (0.6 mmol) in dimethoxyethane (2.5 mL) was added 3-{4-[1-(2,2-Difluoro- ethyl)-3-iodo-1 H-pyrazol-4-yl]-pyrimidin-2-ylamino}-propionitrile B-33-3 (150 mg, 0.37 mmol) and Cesium Fluoride (1.1 mL of a 1 M aqueous solution, 1.1 mmol). The resulting mixture was deoxygenated with a nitrogen bubbler for 5 min and then 1 ,1'-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex (15 mg, 0.019 mmol) was added. The mixture was then heated in an 8O0C oil bath for 20 hours. LCMS indicated the iodide had been completely consumed. The mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organics were dried over magnesium sulfate and reduced to minimum volume. The residue was taken up in dimethoxyethane (3 mL) and then heated at 17O0C in the microwave for 25 minutes to thermolyze the tert-butoxycarbonyl groups. The resulting dark mixture was filtered through a 0.45μ filter and the filtrate reduced to minimum volume. The residue was purified by HPLC to give 59 mg (37%) of B- 79 as a fluffy white solid after lyophilization of the desired fractions. 1 H NMR (400 MHz, ACETON ITRILE- Cf3) δ ppm 8.17 (s, 1 H), 8.15 (d, .7=5.05 Hz, 1 H), 7.83 (s, 1 H), 6.72 (d, J=5.31 Hz, 1 H), 6.27 (tt, J=54.98, 3.76 Hz, 1 H), 5.91 (br.t, J=5.18 Hz, 1 H), 5.34 (br. s., 2 H), 4.59 (td, J=14.65, 3.79 Hz, 2 H), 3.76 (s, 3 H), 3.55 (q, J=6.23 Hz, 2 H), 2.64 (t, J=6.44 Hz, 2 H)
Example C-1: Preparation of [4-[2-((S)-2-Hydroxy-propylamino)-pyrimidin-4-yl]-3-(1H-pyrrolo[2,3- b]pyridin-5-yl)-pyrazol-1-yl]-acetonitrile
Preparation of 5-[4-(2-Methylsulfanyl-pyrimidin-4-yl)-1 -(tetrahydro-pyran-2-yl)-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine (C-1-1)
Figure imgf000096_0001
B C-1 -1
To a solution of 4-[3-lodo-1-(tetrahydro-pyran-2-yl)-1 H-pyrazol-4-yl]-2-methylsulfanyl-pyrimidine B (1.33g, 3.3 mmol) and 5-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine ( 1g, 4.1 mmo)l in DMF ( 30 mL) was added a 2M solution of sodium carbonate (2mL). The sodium carbonate appeared to come out of solution upon addition. The mixture was deoxygenated with a nitrogen bubbler for a few minutes. The palladium catalyst was added and nitrogen bubbling continued for a few minutes before the bubbler was removed. The mixture was heated at 850C for 18hr. LCMS shows complete conversion to product. The mixture was dropped into saturated aqueous NaCI and the resulting solids collected by filtration and rinsed with water. The solids were dissolved in methanol/dichloromethane (1 :9), dried over MgSO4 and reduced to minimum volume. The residue was purified on a short column of silica gel using a gradient of 0-50% ethyl acetate in dichloromethane as eluant to give 5-[4-(2-Methylsulfanyl-pyrimidin-4- yl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-3-yl]-1 H-pyrrolo[2,3-b]pyridine (C-1-1 ) ( 0.89g, 69%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.73 (br. s., 1 H), 8.69 (s, 1 H), 8.43 (d, J=5.31 Hz, 1 H), 8.29 (d, J=2.02 Hz, 1 H), 8.07 (d, J=2.02 Hz, 1 H), 7.51 (t, J=3.03 Hz, 1 H), 7.11 (d, J=5.31 Hz, 1 H), 6.48 (dd, J=3.28, 1.77 Hz, 1 H), 5.53 (dd, J=9.85, 2.27 Hz, 1 H), 4.00 (br. d, J=13.39 Hz, 1 H), 3.61 - 3.76 (br. m, 1 H), 2.10 - 2.24 (br. m, 4 H), 1.91 - 2.06 (br. m, 2 H), 1.65 - 1.80 (br. m, 1 H), 1.50 - 1.63 (br. m, 2 H).
Preparation of 1 -Benzenesulfonyl-5-[4-(2-methylsulfanyl-pyrimidin-4-yl)-1 -(tetrahydro-pyran-2-yl)- 1 H-pyrazol-3-yl]-1 H-pyrrolo[2,3-b]pyridine (C-1 -2)
Figure imgf000096_0002
C-1 -1 C-1 -2
To a solution of the 5-[4-(2-Methylsulfanyl-pyrimidin-4-yl)-1-(tetrahydro-pyran-2-yl)-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine (C-1-1 ) ( 870 mg, 2.22 mmol) in DMF (10 mL) at 250C was added Sodium Hydride (60% dispersion in oil, 133 mg, 3.32 mmol). The resulting suspension was stirred at ambient temperature for a few minutes until gas evolution ceased. Benzenesulfonyl chloride (0.4 mL, 3.13 mmol) was added and the mixture became cloudy. After stirring at ambient temperature for 15 minutes, LCMS showed complete conversion to desired product. The mixture was added slowly to 150ml of saturated aqueous NaCI. The resulting precipitate was filtered, washed with water, and air dried. The solids were dissolved in dichloromethane, dried over MgSO4 and reduced to minimum volume. The residue was purified on a short column of silica gel using a gradient of 0-20% ethyl acetate in dichloromethane as eluent to give 1- Benzenesulfonyl-5-[4-(2-methylsulfanyl-pyrimidin-4-yl)-1-(tetrahydro-pyran-2-yl)-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine (C-1-2) ( 0.83g, 70%) as a yellow foam. 1 H NMR (400 MHz, DMSO-c/6) δ ppm 8.77 (s, 1 H), 8.47 (d, J=5.31 Hz, 1 H), 8.43 (d, J=2.02 Hz, 1 H), 8.16 (d, J=2.02 Hz, 1 H), 8.09 - 8.15 (m, 2 H), 7.95 (d, J=4.04 Hz, 1 H), 7.68 - 7.77 (m, 1 H), 7.57 - 7.67 (m, 2 H), 7.29 (d, J=5.05 Hz, 1 H), 6.86 (d, J=4.04 Hz, 1 H), 5.52 (dd, J=9.85, 2.27 Hz, 1 H), 3.98 (br. d, J=11.87 Hz, 1 H), 3.62 - 3.74 (m, 1 H), 2.07 - 2.23 (br. m, 1 H), 1.90 - 2.05 (br. m, 2 H), 1.66 - 1.77 (br. m, 1 H), 1.65 (s, 3 H), 1.50 - 1.61 (br. m, 2 H).
Preparation of 5-{4-[2-(methylthio)pyrimidin-4-yl]-1H-pyrazol-3-yl}-1-(phenylsulfonyl)-1H- pyrrolo[2,3-b]pyridine (C-1-3)
Figure imgf000097_0001
C-1-2
C-1-3
To a solution of the 1-Benzenesulfonyl-5-[4-(2-methylsulfanyl-pyrimidin-4-yl)-1-(tetrahydro-pyran-2-yl)-1 H- pyrazol-3-yl]-1 H-pyrrolo[2,3-b]pyridine (C-1-2) (750 mg, 1.41 mmol) in MeOH (1 ML) was added a solution of HCI in Dioxane (~4N, 0.1 mL). After stirring at ambient temperature for 45 minutes, the solution was dropped into phosphate buffer (pH 7, 15ml_). The resulting precipitate was collected by filtration, rinsed with water and air dried to give 5-{4-[2-(methylthio)pyrimidin-4-yl]-1 H-pyrazol-3-yl}-1-(phenylsulfonyl)-1 H- pyrrolo[2,3-b]pyridine (C-1-3) ( 622mg, 98%) which was carried on without further purification. 1H NMR (400 MHz, ACETONITRILE-</3) δ ppm 11.51 (br. s., 1 H), 8.47 (d, J=2.02 Hz, 1 H), 8.34 (d, J=5.05 Hz, 1 H), 8.23 (br. s., 1 H), 8.14 (d, J=7.58 Hz, 2 H), 8.10 (d, J=Ml Hz, 1 H), 7.84 (d, J=2.78 Hz, 1 H), 7.68 (t, J=IAb Hz, 1 H), 7.57 (t, J=7.71 Hz, 2 H), 7.07 (d, J=4.80 Hz, 1 H), 6.75 (d, J=3.79 Hz, 1 H), 1.81 (s, 3 H).
Preparation of [3-(1 -Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-(2-methylsulfanyl-pyrimidin- 4-yl)-pyrazol-1 -yl]-acetonitrile (C-1 -4)
Figure imgf000097_0002
To a solution of the 5-{4-[2-(methylthio)pyrimidin-4-yl]-1 H-pyrazol-3-yl}-1-(phenylsulfonyl)-1 H-pyrrolo[2,3- b]pyridine (C-1-3) (638 mg, 1.42 mmol) and bromoacetonitrile (0.5 mL, 7 mmol) in DMF was added freshly ground Potassium Carbonate (254 mg, 1.84 mmol). The resulting suspension was stirred at 750C for 18hr. LCMS showed complete consumption of starting material. The mixture was partitioned between ethyl acetate and saturated aqueous NaCI. The aqueous layer was extracted with ethyl acetate twice. The combined organics were washed with water twice, saturated aqueous NaCI, dried over MgSO4 and reduced to minimum volume. The residue was purified on silica gel using a gradient of 25 to 100% methyl tert-butyl ether in hexanes as eluent to give [3-(1 -Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4- (2-methylsulfanyl-pyhmidin-4-yl)-pyrazol-1-yl]-acetonitrile (C-1-4) ( 440mg, 63%) as a crisp foam. 1H NMR (400 MHz, ACETON ITRILE-CZ3) δ ppm 8.46 (d, J=2.02 Hz, 1 H), 8.36 (d, >5.31 Hz, 1 H), 8.31 (s, 1 H), 8.11 - 8.16 (m, 2 H), 8.09 (d, .7=2.02 Hz, 1 H), 7.83 (d, J=4.04 Hz, 1 H), 7.64 - 7.71 (m, 1 H), 7.57 (t, J=7.71 Hz, 2 H), 7.01 (d, J=5.31 Hz, 1 H), 6.75 (d, J=4.04 Hz, 1 H), 5.26 (s, 2 H), 1.88 (s, 3 H).
Preparation of [3-(1 -Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-(2-methanesulfonyl- pyrimidin-4-yl)-pyrazol-1 -yl]-acetonitrile (C-1 -5)
Figure imgf000098_0001
A solution of the [3-(1-Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-(2methylsulfanyl-pyrimidin-4-yl)- pyrazol-1-yl]-acetonitrile (C-1-4) (175 mg, 0.36 mmol) in THF (2 mL) and H2O (2 mL) was cooled to O0C and OXONE (330 mg, 0.54 mmol, 1.5 eq) was added in one portion. The resulting yellow slurry was stirred at O0C for 10 min and was then stirred at ambient temperature overnight. The resulting mixture was filtered and the solids rinsed with ethyl acetate and water. The filtrate was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate and the combined organics dried over MgSO4 and reduced to minimum volume. The residue was triturated with methyl tert-butyl ether and the solids collected by filtration to give [3-(1 -Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-(2- methanesulfonyl-pyrimidin-4-yl)-pyrazol-1-yl]-acetonitrile (C-1-5) (158 mg, 85%) which was carried forward without further purification. 1H NMR (400 MHz, ACETONITRILE-d3) δ ppm 8.74 (d, J=5.56 Hz, 1 H), 8.53 (d, J=2.02 Hz, 1 H), 8.45 (s, 1 H), 8.18 (d, J=2.27 Hz, 1 H), 8.12 - 8.17 (m, 2 H), 7.84 (d, J=4.04 Hz, 1 H), 7.63 - 7.73 (m, 1 H), 7.55 - 7.62 (m, 2 H), 7.53 (d, J=5.31 Hz, 1 H), 6.75 (d, J=4.04 Hz, 1 H), 5.29 (S, 2 H), 2.78 (s, 3 H).
Preparation of {3-(1 -Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-[2-((S)-2-hydroxy- propylamino)-pyrimidin-4-yl]-pyrazol-1 -yl}-acetonitrile (C-1 -6)
Figure imgf000098_0002
A Mixture of the [3-(1-Benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-(2-methanesulfonyl-pyrimidin-4-yl)- pyrazol-1-yl]-acetonitrile (C-1-5) (310 mg, 0.6 mmol) and (S)-(+)-1-amino-2-propanol ( 134mg, 1.8 mmol) in THF (5 mL) was heated at 8O0C for 18 hr. The mixture was concentrated onto silica gel then purified on silica gel using a gradient of 0-6% methanol in a mixture of dichloromethane and ethyl acetate (1 :1) as eluent to yield 220 mg (72%) of {3-(1-Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-[2-((S)-2-hydroxy- propylamino)-pyrimidin-4-yl]-pyrazol-1-yl}-acetonitrile (C-1-6) as a foam from methyl tert-butyl ether. 1H NMR (400 MHz, ACETON ITRI LE-d3) δ ppm 8.52 (d, J=2.02 Hz, 1 H), 8.20 (s, 1 H), 8.07 - 8.17 (m, 4 H), 7.81 (d, .7=4.04 Hz, 1 H), 7.63 - 7.73 (m, 1 H), 7.52 - 7.60 (m, 2 H), 6.75 (d, J=4.04 Hz, 1 H), 6.53 (br. s., 1 H), 5.67 (br. t, J=4.93 Hz, 1 H), 5.24 (s, 2 H), 3.56 (br. s., 1 H), 2.64 - 3.28 (br. m, 3 H), 0.74 (br. s., 3 H).
Preparation of [4-[2-((S)-2-Hydroxy-propylamino)-pyrimidin-4-yl]-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)- pyrazol-1-yl]-acetonitrile (C-1)
Figure imgf000099_0001
To solution of the {3-(1-Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-4-[2-((S)-2-hydroxy-propylamino)- pyrimidin-4-yl]-pyrazol-1-yl}-acetonitrile (C-1-6) (145 mg, 0.28 mmol) in THF ( 5 mL) at -4O0C was added sodium hydroxide (1.1 mL of a 10mg/mL solution in MeOH, 0.28 mmol). The mixture was allowed to slowly warm to O0C. After 2hr the mixture was diluted with 1OmL THF and stirring continued at O0C for 2 hr. Mixture was partitioned between pH 7 phosphate buffer and ethyl acetate. The aqueous layer was extracted twicewith ethyl acetate. The combined organics were washed with saturated aqueous NaCI, dried over MgSO4 and reduced to minimum volume. The residue was purified by HPLC to give the [4-[2- ((S)-2-Hydroxy-propylamino)-pyrimidin-4-yl]-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1-yl]-acetonitrile (C- 1) in 23% yield. 1H NMR (400 MHz, ACETONITRILE-d3) δ ppm 9.78 (br. s., 1 H), 8.42 (d, J=2.02 Hz, 1 H), 8.22 (S, 1 H), 8.05-8.14 (m, 2 H), 7.38 - 7.45 (m, 1 H)1 6.42 - 6.56 (m, 2 H), 5.74 (br. s., 1 H), 5.25 (s, 2 H), 3.72 (br. s., 1 H), 3.19 (br. s., 1 H), 3.04 (br. s., 1 H), 0.95 (br. s., 3 H).
Example D-1 : Preparation of (2S)-1-(4-(1-isopropyl-3-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol
Figure imgf000100_0001
-J B-B; i/
Pd(PPh3)2CI2, KOAc, DMF
Figure imgf000100_0002
Figure imgf000100_0003
Preparation of 5-bromo-2-fluoronicotinaldehyde (D-1-2).
Figure imgf000100_0004
D-1-1 D-1-2
To a solution of diisopropylamine (17 mL, 0.17 mol) in dry THF (200 mL) was added 2.5 M n-BuLi in hexane (68 mL, 0.17 mol) dropwise at O 0C under N2 atmosphere. After the addition, the resulting mixture was cooled to -65°C. A solution of 5-bromo-2-fluoropyridine (25 g, 0.14 mol) in dry THF (100 mL) was then added dropwise. The resulting mixture was stirred at -65°C for 90 minutes. Then ethyl formate (15.6 g, 0.21 mol) was added dropwise to the mixture. After stirred for 10 minutes, the reaction mixture was quenched with a solution of 10% citric acid in THF (100 mL) at -650C. The resulting mixture was warmed up to room temperature, poured into water (100 mL) and extracted with EtOAc (200 mL). The organic layer was separated and washed with saturated aqueous NaCI (100 mLχ2), dried over Na2SO4 and concentrated in vacuo to yield compound D-1-2 (25 g, 85%) as a yellow solid.
Preparation of 5-bromo-1H-pyrazolo[3,4-b]pyridine (D-1-3).
Figure imgf000101_0001
D-1-2 D"1-3
A solution of compound D-1-2 (20 g, 0.1 mol) and anhydrous hydrazine (18 g, 0.56 mol) in ethanol was heated to reflux overnight. TLC (petroleum ether/EtOAc 2:1 ) indicated complete consumption of starting material. The reaction mixture was concentrated in vacuo to a volume of about 50 ml_ and poured into water (500 ml_), the resulting mixture was filtered. The cake was washed with water (50 ml_χ3) and ether (20 ml_χ3), then dried in vacuo to yield compound D-1-3 (9.0 g, 46%) as a yellow solid.
Preparation of 1-(4-methoxybenzyl)-5-bromo-1H-pyrazolo[3,4-b]pyridine (D-1-4).
Figure imgf000101_0002
D-1-3 □_.,.4 To a solution of compound D-1-3 (3.47 g, 17.5 mmol) in dry DMF (50 mL) was added NaH (77 mg, 19.25 mmol) portionwise at 00C. After the addition, the resulting mixture was stirred at 00C for 30 minutes.
PMBCI (3.29 g, 21 mmol) was then added dropwise at 0°C. The resulting mixture was stirred at room temperature overnight. TLC (petroleum ether/EtOAc 1 :1 ) indicated complete consumption starting material. The reaction mixture was poured into H2O (100 mL) and extracted with EtOAc (100 mLχ3). The combined organic layers were washed with H2O (100 mLχ2) and saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (silica gel, petroleum ether/EtOAc from 50:1 to 4:1 ) to yield pure compound D-1-4 (4.3 g, yield: 77.2%) as a yellow solid.
Preparation of 1 -(4-methoxybenzyl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrazolo[3,4- b]pyridine (D-1-5).
Figure imgf000101_0003
To a stirred solution of compound D-1-4 (4.3 g, 13.5 mmol) in dry DMF (80 mL) were added 4,4,5,5,4l,4",5l,5l-octamethyl-[2,2l]bi[[1 ,3)2]dioxaborolanyl] (6.9 g, 27 mmol), KOAc(3.9 g, 40.5 mmol) and Pd(PPh3J2CI2 (0.43 g, O.δmmol) under N2 atmosphere. The resulting mixture was heated at 80~90°C overnight. TLC (petroleum ether/EtOAc 4:1 ) indicated complete consumption of compound 39. The reaction mixture was poured into H2O (300 mL) and extracted with EtOAc (300 mLχ3). The combined organic layers were washed with H2O (300 mLχ2) and saturated aqueous NaCI (300 mL), dried over Na2SO4 and concentrated in vacuo to yield crude D-1-5 (8 g, yield: 100%) as a black oil, which was directly used to next step without any purification.
Preparation of 1 -(4-methoxybenzyl)-5-(1 -isopropyl-4-(2-(methylthio)pyrimidin-4-yl)-1 H-pyrazol-3-yl)- 1 H-pyrazolo[3,4-b]pyridine (D-1 -6).
P
Figure imgf000102_0001
To a stirred solution of compound B-1-1 (1.8 g, 5 mmol) in toluene (60 mL) and EtOH (20 mL) was added the crude mixture of compound D-1-5 (8 g, 13.5 mmol), 2 N aqueous Na2CO3 (7.5 mL) and Pd(PPh3J4 (0.18 g, 0.11 mmol) under N2 atmosphere. The resulting mixture was heated at reflux overnight. TLC (petroleum ether/EtOAc 2:1 ) indicated complete consumption of compound 7. The reaction mixture was washed with H2O (50 mL) and saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified via column chromatography (silica gel, petroleum ether/EtOAc 2:1 ) to yield crude compound D-1 -6, which was purified via preparative HPLC to yield pure compound D-1 -6 (560 mg, yield: 23.8%) as a yellow oil.
Preparation of 1 -(4-methoxybenzyl)-5-(1 -isopropyl-4-(2-(methylsulfonyl)pyrimidin-4-yl)-1 H-pyrazol- 3-yl)-1 H-pyrazolo[3,4-b]pyridine (D-1 -7).
Figure imgf000102_0002
A mixture of compound D-1-6 (560 mg, 1.19 mmol) and Oxone (1.1 g, 1.79 mmol) in THF (10 mL) and H2O (10 mL) was stirred at room temperature for 2 hours. TLC (petroleum ether/EtOAc 2:1 ) indicated complete consumption of starting material. The reaction mixture was concentrated in vacuo. H2O (30 mL) was added to the residue and the mixture was extracted with EtOAc (50 mL*3). The combined organic layers were washed with saturated aqueous NaCI (50 mL), dried over Na2SO4 and concentrated in vacuo to yield compound D-1 -7 (600 mg, yield: 100%) as a red oil. Preparation of (2S)-1-(4-(3-(1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-1-isopropyl-1H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (D-1 -8).
Figure imgf000103_0001
A mixture of compound D-1-7 (600 mg, 1.2 mmol) and (S)-1-aminopropan-2-ol (528 mg, 7.15 mmol) in THF (30 ml.) was heated at reflux for two days. TLC (CH2CI2/Me0H 15:1 ) indicated complete consumption of starting material. The mixture was concentrated in vacuo and the residue was purified via column chromatography (silica gel, EtOAc) to yield compound D-1-8 (460 mg, yield: 77.4%) as a yellowish oil.
Preparation of (2S)-1 -(4-(1 -isopropyl-3-(1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol (D-1)
Figure imgf000103_0002
A solution of compound D-1-8 (460 mg, 0.92 mmol) in TFA (20 mL) was stirred at room temperature for 3 days. TLC (CH2CI2/Me0H 15:1 ) indicated about half of compound D-1-8 was consumed. The reaction mixture was concentrated in vacuo. The residue was basified to pH~8 by saturated NaHCO3 (10 mL) and extracted with EtOAc (50 mL><3). The combined organic layers were washed with saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified via preparative HPLC to yield D-1 (130 mg, yield: 21.5%) as a yellow solid.
Example D-2: Preparation of (2S)-1 -(4-(1 -isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H- pyrazol-4-yi)pyrimidin-2-ylamino)propan-2-ol
Figure imgf000104_0001
D-2-1 D-2-2 D-2-3
Figure imgf000104_0002
Preparation of S-bromo^-chloro-N-methoxy-N-methylnicotinamide (D-2-2).
Figure imgf000104_0003
D-2-1 D-2-2
To a solution of compound D-2-1 (23.5 g, 0.1 mol) in dry CH2CI2 (400 mL) was added CDI (19.5 g, 0.12 mol) portionwise at room temperature under N2 atmosphere. After the addition, the mixture was stirred for 1 hour. O,N-dimethyl-hydroxylamine (11.5 g, 0.12 mol) was then added portionwise at room temperature. After the addition, the resulting mixture was stirred at room temperature overnight. TLC (petroleum ether/EtOAc 8:1 ) indicated complete consumption of starting material. H2O (200 mL) was added and the organic layer was separated, washed with 1 N HCI (100 mL), 1 N Na2CO3 (100 mL) and saturated aqueous NaCI (200 ml_) in sequence, dried over Na2SO4 and concentrated in vacuo to give compound D- 2-2 (25 g, 90%) as a yellow solid.
Preparation of S-bromo^-chloronicotinaldehyde (D-2-3).
Figure imgf000105_0001
To a stirred solution of compound D-2-2 (25 g, 89.4 mmol) in dry THF (200 mL) was added LiAIH4 (1.7 g, 27 mmol) at -10 0C under N2 atmosphere. After the addition, the reaction mixture was allowed to warm up to room temperature and stirred overnight. TLC (petroleum ether/EtOAc 5:1 ) indicated complete consumption of starting material. To the reaction mixture was added 1 N KHSO4 (200 mL) and extracted with EtOAc (300 mL><3). The combined organic layers were washed with saturated aqueous NaCI (200 mL), dried over Na2SO4 and concentrated in vacuo to yield crude compound D-2-3, which was purified by column chromatography (silica gel, petroleum ether/EtOAc 30:1 ) to yield pure compound D-2-3 (8.0 g, 45%) as a white solid.
Preparation of 1-(5-bromo-2-chloropyridin-3-yl)ethanol (D-2-4).
Figure imgf000105_0002
To a stirred solution of compound D-2-3 (8.0 g, 36.3 mmol) in dry THF (100 mL) was added a solution of 3 M CH3MgBr in THF (18.14 mL, 54.4 mmol) dropwise at -78 0C under N2 atmosphere. After the addition, the resulting mixture was allowed to warmed up to room temperature and stirred overnight. TLC (petroleum ether/EtOAc 8:1 ) indicated most of compound D-2-3 was consumed. H2O (200 mL) was added to the reaction mixture and the mixture was extracted with EtOAc (100 mL*3). The combined organic layers were washed with saturated aqueous NaCI (200 mL), dried over Na2SO4 and concentrated in vacuo to give crude compound D-2-4, which was purified by column chromatography (silica gel, petroleum ether/EtOAc 50:1 ) to yield pure compound D-2-4 (6.3 g, 73.6%) as a yellow oil.
Preparation of 1-(5-bromo-2-chloropyridin-3-yl)ethanone (D-2-5).
Figure imgf000105_0003
To a stirred solution of pyridine (13 g, 0.165 mol) in CH2CI2 (200 mL) was added CrO3 (8.25 g, 0.083 mol) and silica gel (20 mL) portionwise at 0 °C. After the addition, the reaction mixture was stirred for 10 minutes. Compound D-2-4 (6.5 g, 27.5 mmol) was then added and the resulting mixture was stirred at room temperature overnight. TLC (petroleum ether/EtOAc 8:1 ) indicated most of compound D-2-4 was consumed. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give crude compound D-2-5, which was purified by column chromatography (silica gel petroleum ether/EtOAc 20:1) to give pure compound D-2-5 (5 g, yield: 77%) as a yellow oil.
Preparation of 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine (D-2-6).
Figure imgf000106_0001
A mixture of compound D-2-5 (4 g, 16 mmol) and hydrazine (30 mL) in ethanol (300 mL) was stirred at room temperature overnight. TLC (petroleum ether/EtOAc 5:1 ) indicated complete consumption of starting material. The reaction mixture was concentrated in vacuo and the residue was purified via column chromatography (silica gel, petroleum ether/EtOAc 15:1 ) to yield crude compound D-2-6, which was further purified by preparative HPLC to yield pure compound D-2-6 (800 mg, yield: 20%) as a white solid.
Preparation of 1-(4-methoxybenzyl)-5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine (D-2-7).
Figure imgf000106_0002
To a stirred solution of compound D-2-6 (0.6 g, 3 mmol) in dry DMF (50 mL) was added NaH (0.24 g, 6 mmol) portinwise at 0 °C under N2 atmosphere. The resulting mixture was stirred at room temperature for
1 hour. PMBCI (0.52 g, 3.3 mmol) was then added dropwise at 0 0C. The resulting mixture was stirred at room temperature overnight. TLC (petroleum ether/EtOAc 3:1 ) indicated complete consumption of starting material. The reaction mixture was quenched with H2O (50 mL) and extracted with EtOAc (50 mLχ3). The combined organic layers were washed with saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified via column chromatography (silica gel, petroleum ether/EtOAc from 8:1 to 5:1 ) to yield compound D-2-7 (0.7 g, yield: 71 %) as a white solid.
Preparation of 1 -(4-methoxybenzyl)-3-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H- pyrazolo[3,4-b]pyridine (D-2-8).
Figure imgf000107_0001
A solution of compound D-2-7 (0.7 g, 2.1 mmol), 4)4,5,5,41,4',5\51-octamethyl- [2,2'] bi [[1 ,3,2]dioxaborolanyl] (1.05 g, 4.2 mmol), KOAc (0.63 g, 6.3 mmol) and a catalytic amount of
Pd(PPh3J2CI2 in dry DMF (80 ml_) was stirred at 80-90 °C under N2 atmosphere overnight. TLC
(petroleum ether/EtOAc 3:1 ) indicated complete consumption of starting material. H2O (100 ml.) was added and the reaction mixture was extracted with EtOAc (100 mL><3). The combined organic layers were washed with saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated in vacuo to yield crude D-2-8 (0.8 g, yield: 100%) as a brown oil, which was used directly without any further purification.
Preparation of 1 -(4-methoxybenzyl)-5-(1 -isopropyl-4-(2-(methylthio)pyrimidin-4-yl)-1 H-pyrazol-3-yl)- 3-methyl-1 H-pyrazolo[3,4-b]pyridine (D-2-9).
Figure imgf000107_0002
To a stirred solution of compound B-1-1 (0.38 g, 1.05 mmol) in toluene (60 mL) and EtOH (20 mL) were added crude material of compound D-2-8 (0.8 g, 2.1 mmol) and 2 N aq. Na2CO3 (1.6 mL) under N2 atmosphere. After 10 minutes, a catalytic amount of Pd(PPh3J4 was added. The resulting mixture was refluxed overnight. TLC (petroleum ether/EtOAc 2:1) indicated complete consumption of D-2-8. Water (30 mL) was added to the reaction mixture and the mixture was extracted with EtOAc (100 mL*3). The combined organic layers were washed with saturated aqueous NaCI (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified via column chromatography (silica gel, petroleum ether/EtOAc 5:1 ) to yield compound D-2-9 (0.9 g, 30.1%) as a white solid.
Preparation of 1 -(4-methoxybenzyl)-5-(1 -isopropyl-4-(2-(methylsulfonyl)pyrimidin-4-yl)-1 H-pyrazol- 3-yl)-3-methyl-1 H-pyrazolo[3,4-b]pyridine (D-2-10).
Figure imgf000108_0001
A mixture of compound D-2-9 (0.4 g, 0.82 mmol) and Oxone (0.76 g, 1.2 mmol) in THF (10 mL) and H2O (10 mL) was stirred at room temperature for 2 hours. TLC (EtOAc) indicated complete consumption of starting material. The reaction mixture was concentrated in vacuo. H2O (30 mL) was added to the residue and the mixture was extracted with EtOAc (50 mLχ3). The combined organic layers were washed with saturated aqueous NaCI (50 mL), dried over Na2SO4 and concentrated in vacuo to yield compound D-2- 10 (0.42 g, yield: 100%) as a yellow solid.
Preparation of (2S)-1-(4-(3-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1- isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (D-2-11 ).
Figure imgf000108_0002
A mixture of compound D-2-10 (0.42 g, 0.82 mmol) and (S)-1-aminopropan-2-ol (0.6 g, 8.2 mmol) in toluene (25 mL) was refluxed overnight. TLC (EtOAc) indicated complete consumption of starting material. The mixture was concentrated in vacuo and the residue was purified via column chromatography (silica gel, EtOAc) to yield compound D-2-11 (0.4 g, yield: 100%) as a yellow solid.
Preparation of (2S)-1 -(4-(1 -isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (D-2)
Figure imgf000109_0001
A solution of compound D-2-11 (400 mg, 0.82 mmol) in TFA (5 ml_) was stirred at room temperature for 48 hours. TLC (petroleum ether/EtOAc 1 :2) indicated about half of compound D-2-11 was consumed. Et3N (10 ml.) was added to the mixture and the resulting mixture was concentrated in vacuo. The residue was purified by column chromatography (silica gel, petroleum ether/EtOAc 1 :1 ) to yield crude product, which was further purified by preparative HPLC to give pure D-2 (141.1 mg, yield: 47%) as a white solid.
Example F-1 : Preparation of 3-chloro-5-(1-isopropyl-4-(pyrimidin-4-yl)-1 H-pyrazol-3-yl)-1H- pyrrolo[2,3-b]pyridine
Figure imgf000109_0002
F-1
Preparation of 4-lsoxazol-4-ylpyrimidine (F-1 -2)
Figure imgf000109_0003
F-1-1 F-1 -2 Crystalline triphosgene (44.3 g, 0.447 mol, 2.1 eq.) was started to be added to a solution of 4- methylpyrimidine (20.3 g, 0.213 mol) and dimethyl formamide (32.7 g, 0.447 mol, 2.1 eq.) at -100C. This was accompanied by severe heating and densification of the reaction mass. It was necessary to change the cooling mixture several times and to add chloroform into the reaction mixture (totally 60 ml_). After 3 h, when the addition of triphosgene was finished, the cooling mixture was removed, and the reaction mixture was allowed to heat to 35 0C. When the reaction mixture started to cool, chloroform was evaporated, and red a oily residue was triturated with ethyl acetate to give crude compound F-1-1a (yield 78 g).
Compound F-1-1a was carefully sprinkled to a solution of hydroxylamine hydrochloride (17.8 g, 0.258 mol, 1.2 eq) and NaHCO3 (17,9 g, 0.213 mol) in water (300 mL) at 100C under stirring. NaHCO3 (36 g, 2 eq.) was additionally added (caution, foaming) to the obtained mixture, which was accompanied by formation of light crystalline precipitate. The precipitate was subjected to extraction with ethyl acetate. Next day, the extraction was repeated. The combined extracts were evaporated to give compound F-1-2 as a crystalline product (yield 94% calculated for 4 methylpyrimidine, 29.6 g).
Preparation of 3-Oxo-2-pyrimidin-4-ylpropanenitrile (F-1-3)
Figure imgf000110_0001
F-1-2 F-1-3 Compound F-1-2 was sprinkled to a solution of NaOH (8.06 g, 0.201 mol) in the mixture water/ethanol (30 mL/30 mL) under stirring. The mixture spontaneously heated to 7O0C, a brownish-red solution formed, and a light precipitate formed. On densification, water was added. After spontaneous heating ceased, the mixture was stirred at room temperature for 1 h. Ethanol was added, and the solution was rotary evaporated. This operation was repeated twice, and the residue was washed on a filter with ethyl acetate and ether to give compound F-1-3 as beige crystals (yield 100%, 34 g).
Preparation of 4-Pyrimidin-4-yl-1H-pyrazol-3-amine (F-1-4)
Figure imgf000110_0002
F-1-4
F-1-3
Compound F-1-3 (30 g, 0.178 mol) was sprinkled to a solution of hydrazine hydrate (20 mL) in glacial acetic acid (300 mL), which was accompanied by the formation of a dense orange precipitate. The obtained mixture was kept under stirring at 70-800C for 1 h. The precipitate disappeared, and the solution became less intense colored. The reaction mass was evaporated to half-volume and neutralized with excess aqueous ammonia to give compound F-1-4 as a light precipitate (yield 66%, 18.9 g). Preparation of 3-[5-(Methoxycarbonyl)-1 -(tetrahydro-2H-pyran-2-yl)-1 W-indazol-3-yl]benzoic Acid (F-1-5)
Figure imgf000111_0001
A solution of NaNO2 (4.7 g, 0.068 mol) in water (20 mL) was poured at -30C in a thin jet to a solution of compound F-1-4 (10.9 g, 0.068 mol) in a mixture of glacial acetic acid (200 mL) and water (50 mL). The temperature increased to -1 °C, and the solution became orange and transparent. Concentrated H2SO4 (1.85 mL, 0.0338 mol) was poured to the obtained solution, and a solution of Kl (33.7 g, 0.2 mol, 3 eq.) and I2 (35 g, 138 mmol, 2 eq.) was added. The obtained solution was heated to 55 0C for 1 h, and acetic acid was neutralized with a large excess of aqueous ammonia. Iodine was neutralized with excess Na2S2O3, and a light precipitate (16.5 g) formed. The precipitate was separated by filtration, and the mother solution was extracted with ethyl acetate. Ethyl acetate was evaporated, and the residue was dissolved in THF. The solution was passed through silica gel washing out with ethyl acetate and evaporated to give compound F-1-5 (total yield 93%, 17.1 g).
Preparation of 4-(3-lodo-1 -isopropyl-1 H-pyrazol-4-yl)-pyrimidine (F-1 -6)
Figure imgf000111_0002
To a solution of the pyrazole F-1-5 (3.Og, 11 mmol) and K2CO3 (1.98g, 14.3mmol) in DMF was added isopropyl iodide (5.51 ml, 55.1 mmol). The reaction mixture was heated at 55C. After 25hr, more of isopropyl iodide (1ml lOmmol), and of K2CO3 (457mg, 3.3mmol) was added. Stirred for 2hr more.
Cooled. Poured into 300ml sat NaCI soln and extracted with TBME (2x). Combined organic layers were washed with saturated aqueous NaCI, dried over MgSO4 and cone under reduced pressure to a yellow/orange solid. Recrystallized from TBME. TLC analysis showed the crystalline product to be enriched in one isomer of the isopropyl product F-1-6. Triturated the solid with TBME (3x) to give 680mg of It. yellow powder which shows pure isomer F-1-6.
Preparation of 3-chloro-5-(1 -isopropyl-4-(pyrimidin-4-yl)-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine
Figure imgf000112_0001
F-1
A mixture of 4-(3-lodo-1-isopropyl-1 H-pyrazol-4-yl)-pyrimidine (0.05 g, 0.2 mmol), 3-chloro-5-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 H-pyrrolo[2,3-b]pyridine (0.089 g, 0.318 mmol) and 2 M aq Na2CO3 (0.067 g, 0.636 mmol, 0.318 mL 3.0 Eq) in DMF (4ml_) was bubbled with Nitrogen for 15 min and DPPF PdCI2 (0.014Og, 0.019 mmol, 0.06 Eq) was added and then heated in biotage microwave initiator for 2.0 hour at 100 0C and under a high absorption. The resultant black reaction was cooled to room temperature. The reaction was poured into H2O (100 mL) and extracted (3x50 mL EtOAC). The combined organics were dried over Na2SO4 and concentrated in vacuo to a black oil which was purified by Biotage column (Si 25 + M) packed with hexanes and eluted with (5%MeOH/EtOAc)/Hexanes (0-50%: 700 mL, 50-100%: 700 mL, 100%; 700 mL, 27 mL fractions) to yield the product F-1 as an off-white solid (0.025, 50%).
Example G-1 : Preparation of (2S)-1-(4-(3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1- (tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol
Preparation of methyl 1H-pyrrolo[2,3-b]pyridine-5-carboxylate (G-1 -1a)
Figure imgf000112_0002
G-1-1 G-1 -1a
A mixture of 5-bromo-1 H-pyrrolo[2,3-b]pyridine (90 g, 0.4 mol) and dppp (3 g, 0.072 mol) in DMSO (300 mL) and MeOH (300 mL) was added Pd(OAc)2 (16.5 g, 0.072 mol). The resulting mixture was degassed under N2 for 2 min and then heated to 1000C under 2 MPa of CO gas for two days. TLC (Petroleum ether: EtOAc = 4:1 ) showed the reaction was complete. The mixture was cooled and filtered then concentrated. The obtained residue was poured into ice-water. The formed solid was collected and dried in vacuum to give crude compound 5 (86.1 g, crude), which was directly used to the next reaction without further purification.
Preparation of methyl 1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (G-1 -2)
Figure imgf000112_0003
G-1 -1a G-1 -2 To a solution of G-1-1a (58 g, 0.33 mol) in dry THF (800 mL) was added NaH (20 g, 0.495 mol) at 0-100C in small portions. The resulting mixture was stirred at 1O0C for 1 h. BsCI (70.1 g, 0.397 mol) was added drop-wise. The resulting mixture was allowed to warm to room temperature and stirred overnight. TLC (Petroleum ether: EtOAc = 2:1 ) indicated the reaction was complete. The reaction mixture was cooled and quenched with water. The mixture was extracted with EtOAc (400 mLχ3). The combined organic layers were washed with saturated aqueous NaCI, dried with Na2SO4, filtered and concentrated to give crude product, which was purified by re-crystallization with petroleum ether: EtOAc =3:1 to give compound G-1-2 (60 g , 57.6%) as a grey yellow solid.
Preparation of 2-(2-(methylthio)pyrimidin-4-yl)-1 -(1 -(phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridin-5- yl)ethanone (G-1-3)
Figure imgf000113_0001
n-BuLi (2.5 M, 93 mL, 0.233 mol) was added drop-wise to a solution of i-Pr2NH (32.5 mL, 0.233 mol) in dry THF (420 mL) at -780C and the resulting solution was stirred at -780C for 30 min. Then, a solution of 4- methyl-2-(methylthio)pyrimidine (22.33 g, 0.16 mol) in dry THF (110 mL) was added drop-wise and the resulting mixture was stirred at -780C for another 30 min. A solution of compound G-1-2 (50.0 g, 0.145 mol) in dry THF (250 mL) was then added drop-wise at -11O0C. After the addition, the resulting mixture was stirred at -11O0C for 10 min. TLC (hexane: EtOAc 1 :1 ) indicated the reaction was complete. EtOAc (300 mL) and H2O (300 mL) were added to the reaction mixture to quench the reaction. The organic layer was separated and the aq. layer was extracted with EtOAc (300 mLx3). The combined organic layers were washed with saturated aqueous NaCI (500 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (CH2CI2) to give compound 7 (36.0 g, 58.5%) as a yellow solid.
Preparation of (Z)-3-(dimethylamino)-2-(2-(methylthio)pyrimidin-4-yl)-1 -(1 -(phenylsulfonyl)-i H- pyrrolo[2,3-b]pyridin-5-yl)prop-2-en-1 -one (G-1 -4)
Figure imgf000113_0002
A solution of compound G-1-3 (30 g, 70.7 mmol) in DMF-DMA (300 mL) was heated to 8O0C for 3.5 h. TLC (CH2CI2: MeOH= 20: 1 ) indicated the reaction was complete. The solvent was concentrated under reduced pressure to give crude compound G-1-4 (36 g) as a dark red oil, which was directly used to the next reaction without purification.
Preparation of 5-(4-(2-(methylthio)pyrimidin-4-yl)-1 H-pyrazol-5-yl)-1 -(phenylsulfonyl)-i H- 5 pyrrolo[2,3-b]pyridine (G-1-5)
Figure imgf000114_0001
A solution of compound G-1-4 (36 g, crude) in EtOH (360 mL) was added NH2NH2-H2O (30 ml_). The mixture was stirred at room temperature for 5h. The product was deposited from the reaction mixture. The 10 mixture was filtered and the solid was washed with EtOH (50 mL*3) to give the product (19.6 g, 62.1 % in two steps) as a orange solid.
Preparation of 5-(4-(2-(methylthio)pyrimidin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazol-3-yl)-1H- pyrrolo[2,3-b]pyridine (G-1-6)
Figure imgf000114_0002
I5 G-1-5 G-1-6
A mixture of compound G-1-5 (1.9 g, 4.24 mmol),
Figure imgf000114_0003
(1.02 g, 5.088 mmol), Cs2CO3 (4.13 g, 12.72 mol) in DMSO (20 mL) was heated to 8O0C and stirred overnight. The mixture was allowed to cool
.0 to room temperature and diluted with water (100 mL) and CH2CI2 (100 mL). The organic layer was separated and the aqueous was extracted with CH2CI2 for three times. The combined organic layer was washed with saturated aqueous NaCI (300 mLχ3), dried over anhydrous Na2SO4, evap. to give the crude compound, which was purified by column chromatography and then via prep. HPLC to afford compound G-1-6 (700 mg, 43.75%) as a yellow solid.
>5
Preparation of 5-(4-(2-(methylthio)pyrimidin-4-yl)-1 -(tetrahydrof uran-3-yl)-1 H-pyrazol-3-yl)-1 - (phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridine (G-1 -7)
Figure imgf000115_0001
To a cooled mixture of compound G-1-6 (370 mg, 0.98 mmol) in THF (30 ml_) was added NaH (47.0 mg, 1.176 mmol, 60% in oil) slowly. After the addition, the mixture was stirred for 1 hour, followed by adding BsCI (207.56 mg, 1.176 mmol) and stirred at room temperature for two hours until TLC analysis (MeOH/CH∑Cb = 1/10) showed the starting material was consumed. The resultant mixture was then quenched with saturated aq. NH4CI and concentrated. The residue was extracted with EtOAc (50 m><3). The combined organic layer was washed with saturated aqueous NaCI (300 mL.χ3), dried over anhydrous Na2SO4, and evaporated to give the crude compound G-1-7 (600 mg, 100%), which was used for next step directly without further purification.
Preparation of 5-(4-(2-(methylsulfonyl)pyrimidin-4-yl)-1 -(tetrahydrof uran-3-yl)-1 H-pyrazol-3-yl)-1 - (phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridine (G-1 -8)
Figure imgf000115_0002
The crude compound G-1-7 (600 mg, 0.98 mmol) was combined with Oxone (0.90 g, 1.47 mmol) in THF/H2O (1/1 , 15 mL) and stirred at room temperature for 5 hours until TLC analysis (EtOAc/Petroleum = 1/2) showed the starting material was consumed. The resulting mixture was diluted with EtOAc (100 mL) and water (50 mL). The organic layer was separated and the aqueous was extracted with EtOAc for three times. The combined organic layer was then washed with water (100 mLχ1 ), saturated aq. NaHCO3 (100 mLχ2), saturated aqueous NaCI (100 mL), separately. The resultant organic layer was dried over anhydrous Na2SO4, evap. to give compound G-1 -8 (600 mg, 100%), which was used for next step directly without further purification.
Preparation of (2S)-1 -(4-(3-(1 -(phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridin-5-yl)-1 -(tetrahydrof uran-3- yl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (G-1 -9)
Figure imgf000116_0001
G-1-9
A mixture of compound G-1-8 (600 mg, 0.98 mmol), S-1-aminopropan-2-ol (367.5 mg, 4.9 mmol) in THF (25 ml_) was heated to reflux and stirred for 24 hours until TLC analysis (MeOH/ CH2CI2= 1/10) showed the starting material was consumed. The resulting mixture was then concentrated to dryness and the residue was dissolved in CH2CI2 (200 ml_), washed with water (100 mL*2) and saturated aqueous NaCI (100 ml_χ1 ), dried over anhydrous Na2SO4, followed by evaporation to give Compound G-1-9 (500 mg, 100%) as yellow oil.
Preparation of (2S)-1 -(4-(3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -(tetrahydrof uran-3-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol (G-1-10)
Figure imgf000116_0002
To the solution of crude compound G-1-9 (500 mg, 0.98 mmol) in MeOH (15 ml_) was added the solution of NaOH (78.4 mg, 1.96 mmol) in H2O (3 mL). The mixture was then gently heated and stirred overnight. TLC analysis (MeOH/CH2CI2 = 1/10) showed the completely consumption of the starting material and formation of new product. Thus, the resulting mixture was diluted with EtOAc (250 mL) and the organic layer was separated and washed with saturated aqueous NaCI (100 mLχ2), dried over anhydrous Na2SO4, evap. to give the crude product G-1-10 (400 mg, 100%), which was used for next step directly.
Preparation of (2S)-1 -(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -(tetrahydrof uran-3-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol (G-1)
Figure imgf000116_0003
G-1-10 G-1 The crude azaindole G-1-10 (400 mg, 0.98 mmol), N-chlorosuccinimide (NCS, 130.83 mg, 0.98 mmol) in DMF (50 mL) under N2 atmosphere was heated to 4O0C and stirred overnight. LC-MS showed the starting material was completely consumption. The resultant mixture was then diluted with EtOAc (500 mL). The organic layer was separated and washed with water and saturated aqueous NaCI for several times, dried over anhydrous Na2SO4, evap. to give the crude product (380 mg). The crude product was purified by prep. HPLC to afford the product G-1 (170 mg, 39.53%) as green solid. 1 H NMR (400 MHz, CDCI3): 5 11.281 (S, 1 H), 9.809 (s, 1 H), 8.508 (s, 1 H), 8.284 (s, 1 H), 8.2166 (m, 1 H), 7.811 (s, 1 H), 7.353 (s, 1 H), 7.194 (s, 1 H), 6.604 (s, 1 H), 5.044 (s, 1 H), 4.190-4.122 (m, 2H), 4.061-4.022 (m, 1H), 3.966-3.908 (m, 1 H), 2.940 (s, 2H), 2.583-2.510 (m, 1H), 2.490-2.364 (m, 1 H), 0.917 (s, 3H).
Example H-1 : 4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -isopropyl-1 H-pyrazol-4-yl)pyridin-2- amine
Preparation of 5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (H-1 -2)
Figure imgf000117_0001
H-1-1 H-1 -2
To a suspension of NaH (87 g, 2.18 mol, 60% in oil) in dry THF (1 L) was added dropwise a solution of 5- bromo-1 H-pyrrolo[2,3-b]pyridine H-1-1 (120 g, 0.62 mol) in dry THF (1 L) at O0C. After addition, the mixture was stirred at O0C under N2 for 0.5 h. To the mixture was added dropwise BsCI (219.5 g, 1.24 mol) at 50C. After the addition, the mixture was stirred at room temperature overnight. TLC (Petroleum ether/EtOAc 5:1 ) showed the reaction was complete. The reaction mixture was poured slowly into ice-cold saturated NH4CI (500 mL). The mixture was extracted with EtOAc (600 mLχ2). The combined organic layers were washed with saturated aqueous NaCI (700 mL), dried over Na2SO4 and concentrated in vacuo. The residue was washed with Petroleum ether/EtOAc (15:1 , 1.5 L) to give compound H-1-2 (198 g, 94.8%) as an off-white solid.
Preparation of 5-(1-ethoxyvinyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (H-1 -3)
Figure imgf000117_0002
To a solution of compound H-1-2 (110 g, 0.33 mol) and 2-ethoxyprop-1-ene (141.3 g, 0.39 mol) in toluene (2 L) was added Pd(PPh3J2CI2 (11.4 g, 16.3 mmol) under N2. The mixture was refluxed overnight. TLC (petroleum ether/EtOAc 5:1 ) showed the reaction was complete. The reaction mixture was directly used in next step.
Preparation of 1 -(1 -(phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridin-5-yl)ethanone (H-1 -4)
Figure imgf000118_0001
To a mixture of compound H-1-3 (216 g, 0.66 mol) in toluene (2 L) was added HCI (3 N, 440 mL, 1.32 mol). The mixture was stirred at room temperature for 2 h. TLC (petroleum ether/EtOAc 3:1 ) showed the reaction was complete. The mixture was concentrated in vacuo. The residue was purified via column chromatography (silica gel, petroleum ether/EtOAc 5:1-3:1 ) to give compound H-1-4 (188 g, 95.0%) as an off-white solid.
Preparation of (E)-3-(dimethylamino)-1 -(1 -(phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-en-
Figure imgf000118_0002
A mixture of compound H-1-4 (97.5 g, 0.325 mol) in DMF-DMA (500 mL) was refluxed under N2 overnight. TLC (petroleum ether/EtOAc 1 :1 ) showed the reaction was complete. The reaction mixture was concentrated in vacuo. The residue was washed with EtOAc to give compound H-1-5 (35 g, 30.3%) as a yellow solid and crude compound H-1-5 (90 g) as brown oil.
Preparation of 1-(phenylsulfonyl)-5-(1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridine (H-1-6)
Figure imgf000118_0003
To a mixture of compound H-1-5 (50 g, 0.14 mol) in EtOH (200 mL) was added compound 5B (6.8 g, 0.21 mol) under N2. After the addition, the mixture was refluxed overnight. TLC (petroleum ether/EtOAc 1 :1 ) showed the reaction was complete. About half of the solvent of EtOH was removed in vacuum and the resulting mixture was filtered. The cake was dried in vacuum to give compound H-1-6 (34 g, 75%) as a gray solid.
Preparation of 5-(1 -isopropyl-1 H-pyrazol-3-yl)-1 -(phenylsulfonyl)-i H-pyrrolo[2,3-b]pyridine (H-1 -7)
Figure imgf000118_0004
H-1-6 To a mixture of NaH (2.96 g, 74.1 mmol, 60% in oil) in DMF (200 ml.) was added portionwise compound H-1-6 (20 g, 61.7 mmol) at O0C under N2. After stirring at O0C for 0.5 h, isopropyl iodide (31.5 g, 185.2 mmol) was added dropwise to the mixture at O0C. The resulting mixture was stirred at 00C for 0.5 h. TLC (petroleum ether/EtOAc 1 :1 ) showed most of compound H-1-6 was consumed. The reaction mixture was poured into ice-cold saturated NH4CI (1000 ml_). The mixture was extracted with EtOAc (400 ml_). The aq. layer was basified with K2CO3 to a pH~8, saturated with NaCI and extracted with EtOAc (400 mL). The combined organic layers were washed with saturated aqueous NaCI (400 ml_χ5), dried over Na2SO4 and concentrated in vacuo. The residue was purified via column chromagraphy (silica gel, petroleum ether/EtOAc 10:1 ) to give compound H-1-7 (9 g, 38.1%) as a white solid and crude compound H-1-7 (3 g) as brown oil.
Preparation of 5-(4-bromo-1 -isopropyl-1 H-pyrazol-3-yl)-1 -(phenylsulfonyl)-i H-pyrrolo[2,3- b] pyridine (H -1-8)
Figure imgf000119_0001
To a solution of compound H-1-7 (5 g, 14 mmol) in CHCI3 (100 mL) was added NBS (2.8 g, 16 mmol) under N2. After the addition, the mixture was stirred at room temperature for 3h. TLC (petroleum ether/EtOAc 3:1 ) showed the reaction was complete. The reaction mixture was concentrated in vacuo. To the residue was added EtOAc (200 mL). The mixture was washed with water (200 mL) and saturated aqueous NaCI (200 mL), dried over Na2SO4 and concentrated in vacuo. The residue was washed with petroleum ether/EtOAc (3:1 , 15 mL) to give crude compound H-1-8 (4.5 g, 72%) as a yellow solid. The crude solids were re-crystallized from CH2CI2/petroleum ether (1 :20, 50 mL) to give pure compound H-1-8 (4.35 g, 70%) as an off-white solid.
Preparation of 5-(4-bromo-1 -isopropyl-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine (H-1 -9)
Figure imgf000119_0002
A solution of KOH in 8 ml water was added to a suspension of the Bs protected azaindole (H-1-8) in 50ml EtOH. Stirred at room temperature overnight. The reaction was concentrated by rotary evaporation. The concentrated reaction mixture was diluted with EtOAc and saturated aqueous NaCI, and the layers were separated. The aqueous layer was re-extracted with EtOAc. The combined organic layers were washed with saturated aqueous NaCI, and dried over MgSO4. The solution was filtered and concentrated under reduced pressure to give a yellow solid. Trituration with TBME (2x) gave 3.37g of H-1- 9 as a yellow solid. The product was used in the next step without further purification. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.47 (d, J=6.82 Hz, 6 H) 4.36 - 4.66 (m, 1 H) 6.53 (d, J=2.53 Hz, 1 H) 7.40 - 7.60 (m, 1 H) 8.15 (s, 1 H) 8.30 (d, J=2.02 Hz, 1 H) 8.61 (d, J=2.02 Hz, 1 H) 11.76 (br. s., 1 H).
Preparation of 4-(1 -isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyridin-2-amine (H-1 -
Figure imgf000120_0001
A mixture of the pyrazole H-1-9 (400mg, 1.31mmol), 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyridin-2-amine (375mg, 1.70mmol), and 1 N sodium carbonate (4ml, 4mmol) in 5 mL of DME was flushed with nitrogen for 5 min. 1 ,1'-Bis(diphenylphospino)ferrocene palladium (II) chloride (96mg, 0.131 mmol) was then added and the mixture was heated in an oil bath. Reaction turned dark within 5min. Heating at 8O0C was continued for an additional 18 hours at which time 150mg more of 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine and 25mg more 1 ,1'-bis(diphenylphospino)ferrocene palladium (II) chloride were added. After degassing, the reaction was sealed and placed in microwave for 60 min at 8O0C. The mixture was filtered and the solids rinsed with water and MeOH. The filtrate was partitioned between ethyl acetate and saturated aqueous NaCI. The aqueous layer was extracted with ethyl acetate (2x). The combined organics were washed with water, saturated aqueous NaCI, and dried over MgSO4, and concentrated under vacuum to a crude brown oil (570mg) which was purified by reverse phase HPLC to give 51 mg (12% yield) of H-1 -10 as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.50 (d, J=6.57 Hz, 6 H) 4.45 - 4.65 (s, 1 H) 5.79 (s, 2 H) 6.25 - 6.38 (m, 2 H) 6.45 (dd, J=3.41 , 1.89 Hz, 1 H) 7.40 - 7.55 (m, 1 H) 7.71 - 7.86 (m, 1 H) 7.95 (d, J=2.02 Hz, 1 H) 8.09 (s, 1 H) 8.22 (d, J=1.77 Hz, 1 H) 11.68 (br. s., 1 H).
Preparation of 4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -isopropyl-1 H-pyrazol-4-yl)pyridin-2- amine (H-1)
Figure imgf000120_0002
A mixture 4-(1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyridin-2-amine (H-1 -10) (40mg, 0.13mmol) and N-chlorosuccinimide (19.3mg, 0.14mmol) in CH2CI2 (2ml) was stirred at room temperature for 18 hours. Another portion of N-chlorosuccinimide (5mg, 0.04mmol) was added and stirring continued at room temperature for an additional 4 hours. The reaction was concentrated under reduced pressure and the residue was purified by reverse phase HPLC to give 14mg (31% yield) 4-(3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -isopropyl-1 H-pyrazol-4-yl)pyridin-2-amine (H-1) as a white solid.1 H NMR (400 MHz, DMSO-d6) δ ppm 1.51 (d, J=6.82 Hz, 6 H) 4.43 - 4.69 (m, 1 H) 6.22 - 6.63 (m, 4 H) 7.72 (d, J=2.78 Hz, 1 H) 7.82 (d, J=5.81 Hz1 1 H) 7.92 (d, J=1.77 Hz, 1 H) 8.23 (s, 1 H) 8.30 (d, J=2.02 Hz, 1 H) 12.08 (d, J=1.77 Hz, 1 H).
Example 1-1 : Preparation of (2S)-1-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1H- pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol
Preparation of 1-1-1
Figure imgf000121_0001
1-1-1 To a solution of 5-bromo-3-methoxypyrazin-2-amine (4.05g, 19.8mmol) in 70 mL dry THF was added DMAP (1.24g, 10,1 mmol) followed by boc anhydride (10.4g, 47.6mmol) in one portion at room temperature. The resulting mixture was allowed to stir at room temperature. When the starting material was gone by TLC, the reaction mixture was concentrated under reduced pressure to an amber oil. A precipitate developed when the oil residue was slurried in 3:1 Hexanes/EtOAc which was collected. The precipitate was dissolved in EtOAc and washed with saturated aqueous NaCI with some 0.5N HCI so pH was -5. The organic layer was dried over MgSO4 and cone. The crude product was purified by silica gel chromatography (eluting 3:1 Hexanes/EtOAc) to give 5.4Og of compound 1-1-1 as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.36 (s, 18 H) 3.99 (s, 3 H) 8.37 (s, 1 H).
Preparation of (2S)-1 -({4-[1 -(2,2-difluoroethyl)-3-(trimethylstannyl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-2-ol (1-1-2)
Figure imgf000121_0002
1-1-2
1-1-3
A solution of (2S)-1-({4-[1-(2,2-difluoroethyl)-3-iodo-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol (2.0 g, 4.9 mmol) and hexamethylditin (1.9 g, 5.9 mmol) in toluene (15 mL) was degassed with a Nitrogen bubbler for 5 minutes prior to the addition of Tetrakis(triphenylphoshine)palladium (0) (566 mg, 0.489 mmol). The resulting mixture was sealed in a 20 mL microwave reaction vial and heated in an oil bath at 9O0C for 18 hrs then at 1100C for 2 hrs. The mixture was removed from the oil bath and allowed to cool to room temperature. The mixture was loaded directly onto silica gel and purified using a gradient of 0-35% ethyl acetate in dichloromethane as eluent to give 1.26g (58%) of 1-1-3 as an oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.17 (d, J=5.31 Hz, 1 H), 7.99 (s, 1 H), 6.68 (d, J=5.31 Hz, 1 H), 6.15 (tt, J=55.52, 4.55, 4.42 Hz, 1 H), 5.23 (br. t, J=5.31 Hz, 1 H), 4.56 (td, J=13.52, 4.29 Hz, 2 H), 3.91 - 4.17 (m, 1 H), 3.51 - 3.75 (m, 1 H), 3.28 - 3.48 (m, 1 H), 1.25 (d, J=6.32 Hz, 3 H), 0.36 (t, J=28.55 Hz, 9 H)
Preparation of (2S)-1 -({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1 -(2,2-dif luoroethyl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propan-2-ol (1-1 )
Figure imgf000122_0001
A mixture of di-te/t-butyl (5-bromo-3-methoxypyrazin-2-yl)imidodicarbonate (517 mg, 1.28 mmol), (2S)-1- ({4-[1-(2,2-difluoroethyl)-3-(trimethylstannyl)-1/-/-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol (570 mg, 1.28 mmol), Copper iodide (5 mg, 0.026 mmol) in DMF (13 ml_) was deoxygenated with a N2 bubbler for a few minutes before adding Tetrakis(triphenylphoshine)palladium (0) (74 mg, 0.064 mmol). The mixture was sealed in a microwave vial and heated in an oil bath at 100C for 18 hrs. This mixture was then heated in the microwave at 17O0C for 20 minutes to themolyze the tert-butoxycarbonyl groups. The mixture was partitioned between ethyl acetate and saturated aqueous NaCI. Some dark insoluble solids did not go into either phase and were removed by filtration. The layers were separated and the aqueous layer was extracted twice with ethyl acetate. The combined organics were washed once each with water and saturated aqueous NaCI, dried over Magnesium sulfate and reduced to minimum volume. The residue was then purified on silica gel using a gradient of 0-8% methanol (containing 10% ammonium hydroxide) in a mixture of tert-butyl methyl ether and dichloromethane (1 :1 ) as eluent. A small amount of the product still containing the tert-butoxycarbonyl groups was recovered from the column. This material was treated with 10% hydrochloric acid in methanol at 7O0C for 2 hours to complete the deprotection. The mixture was partitioned between aqueous Sodium bicarbonate and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined organics were washed with water (1x), saturated aqueous NaCI (1x), dried over MgSO4 and reduced to minimum volume. The residue was then purified on silica gel in a similar fashion to obtain a second batch of product. The batched were combined and dissolved in a mixture of methanol and water then lyophilized to give 180 mg (33%) (2S)-1-({4-[3-(5- amino-6-methoxypyrazin-2-yl)-1 -(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol (1-1 ) as a fluffy white solid. 1 H NMR (400 MHz, ACETONITRILE-d3) δ ppm 8.05 - 8.15 (m, 2 H)1 7.83 (s, 1 H), 6.65 (d, J=5.31 Hz, 1 H), 6.27 (tt, J=54.95, 3.79 Hz, 1 H), 5.73 (br. t, J=4.93 Hz, 1 H), 5.34 (br. s., 2 H), 4.58 (td, J=14.72, 3.66 Hz, 2 H), 3.81 (br. s., 1 H), 3.76 (s, 3 H), 3.54 (br. s., 1 H), 3.27 - 3.41 (br. m, 1 H), 3.06 - 3.23 (br. m, 1 H), 1.08 (d, J=6.32 Hz, 3 H).
Preparation of (2S)-1 -(4-(1 -(2,2-dif luoroethyl)-3-iodo-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2- ol (1-1-2)
Step i :
Figure imgf000123_0001
1-1 -2a 1-1 -2b
A mixture of compound 1-1 -2a (22 g, 69.2 mmol), 1 ,1-difluoro-2-iodoethane (16 g, 83.3 mmol) and K2CO3 (19.2 g, 0.138 mol) in DMF (80 mL) was stirred at 3O0C overnight. When TLC (EtOAc/Petroleum ether = 1 :4) showed the reaction was complete, DMF was evaporated under reduced pressure. The residue was taken up with EtOAc (500 mL). The mixture was washed with brine, dried over Na2SO4 and concentrated to give crude product, which was purified via SFC to give the product (12.1 g, 45.8%) as a yellow solid. Step 2:
Figure imgf000123_0002
l-1-2b '-1 "2c
To a solution of 1-1 -2b (10 g, 26.2 mmol) in THF (100 mL) and water (100 mL) was added oxone (24 g, 39.1 mmol) at 0 ~ 50C. After the addition, the mixture was stirred at room temperature overnight. TLC (EtOAc/Petroleum ether = 1 :2) showed the reaction was complete, the mixture was concentrated to 1/2 volume, then EtOAc (200 mL) was added and the organic layer was separated, washed with brine, dried over Na2SO4 and concentrated to give 1-1 -2c (10.9 g, 100%) as a yellow solid. Step 3:
Figure imgf000123_0003
A mixture of l-1-2c (10.9 g, 26.3 mmol) and (S)-1-aminopropan-2-ol (7.9 g, 0.105 mol) in THF (100 mL) was heated to reflux overnight. When TLC (CH2CI2: MeOH = 10:1 ) showed the reaction was complete, EtOAc (300 mL) and brine (100 mL) were added to the mixture, and the layers were separated. The organic layer was washed with brine (80 mL><5), dried over Na2SO4, filtered and concentrated to give the product 1-1-2 (10.1 g, 93.9%) as a pale solid.
Table 1
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
(d, 1 1 H), (s, 2 s., 2 H),
(s, 1 1 H), 5.59 (t, 1 H),
8.12 (d, (m, 2 3.53 (s,
(d, 1 8.07 s., 1 5.49 s., 2 2 H), 4 H).
1 H), (d, 1 H), 3.39 (br. s.,
(d, 1 7.31 6.45 (m, 4.07 H), 3.36 1.18
Figure imgf000128_0001
1 H), (br. t, 3 H), (s, 9 M+H:
1 H), - 5.70 4.49 - (q, 2
1 H), (tt, 1 2 H), (q, 2
(d, 1 8.08 (d, H), 3.39
(d, 1 8.12 1 H), H), m, 1 H).
ppm H), H), 4.69 (t, 2 H), (d, 1 M+H:
Figure imgf000129_0001
Figure imgf000130_0001
ITRI LE- (br. s., 1 s., 1 H), 2 H), 5.82 7.16 (s, 1 8.17 (d,
6 H), s., 1 H), 5.54 1 H), 6.66 (d, (s, 2
δ ppm 7.77 H), (s, 1
(br. s., 2 H), 7.15 (s, 1 8.41 1 H).
6 H), (m, 1 2 H), 7.16 7.99
Figure imgf000131_0001
(br. s., H), 5.46 1 H), H), 8.41
3 H), 3.74 (s, 5.89 (br. s., 1 2 H), 8.18
ITRI LE- 3.71 - 6.10 (m, H), (m, 2 H), 9.97
(br. s., 2 s., 2 H), (br. s., 1 8.27
s., 2 1 H), (d, 1 2 9.69
s., 2 H), 6.64 1 H) (br.
Figure imgf000132_0001
3 H), s., 2 H), 6.70 (d, 1 s., 1
ITRI LE- s., 2 (spt, 1 H), 1 H), 7.38 1 H), (br.
1 H), 6.57 (d, 1 5.24 (t, 1 H), H), 3.74 - 3.83
δ ppm H), 8.43 (d, 1 1 H), 7.75 6.59 (d, 1 3 H).
δ ppm (d, 1 H), (td, 1 2 H),
δ ppm 7.65 (br. s., 3.80 (m, - 1.18 M+H:
Figure imgf000133_0001
δ ppm (d, 1 H), 8.23 1 H), H), 6.26 (d, 1 2.26 (s,
δ ppm 8.26 (br. s., 1 H), 3.79 - H), (m, 2 388
δ ppm H), 8.36 (s, 1 1 H), 7.74 (d, 1 H), H).
δ ppm (d, 1 7.49 1 H), H) 2.31 3 H).
δ ppm (d, 1 7.57 H), H),
δ ppm - (d, 1 7.77 (m, (s, 2 395.2
Figure imgf000134_0001
δ ppm (s, 1 1 H), 8.43 (d, 1 H), 1 H), H),
δ ppm 1 H), 8.30 (s, 1 1 H), 7.73 (d, 1 H),
(br. s., 8.01 1 H), 1 H), (m, 1 1.15
(s, - 2.39 H), (d, 1 (d, 8.13 1 H),
δ ppm 3 H), 2 H), 1 1 H), H),
2.66 (t, H), 3.85 2 H), 4.37 - (t, 1 (d,
Figure imgf000135_0001
3.57 3.83 - 2 H), 4.37 - (t, 1 (d, 1 H), (s, 1
δ ppm 2.50 6.72 (br. (d, s., 1 M+H:
2 H), H), 4.59 1 H), 6.59 1 H),
- 3.87 - (dd, - 5.09 1 H), (d, 1 M+H:
s., 2 H), - (s, 1 9.50
2.50 - 4.00 - 1 H), (dd, 1 3 H), M+H:
Figure imgf000136_0001
(m, (dd, 1 1 H), 4.16 2 H), 4.46 (tt, 1 7.31 (d, 8.21 s., 1
δ ppm - H), 4.20 - 1 H), 7.18 (s, 1 1 H), 8.37 M+H:
s., 2 5.54 (d, 1 8.23
1 H), (tt, 1 2 H), (q, 2
s), 7.91 (2H, d), 6.75(1 H, d), H, t).
Figure imgf000137_0001
s), H, d), H, d), t), s).
(m, H), 4.82 1 H), (d, 1
(m, (br. s., (m, 1 2 H), (d, 1 8.02 (s,
1 H), 1 H), H), (s, 1 8.05 1 H)
1 H), (m, 2 3.44 - 3.54 3.97 - 4.06 (m, (m, 1 1 H), (d, 1
(m, - 3.35 (s, 1 H), - 5.58 (m, 1 7.32 1 H), (s, 1
Figure imgf000138_0001
Figure imgf000139_0001
2.40 - 2.61 (m, (td, 2 H), 6.52 (d, 8.09 1 H),
(m, 3.57 - (s, 1 8.15 1 H),
3.62 (s, (td, 2 7.70 1 H),
(d, 1 H), 8.07 (d, 1 H), 1 H), 4.58 (br. s., -
(br. s., (m, 2 H), 1 H), 3.56 2.38
(d, 1 7.98 (d, 1 H), 4.48 (br. 3.23 - (d, 3
Figure imgf000140_0001
(d, 1 H), 8.11 (d, 1 H), J=6.57 - 4.03 (br. 3.24 -
(d, 1 1 H), (t, 1 s., 1 s., 1 H), H),
(m, (s, 1 5.68 1 H), (d, 1 9.33 (s,
2 H), (m, 1 1 H), (t, 1 7.43 1 H),
ppm - H), (s, 1 1 H), (d, 1
(m, (s, 3 2 H), (tt, 1 7.93 1 H).
Figure imgf000141_0001
(m, 5.41 1 H), (s, 2 1 H).
ppm 2 H), (d, 1 8.16 1 H).
ppm H), (d, 1 8.52
(td, 2 H), (d, 1 H), 8.09 1 H),
δ ppm (m, 4.71 2H), (m,
(quin, 2 (s, 3 H), 1 H), 4.33 (t, (s, 1 H), 8.03 s., 1
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
δ ppm H), 1 H), H), s., 1 H), s., 1 H), 1 H); due to
δ ppm 6.43 (br. (s, 1 2 H), with M+H:
δ ppm 4.62 (br. s., (br. s., 1 (br. s., 1 H), protons
δ ppm 1 H), H), (br. s., 1 H), s., 1 H), H), s., 1 H), with M+H:
δ ppm 4.59 6.39 (br. (br. s., s., 1 water
Figure imgf000145_0001
δ ppm - 4.03 - 4.63 (br. s., s., 1 s., 1 H), H), with M+H:
δ ppm 4.10 1 H), 6.45 7.46 (br. 1 H), H), with 429.2
δ ppm H), H), s., 1 H), H), 1 H); due
δ ppm 6.48 7.47 (br. (br. s., (br. s., 1 visible water
Figure imgf000146_0001
δ ppm 3.08 6.47 (br. (br. s., s., 1 with M+H:
2 H), 3.02 (t, (td, 2 1 H), 6.23 1 H), (s, 1
(br. s., 8.03 1 H), 3.96 -
(d, 1 H), 8.07 (d, 1 H), 1 H), 4.58 (br. s., -
(br. s., (m, 2 H), 1 H), 3.56 2.38
(d, 1 H), 7.98 6.44 (d, 1 H), 4.48 (br. 3.23 - (d, 3
Figure imgf000147_0001
δ ppm (d, 1 1 H), 7.32 (t, H), 5.15 (t, 1 2 H), M+H:
δ ppm (d, 1 H), 8.26 1 H), 2 H), 6.34 (d, 1 1.55 (s,
δ ppm (d, 1 8.10 1 H), H).
1 H), (d, 1 5.24 (t, 1 H), - 3.83
δ ppm H), 8.49 (s, 1 7.17 3 H),
11.281 H), 8.28 1 H), (s, 1 H), 4.06- H), 2.94
1 H), (d, 1 s., 2 H), (br. q,
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Example J: Raf Biochemical Assay
Compounds of the present invention were evaluated for potency against b-Raf using an in vitro kinase assay. Raf kinase activity is measured in vitro by determining transfer of radiolabeled 32-P phosphate from ATP to the specific Raf substrate Mek1. Full-length wild type b-Raf is expressed in recombinant form and purified from bacterial or insect cells. Recombinant Mek1 is purified from E. coli bacterial cells. In one assay format (designated G1 ), the full-length wild type Mek1 is used as the b-Raf substrate. In a second assay format (designated G2), the full-length K97R Mek1 mutant is used as the b- Raf substrate.
In vitro kinase assays are performed in solution containing the following; 50 mM Hepes (pH 7.4), 5 nM b-Raf, 0.8 μM Mek1 , 10 mM MgCI2, 25 μM ATP, 0.002% (v/v) Tween-20, 5 μg/mL leupeptin, 1.2 mM DTT, 2% (v/v) DMSO, 0.2-1.0 μCi [γ-32P]ATP per well.
The assays are performed in wells of a 96 well polypropylene round bottom plate, each well containing 43.5 μL assay mix and 1.5 μL inhibitor compound or DMSO vehicle. 15 μL of b-Raf mix is added and the plate is shaken on a plate shaker and preincubated for 10 minutes at ambient temperature. The reaction is started by addition of 15 μL ATP mix and shaking. The reaction is terminated after 40 minutes by addition of 25 μL 0.5 M EDTA (pH 7.4).
60 μL of the stopped reaction is transferred to a well of a 96-well nylon 66 Biodyne A membrane
Silent Screen filter plate (Nalge/Nunc: 256081 ). The wells are filtered and washed five times with 0.85% phosphoric acid. The filter is placed in a tray with about 50 mL 0.85% phosphoric acid and gently rotated for 10 minutes on an orbital shaker. The procedure is repeated once with fresh 0.85% phosphoric acid.
Five samples of 0.5 μL of ATP mix are also spotted onto filter paper for calculation of specific activity. The filters are air dried for one hour and sandwiched between cellophane wrap on an Amersham Biosciences
Storage Phosphor Screen and developed at least over night. The image is read using a Molecular Dynamics Storm 840 phosphoimager. Volumes of spots are calculated using lmageQuant5.1.
Raf kinase activity is calculated from the specific activity of [32-P] ATP, 32-P incorporation into Mek1 , and the concentration of b-Raf.
Example K: Raf Cellular Assay Compounds of the present invention were evaluated for potency against b-Raf using a cellular assay as follows. The activity of Raf kinases in cells is determined by measuring the level of phosphorylation of Mek1/2 at serine 217/221 , the site phosphorylated by Raf kinases in vivo. Mek1/2 Ser phosphorylation is measured using anti-phospho-Mek1/2 antibodies (Cell Signaling #9121) in an ELISA format. Healthy growing human melanoma A2058 cells (harboring a b-Raf mutation) are used for the assay. A2058 cells are grown in 10% FBS DMEM medium. When the cells are near 85%+ confluence, the cells are rinsed with PBS once and trypsinized with trypsin/EDTA for 3 minutes. The cells are resuspended in 10% FBS DMEM and are centrifuged down at 1000 rpm for 5 minutes. The cells are resuspended in 10% FBS DMEM and counted on a cell counter. The cells are seeded at 50,000 cells/well in a volume of 100 μL/well in 10% FBS DMEM in a 96 well flat-bottom plate. The negative control wells receive only 100 μL of 10% FBS DMEM medium without cells. The plate is incubated overnight in a cell culture incubator with 5% CO2 at 37 0C.
On day 2, testing compounds are prepared in 10% FBS DMEM medium and serially diluted at 1 :3 for 11 test concentrations. Each concentration of the compounds is tested in duplicate. The compound solutions are added at 25 μL/well to the corresponding wells in the cell plate, and 25 μL/well of the vehicle (0.5% DMSO in 10% FBS DMEM) is added to the negative control wells (no cells) and the positive control wells (cells without compounds). The plate is incubated for 1 hour in a cell culture incubator with 5% CO2 at 37 0C. After 1 hour of incubation, the medium is removed, 100 μL/well of cell lysis buffer is added into the cell plate, and the plate is shaken for 15 minutes at room temperature. After 15 minutes, the cell lysates are transferred to an ELISA plate (pre-coated with anti-Mek1 anti-body, Cell Signaling #2352), and the plate is incubated with gentle shaking for 2 hours at room temperature. After 2 hours, the contents of the wells are aspirated and the wells are washed 4 times with wash buffer. 100 μL of phospho-Mek1/2 detection antibody (Cell Signaling #9121 ) is added into each well and the plate is incubated with gentle shaking for 1 hour at room temperature. After 1 hour, the wells are aspirated and washed 4 times with wash buffer. 100 μL of anti-rabbit IgG HRP-linked antibody (Cell Signaling #7074) is added to each well, and the plate is incubated with gentle shaking for 1 hour at room temperature. After 1 hour, the contents of the wells are aspirated and the wells are washed 4 times with wash buffer. 100 μl_ of TMB substrate solution (Sigma #T0440) is added into each well, and the plate is incubated with gentle shaking at room temperature for 10 to 20 minutes. After color development, 100 μL of stop solution (1N hydrochloric acid) is added to each well to terminate color development. The plate is read at 450 nm on an ELISA plate reader.
Figure imgf000152_0001
Table 3
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001

Claims

Claims We claim:
1 ) In another embodiment, the present invention is a compound of Formula (II)
Figure imgf000157_0001
(H) wherein:
X is N or CR7;
R1 is H, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-Cg heteroaryl is optionally substituted with one or more R8;
R2 is C2-C9 cycloheteroalkyl or C2-C9 heteroaryl, wherein each of said C2-C9 cycloheteroalkyl and
C5-Ci4 heteroaryl is optionally substituted with one or more R8; or optionally where R2 is C2-C9 heteroaryl, the hydrogen atoms on any 2 adjacent ring atoms may combine to form a 5-7 membered cycloalkyl optionally substituted by one or more R8, a 5-7 membered cycloheteroalkyl optionally substituted by one or more R8, or a 5-7 membered heteroaryl optionally substituted by one or more R8;
R3 is H or -NR9R10; or where X is CR7, R3 may combine with R7 to form a 5-7 membered heteroaryl optionally substituted by one or more R8, 5-7 membered cycloheteroalkyl optionally substituted by one or more R8, phenyl optionally substituted by one or more R8, or 5-7 membered cycloalkyl optionally substituted by one or more R8;
R4, R5, R6, R7 are each independently H, -NR11R12, -CN, -C(O)R11, -C(O)OR11, -NO2, -SR11, -
S(O)2R11, -OR11, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-Cj4 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl wherein each of said CrC6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-Cg cycloheteroalkyl, or C2-Cg heteroaryl is optionally substituted with one or more R8; each R8 is independently -OR11, fluorine, chlorine, bromine, oxo, cyano, -NR13R14,
-C(O)N(R13R14), -C(O)R13, -C(O)OR13, -NO2, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl,
C6-C14 aryl, C2-C9 cycloheteroalkyl, C2-C9 heteroaryl, or -(CH2)nC(O)R11, wherein each of said C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with one or more R11;
R9 and R10 are each independently H, -C(O)N(R13R14), -C(O)R13, -C(O)OR13, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, or C2-C9 heteroaryl, wherein each of said C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl is optionally substituted with at least one R11; or R9 and R10 taken together with the nitrogen to which they are attached combine to form a 4-7 membered cycloheteroalkyl ring optionally substituted with one or more R11; each R11 and R12 is independently fluorine, chlorine, bromine, -OH, -C(O)R13, -C(O)OR13, -SR13, - S(O)2R13, -OR13, -NR13R14, -C(O)N(R13R14), cyano, C1-C6 alkyl, C1-C11 heteroalkyl, C3-C8 cycloalkyl, -O- (C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more R13; each R13 and R14 is independently H, oxo, C1-C6 alkyl, C1-C11 heteroalkyl, C3-C8 cycloalkyl, -O-
(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein each of C3-C8 cycloalkyl, -0-(C3-C8 cycloalkyl), -S-(C3-C8 cycloalkyl), C6-C14 aryl, -0-(C6-C14 aryl), -S-(C6-C14 aryl), C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, is optionally substituted with one or more group selected from fluorine, chlorine, bromine, -OH, cyano, and C1-C6 alkyl; n is O, 1 , 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
2) The compound according to claim 1 , wherein X is N, or a pharmaceutically acceptable salt thereof. 3) The compound according to claim 1 , wherein X is CR7, or a pharmaceutically acceptable salt thereof.
4) The compound according to claim 1 , wherein R4 is H, or a pharmaceutically acceptable salt thereof.
5) The compound according to claim 1 , wherein R5 is H, or a pharmaceutically acceptable salt thereof.
6) The compound according to claim 1 , wherein R6 is H, or a pharmaceutically acceptable salt thereof.
7) The compound according to claim 1 , wherein R4, R5, and R6 are H, or a pharmaceutically acceptable salt thereof. 8) The compound according to claim 1 , wherein R1 is C1-C6 alkyl optionally substituted with one or more R8, or a pharmaceutically acceptable salt thereof.
9) The compound according to claim 1 , wherein R1 is selected from methyl, ethyl, isopropyl, cyclopropyl, 2,2-difluoroethyl, cyanomethyl, difluorocyclobutanyl, (3-methyloxetan-3-yl)methyl, 1 ,1- dimethyl-2-hydroxyethyl, 1-methyl-i-cyanoethyl, difluoromethyl, tert-butyl, 3-hydroxypropan-2-yl, piperidinyl, N-acetyl-piperidinyl, H, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 4-cyanophenyl, cis- fluorocyclobutanyl, trans-fluorocyclobutanyl, oxetanyl, and N-methyl-piperidinyl, or a pharmaceutically acceptable salt thereof.
10) The compound according to claim 9, wherein R1 is selected from methyl, isopropyl, (3- methyloxetan-3-yl)methyl, 2,2-difluoroethyl, and cyanomethyl, or a pharmaceutically acceptable salt thereof. 11 ) The compound according to claim 1 , wherein R is selected from the group consisting of
Figure imgf000159_0001
Figure imgf000160_0001
or a pharmaceutically acceptable salt thereof.
12) The compound according to claim 1 , wherein R3 is -NR9R10.
13) The compound according to claim 12, wherein R3 is NH2, H,
Figure imgf000161_0001
Figure imgf000162_0001
or a pharmaceutically acceptable salt thereof.
14) The compound according to claim 1 , wherein the compound is selected from the group consisting of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin- 5-yl)-1 H-pyrazol-4-yl]-N-[2-(1 H-pyrazol-1-yl)ethyl]pyrimidin-2-amine, (2S)-1-(4-(1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyhmidin-2-ylamino)propan-2-ol, N-(2-fluoroethyl)-4-[1- isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1-(4-(3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-methyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 2-({4-[1-isopropyl-3- (1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethanol, 4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N-[2-(1 H-pyrazol-4-yl)ethyl]pyrimidin-2-amine, (2S)-1-(4-(3- (2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, [4- [2-((S)-2-Hydroxy-propylamino)-pyrimidin-4-yl]-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1-yl]-acetonitrile, 1-[2-({4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethyl]pyridin- 2(1 H)-one, (2R)-2-({4-[1-isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-1-ol, N-[(1-ethyl-1 H-pyrazol-4-yl)methyl]-4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)- 1 H-pyrazol-4-yl]pyrimidin-2-amine, N-[(2,5-dimethyl-1 ,3-oxazol-4-yl)methyl]-4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5- yl)-1 H-pyrazol-4-yl]-N-(tetrahydrofuran-3-ylmethyl)pyrimidin-2-amine, 4-(1-isopropyl-3-(1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)-N-(pyridin-2-ylmethyl)pyrimidin-2-amine, (2S)-1-(4-(1-isopropyl-3-(1 H- pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 4-[1-isopropyl-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N-(2-methoxyethyl)pyrimidin-2-amine, 1 -ethyl-4-[({4-[1 - isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)methyl]pyrrolidin-2-one, (2S)-1-(4-(1-isopropyl-3-(5-methyl-6-(methylamino)pyridin-3-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(2-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(5-methyl-5H-pyrrolo[2,3-b]pyrazin-3-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-methyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(2-methylimidazo[1 ,2-a]pyrimidin-6- yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-isopropyl-3-(6-(methylamino)pyridin-3- yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethylimidazo[1 ,2-a]pyrimidin-6- yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-(2,2-difluoroethyl)-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4- (3-(3-chloro-2-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(1-((3-methyloxetan-3-yl)methyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 5-(4-(2-((S)-2-hydroxypropylamino)pyrimidin-4-yl)-1- isopropyl-1 H-pyrazol-3-yl)-3,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-2(3H)-one, (2S)-1 -(4-(3-(3,3-dimethyl-2,3- dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-methyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol and (2S)- 1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-((3-methyloxetan-3-yl)methyl)-1 H-pyrazol-4-yl)pyrimidin- 2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. 15) The compound according to claim 1 , wherein the compound is selected from the group consisting of (2S)-1-(4-(1-isopropyl-3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(2,3-dimethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- (2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol and (2S)-1-(4-(1-isopropyl-3-(3-methyl- 1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol; or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(2,3-dimethyl-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof. In a further embodiment, the compound is (2S)-1-(4-(3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, or a pharmaceutically acceptable salt thereof.
16) The compound according to claim 1 , wherein the compound is selected from 4-[3-(6-amino-5- methoxypyridin-3-yl)-1-isopropyl-1 H-pyrazol-4-yl]-N-cyclopropylpyrimidin-2-amine, (2S)-1-({4-[3-(3-chloro- 1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(3,3-difluorocyclobutyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3-(6-amino-5-methylpyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-2-ol, 3-({4-[3-(3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2,2-difluoroethyl)-3-(3-fluoro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(2,3-dihydro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4- [1-(2-hydroxy-1 ,1-dimethylethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[3-(3-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)- 1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, N-{5-[4-{2-[(2- cyanoethyl)amino]pyrimidin-4-yl}-1-(2,2-difluoroethyl)-1 H-pyrazol-3-yl]-4-methylpyridin-2-yl}acetamide, N- [1-(cyclopropyl-sulfonyl)piperidin-4-yl]-4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol- 4-yl]pyrimidin-2-amine, 3-({4-[1-(2,2-difluoroethyl)-3-(6-methylpyridin-3-yl)-1H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, (2S)-1-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-4-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propan-2-ol, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-tert-butyl-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-isopropyl-1H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1 -(2,2-difluoroethyl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2- difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 2-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-4-(2-{[(2S)-2-hydroxypropyl]amino}pyrimidin-4-yl)-1 H-pyrazol-1 -yl]-2-methylpropanenitrile, (2S)-1 -({4- [1-(2,2-difluoroethyl)-3-(1-methyl-1H-pyrrolo[3,2-b]pyridin-6-yl)-1H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-2-ol, 3-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, and 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(1-methyl-1 H- pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof.
17) The compound according to claim 1 , wherein the compound is selected from 3-({4-[1-(2- hydroxy-1 ,1-dimethylethyl)-3-(1-methyl-1 H-pyrrolo[3,2-b]pyridin-6-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, (2S)-1-[(4-{3-[6-amino-5-(difluoromethoxy)-pyridin-3-yl]-1-isopropyl-1 H-pyrazol-4- yl}pyrimidin-2-yl)amino]propan-2-ol, 4-[1-(difluoromethyl)-3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazol-4-yl]pyrimidin-2-amine, (2S)-1 -({4-[3-(6-amino-5-methoxypyridin-3-yl)-1 -(difluoromethyl)-i H- pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3-(2-aminopyrimidinT5-yl)-1-isopropyl-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -
(difluoromethyl)-1H-pyrazol-4-yl]pyrimidin-2-amine, 3-({4-[1-(difluoromethyl)-3-(3-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 2-amino-5-[4-(2-{[(2S)-2- hydroxypropyl]-amino}pyrimidin-4-yl)-1-isopropyl-iH-pyrazol-3-yl]pyridin-3-ol, 3-({4-[1-(2,2-difluoroethyl)-3- (5-methoxypyridin-3-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(6-amino-5- methylpyridin-3-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 2- [4-{2-[(2,2-difluoroethyl)amino]pyrimidin-4-yl}-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-1-yl]-2- methylpropan-1-ol, 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(5-methoxypyridin-3-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)-propanenitrile, 3-({4-[1 -isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[3-(5-acetyl-6-aminopyridin-3-yl)-1-isopropyl-1H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-{[4-(1-isopropyl-3-pyridin-3-yl-1 H-pyrazol-4-yl)pyrimidin- 2-yl]amino}-propanenitrile, 4-[3-(6-amino-5-methoxypyridin-3-yl)-1-tert-butyl-1 H-pyrazol-4-yl]-N-(2,2- difluoroethyl)pyrimidin-2-amine, (2R)-2-[4-(2-aminopyrimidin-4-yl)-3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5- yl)-1 H-pyrazol-1 -yl]propan-1-ol, 4-[3-(6-amino-5-methoxypyridin-3-yl)-1-cyclopropyl-1 H-pyrazol-4- yl]pyrimidin-2-amine, 3-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1 -cyclopropyl-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)-propanenitrile, 2-[4-(2-aminopyrimidin-4-yl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-1-yl]-2-methylpropan-1-ol, 4-[3-(6-amino-5-methoxypyridin-3-yl)-1 -cyclopropyl-1 H-pyrazol-4-yl]-N- (2,2-difluoroethyl)pyrimidin-2-amine, and 4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H- pyrazol-4-yl]pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof. 18) The compound according to claim 1 , wherein the compound is selected from (2S)-1-({4-[3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 -ethyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[1 - isopropyl-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-piperidin-4-yl-1 H-pyrazol-4-yl]pyrimidin-2-amine, 3-chloro-5-(1-piperidin-4-yl- 4-pyrimidin-4-yl-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine, 4-[1-tert-butyl-3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1-({4-[1-tert-butyl-3-(3-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[1-(1-acetylpiperidin-4-yl)-3-(3-chloro- 1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)-pyrimidin-2-amine, 4-[3-(6-amino-5- methoxypyridin-3-yl)-1H-pyrazol-4-yl]-N-(2,2-difluoroethyl)-pyrimidin-2-amine, 3-({4-[3-(6-amino-5- methoxypyridin-3-yl)-1 -(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 4- [3-(6-amino-5-methoxypyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)- pyrimidin-2-amine, 3-({4-[1 -tert-butyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin- 2-yl}amino)propanenitrile, 3-({4-[1-tert-butyl-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, 3-[(4-{3-(5-methoxypyridin-3-yl)-1-[(3R)-tetrahydrofuran-3-yl]-1 H- pyrazol-4-yl}pyrimidin-2-yl)amino]propanenitrile, 3-({4-[1-tert-butyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)-propanenitrile, 3-[(4-{3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-[(3R)- tetrahydrofuran-3-yl]-1 H-pyrazol-4-yl}pyrimidin-2-yl)amino]propanenitrile, (2S)-1 -({4-[3-(3-chloro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-piperidin-4-yl-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)pyrimidin- 2-amine, 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)- propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 4-[3-(6-amino-5-methoxypyridin-3-yl)-4-{2-[(2-hydroxyethyl)-amino]pyrimidin-4-yl}- 1 H-pyrazol-1-yl]-benzonitrile, 4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]-N- (6-methoxypyridin-3-yl)pyrimidin-2-amine, 3-(4-(3-(6-amino-5-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, 3-(4-(3-(6-amino-5-methoxypyridin-3-yl)-1-(2,2- difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, (S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-((1s,3s)-3-fluorocyclobutyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, (S)-1-(4-(3- (6-amino-5-methoxypyridin-3-yl)-1-((1r,3r)-3-fluorocyclobutyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan- 2-ol, (S)-1-(4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-((1 r,3r)-3-fluorocyclobutyl)-1 H-pyrazol-4- yl)pyrimidin-2-ylamino)propan-2-ol, (2S)-1-(4-(1-(2,2-difluoroethyl)-3-(3-methyl-2,3-dihydro-1H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 3-(4-(1-(2,2-difluoroethyl)-3-(2,3-dihydro- 1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, and 1-(4-(1-(2,2- difluoroethyl)-3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-2- methylpropan-2-ol, or a pharmaceutically acceptable salt thereof. 19) The compound according to claim 1 , wherein the compound is selected from N-(2,2- difluoroethyl)-4-(1-(2,2-difluoroethyl)-3-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4- yl)pyrimidin-2-amine, 3-(4-(1-(2,2-difluoroethyl)-3-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrazol-4- yl)pyrimidin-2-ylamino)propanenitrile, (S)-1-(4-(1-(2,2-difluoroethyl)-3-((R)-3-methyl-2,3-dihydro-1H- pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol, 3-(4-(1-(2,2-difluoroethyl)-3-(3- methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, 3-(4-(1-(1- hydroxy-2-methylpropan-2-yl)-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2- ylamino)propanenitrile, 3-(4-(1-(2,2-difluoroethyl)-3-(2-oxo-2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazol-4-yl)-pyrimidin-2-ylamino)propanenitrile, (2S)-1-({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1- (2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3-(3-chloro-2-methyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-[(4-{3-(3- chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-[(3-methyloxetan-3-yl)methyl]-1 H-pyrazol-4-yl}pyrimidin-2- yl)amino]propan-2-ol, (2S)-1-({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-oxetan-3-yl-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[1-(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1 -({4-[1 -(2,2-difluoroethyl)-3-(3-fluoro-1 H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[1-(2,2- difluoroethyl)-3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2- ol, 5-[1 -(2,2-difIuoroethyl)-4-(2-{[(2S)-2-hydroxypropyl]amino}pyrimidin-4-yl)-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine-3-carbonitrile, (2S)-1-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)- 1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, 2-({4-[1-(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethanol, 2-({4-[3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5- yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)ethanol, 4-[3-(3-chloro-1H-pyrrolo[2,3- b]pyridin-5-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[1-(2,2-difluoroethyl)-3-(3-methyl- 1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, (2S)-1 -({4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-(1-methylpiperidin-4-yl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3- (S-chloro-I H-pyrrolop.S-blpyridin-S-ylJ-I^S-methoxypropyO-IH-pyrazoW-yllpyrimidin^-ylJaminoJpropan- 2-ol, (2S)-1-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propan-2-ol, (2S)-1-({4-[3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-(1-methylpiperidin-4-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, N-(2,2-difluoroethyl)-4-[1-(1-methylpiperidin-4-yl)-3-(3- methyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-1-(1-methylpiperidin-4-yl)-1 H-pyrazol-4-yl]-N-(2,2-difluoroethyl)pyrimidin-2-amine, 4-[3-(6- amino-5-methoxypyridin-3-yl)-1H-pyrazol-4-yl]pyrimidin-2-amine, 3-(4-(1-(2,2-difIuoroethyl)-3-(1- cyanoethyl-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propanenitrile, 3-({4-[3-(3- chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2-hydroxy-1 ,1-dimethylethyl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)-propanenitrile, 2-[4-(2-amino-pyrimidin-4-yl)-3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazol-1-yl]-2-methylpropan-1-ol, 3-chlord-5-(1-isopropyl-4-pyrimidin-4-yl-1 H-pyrazol-3-yl)-1 H- pyrrolo[2,3-b]pyridine, 3-chloro-5-[1-(1-methylpiperidin-4-yl)-4-pyrimidin-4-yl-1 H-pyrazol-3-yl]-1 H- pyrrolo[2,3-b]pyridine, 5-(1 -tert-butyl-4-pyrimidin-4-yl-1 H-pyrazol-3-yl)-3-methoxypyridin-2-amine, (2S)-1 - (4-(3-(3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)pyrimidin-2- ylamino)propan-2-ol, 3-({4-[3-(6-amino-5-methoxypyridin-3-yl)-1-methyl-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, N-(2,2-difluoroethyl)-4-[1-(2,2-difluoroethyl)-3-(3-methyl-1H-pyrazolo[3,4- b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2-amine, 4-[1 -(2,2-difluoroethyl)-3-(3-methyl-1 H-pyrazolo[3,4- b]pyridin-5-yl)-1H-pyrazol-4-yl]-N-(tetrahydrofuran-3-yl)pyrimidin-2-amine, 2-[3-(3-chloro-1 H-pyrrolo[2,3- b]pyridin-5-yl)-4-{2-[(2-hydroxyethyl)amino]pyrimidin-4-yl}-1 H-pyrazol-1-yl]-2-methylpropanenitrile, 2-[4-(2- aminopyrimidin-4-yl)-3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-1-yl]-2-methylpropanenitrile, 3- (4-(3-(6-amino-5-methylpyridin-3-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)- propanenitrile, 4-(3-(3-chloro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1 H-pyrazol-4-yl)pyridin-2-amine, 4- (1-isopropyl-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyridin-2-amine, 4-(1-isopropyl-3-(1H- pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl)-1 H-pyrrolo[2,3-b]pyridine, 3-chloro-5-(1-isopropyl-4-(1 H- pyrrolo[2,3-b]pyridin-4-yl)-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3-b]pyridine, (2S)-1 -({4-[3-(5-amino-6- methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol, (2S)-1-({4-[3- (7-chloro-5H-pyrrolo[2,3-b]pyrazin-2-yl)-1-isopropyl-1 H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-ol , or a pharmaceutically acceptable salt thereof.
20) The compound according to claim 1 , wherein the compound is selected from 3-({4-[1-(2- hydroxy-1 ,1-dimethylethyl)-3-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl]pyhmidin-2-yl}amino)propanenitrile, 3-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, (2S)-1-(4-(1-isopropyl-3-(3-methyl-1 H-pyrazolo[3,4-b]pyridin-5-yl)- 1 H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol and 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1-(2,2- difluoroethyl)-1 H-pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, or a pharmaceutically acceptable salt thereof.
21 ) The compound according to claim 1 , wherein the compound is selected from 3-({4-[1-(2- hydroxy-1 ,1-dimethylethyl)-3-(5-methoxypyridin-3-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, 3-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-pyrazol-4-yl]pyrimidin-2- yl}amino)propanenitrile, 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1 H-pyrazol-4- yl]pyrimidin-2-yl}amino)propanenitrile, and 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1-(2,2-difluoroethyl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, or a pharmaceutically acceptable salt thereof.
22) A compound comprising 3-({4-[1-(2-hydroxy-1 ,1-dimethylethyl)-3-(5-methoxypyridin-3-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof.
23) A compound comprising 3-({4-[1-(2,2-difluoroethyl)-3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof.
24) A compound comprising 3-({4-[3-(5-amino-6-methoxypyrazin-2-yl)-1-(2,2-difluoroethyl)-1H- pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, or a pharmaceutically acceptable salt thereof.
25) A compound comprising 3-(4-(3-(5-acetyl-6-aminopyridin-3-yl)-1-(2,2-difluoroethyl)-1 H- pyrazol-4-yl)pyrimidin-2-ylamino)-propanenitrile, or a pharmaceutically acceptable salt thereof. 26) A pharmaceutical composition, comprising at least one compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
27) A method of treating abnormal cell growth, or any Raf-mediated disease or condition, in a mammal in need thereof, comprising the step of administering to said mammal a therapeutically effective amount of at least one compound according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof.
28) The method of claim 27, wherein the abnormal cell growth is cancerous.
29) The method of claim 27, wherein the abnormal cell growth in non-cancerous. 30) A method of inhibiting Raf enzymatic activity, comprising contacting a Raf enzyme with a Raf- inhibiting amount of at least one compound according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof.
31 ) The use of a compound according to any one of claims 1-25, or a salt or solvate thereof, in the manufacture of a medicament for the treatment of abnormal cell growth in a mammal.
PCT/IB2008/001952 2007-08-01 2008-07-21 Pyrazole compounds and their use as raf inhibitors WO2009016460A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2008281543A AU2008281543A1 (en) 2007-08-01 2008-07-21 Pyrazole compounds and their use as Raf inhibitors
BRPI0815042-7A2A BRPI0815042A2 (en) 2007-08-01 2008-07-21 PIRAZOL COMPOUNDS
EA201000113A EA201000113A1 (en) 2007-08-01 2008-07-21 PYRAZOL COMPOUNDS
EP08788934A EP2183243A2 (en) 2007-08-01 2008-07-21 Pyrazole compounds and their use as raf inhibitors
AP2010005167A AP2010005167A0 (en) 2007-08-01 2008-07-21 Pyrazole compounds and their use as RAF inhibitors
CA2695114A CA2695114A1 (en) 2007-08-01 2008-07-21 Pyrazole compounds and their use as raf inhibitors
CN200880109854A CN101815712A (en) 2007-08-01 2008-07-21 Pyrazole compound and as the purposes of RAF inhibitor
JP2010518763A JP4792126B2 (en) 2007-08-01 2008-07-21 Pyrazole compounds and their use as Raf inhibitors
TNP2010000052A TN2010000052A1 (en) 2007-08-01 2010-01-29 PYRAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF RAF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95323507P 2007-08-01 2007-08-01
US60/953,235 2007-08-01
US8005408P 2008-07-11 2008-07-11
US61/080,054 2008-07-11

Publications (3)

Publication Number Publication Date
WO2009016460A2 true WO2009016460A2 (en) 2009-02-05
WO2009016460A3 WO2009016460A3 (en) 2009-03-26
WO2009016460A8 WO2009016460A8 (en) 2009-10-15

Family

ID=40122511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001952 WO2009016460A2 (en) 2007-08-01 2008-07-21 Pyrazole compounds and their use as raf inhibitors

Country Status (24)

Country Link
US (1) US7772246B2 (en)
EP (1) EP2183243A2 (en)
JP (1) JP4792126B2 (en)
KR (1) KR20100038119A (en)
CN (1) CN101815712A (en)
AP (1) AP2010005167A0 (en)
AR (1) AR067759A1 (en)
AU (1) AU2008281543A1 (en)
BR (1) BRPI0815042A2 (en)
CA (1) CA2695114A1 (en)
CL (1) CL2008002255A1 (en)
CO (1) CO6251265A2 (en)
CR (1) CR11241A (en)
DO (1) DOP2010000047A (en)
EA (1) EA201000113A1 (en)
EC (1) ECSP109922A (en)
MA (1) MA31574B1 (en)
PA (1) PA8791801A1 (en)
PE (1) PE20090952A1 (en)
SV (1) SV2010003472A (en)
TN (1) TN2010000052A1 (en)
TW (1) TW200911243A (en)
UY (1) UY31260A1 (en)
WO (1) WO2009016460A2 (en)

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016490A1 (en) 2008-08-05 2010-02-11 第一三共株式会社 Imidazopyridin-2-on derivative
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
WO2011015522A2 (en) 2009-08-03 2011-02-10 F. Hoffmann-La Roche Ag Process for the manufacture of pharmaceutically active compounds
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2011042389A2 (en) 2009-10-09 2011-04-14 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles
JP2013504532A (en) * 2009-09-10 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー JAK inhibitors
WO2012010538A3 (en) * 2010-07-21 2013-02-21 F. Hoffmann-La Roche Ag Novel processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
US8410112B2 (en) 2008-11-10 2013-04-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US8841308B2 (en) 2008-12-19 2014-09-23 Vertex Pharmaceuticals Incorporated Pyrazin-2-amines useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846686B2 (en) 2011-09-30 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8877759B2 (en) 2011-04-05 2014-11-04 Vertex Pharnaceuticals Incorporated Aminopyrazines as ATR kinase inhibitors
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9035053B2 (en) 2011-09-30 2015-05-19 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9540362B2 (en) 2013-02-20 2017-01-10 Lg Life Sciences Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9791456B2 (en) 2012-10-04 2017-10-17 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10478430B2 (en) 2012-04-05 2019-11-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
EP3615083A4 (en) * 2017-04-28 2021-05-19 Zamboni Chem Solutions Inc. Raf-degrading conjugate compounds
US11021444B2 (en) 2013-08-21 2021-06-01 Janssen Biopharma, Inc. Antiviral compounds
WO2021124222A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
CN114181197A (en) * 2022-02-16 2022-03-15 北京康立生医药技术开发有限公司 Preparation method, preparation and purity analysis method of medicine for treating intestinal cancer
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
EP4237412A4 (en) * 2020-10-30 2024-04-10 Novartis AG New crystalline forms of a kras g12c inhibitor compound
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407132T1 (en) * 2000-12-05 2008-09-15 Vertex Pharma INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
CL2009001884A1 (en) * 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
CN103159736B (en) * 2011-12-10 2015-05-13 通化济达医药有限公司 Substitutional pyrazol kinase inhibitor
EP2945938B1 (en) * 2013-01-18 2018-03-07 F. Hoffmann-La Roche AG 3-substituted pyrazoles and use as dlk inhibitors
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
KR102244719B1 (en) * 2013-03-15 2021-04-26 플렉시콘 인코퍼레이티드 Heterocyclic compounds and uses thereof
CN103626767A (en) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 Azaindole with regionselectivity and synthetic method thereof
CN105777743A (en) * 2014-12-19 2016-07-20 奥浦顿（上海）医药科技有限公司 Preparation method and application of pyrazolo[3, 4-b]pyridine compound intermediate
CN106187899B (en) * 2016-06-28 2019-07-16 绍兴文理学院 A kind of synthetic method of fluoro azepine aromatic hydrocarbons
US10954216B2 (en) * 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
CN111194318B (en) 2017-10-13 2023-06-09 Opna生物公司 Solid forms of compounds for modulating kinases
CN109575019B (en) * 2018-12-26 2020-04-14 苏州闻智生物科技有限公司 Preparation method of 5-bromo-7-azaindole
AR120184A1 (en) 2019-10-11 2022-02-02 Incyte Corp BICYCLIC AMINES AS INHIBITORS OF CDK2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062787A1 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
WO2002066462A1 (en) * 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression
WO2003055860A1 (en) * 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
WO2004005282A1 (en) * 2002-07-09 2004-01-15 Novartis Ag PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
KR100697585B1 (en) * 1999-06-03 2007-03-22 아스카 세이야쿠 가부시키가이샤 Substituted pyrazole compounds
AU7922100A (en) 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
JP4316893B2 (en) * 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of Src and other protein kinases
MXPA04011638A (en) * 2002-06-05 2005-03-07 Pharmacia Corp Pyrazole-derivatives as p38 kinase inhibitors.
CL2004000234A1 (en) * 2003-02-12 2005-04-15 Biogen Idec Inc DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
EP1841757B1 (en) * 2005-01-07 2010-06-30 Pfizer Products Incorporated Heteroaromatic quinoline compounds and their use as pde10 inhibitors
EP2024353A2 (en) 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062787A1 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
WO2002066462A1 (en) * 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression
WO2003055860A1 (en) * 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
WO2004005282A1 (en) * 2002-07-09 2004-01-15 Novartis Ag PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAWYER, J. SCOTT ET AL: "Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-.beta. Type I Receptor Kinase Domain" JOURNAL OF MEDICINAL CHEMISTRY , 46(19), 3953-3956 CODEN: JMCMAR; ISSN: 0022-2623, 2003, XP002508872 *

Cited By (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2010016490A1 (en) 2008-08-05 2010-02-11 第一三共株式会社 Imidazopyridin-2-on derivative
US8410112B2 (en) 2008-11-10 2013-04-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9701674B2 (en) 2008-12-19 2017-07-11 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US8841308B2 (en) 2008-12-19 2014-09-23 Vertex Pharmaceuticals Incorporated Pyrazin-2-amines useful as inhibitors of ATR kinase
US10961232B2 (en) 2008-12-19 2021-03-30 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US9365557B2 (en) 2008-12-19 2016-06-14 Vertex Pharmaceuticals Incorporated Substituted pyrazin-2-amines as inhibitors of ATR kinase
US10479784B2 (en) 2008-12-19 2019-11-19 Vertex Pharmaceuticals Incorporated Substituted pyrazin-2-amines as inhibitors of ATR kinase
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8530661B2 (en) 2009-08-03 2013-09-10 Hoffmann-La Roche, Inc. Process for the manufacture of pharmaceutically active compounds
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US8741920B2 (en) 2009-08-03 2014-06-03 Hoffmann-La Roche, Inc. Process for the manufacture of pharmaceutically active compounds
CN104910150A (en) * 2009-08-03 2015-09-16 霍夫曼-拉罗奇有限公司 Process for the manufacture of pharmaceutically active compounds
WO2011015522A2 (en) 2009-08-03 2011-02-10 F. Hoffmann-La Roche Ag Process for the manufacture of pharmaceutically active compounds
CN104910150B (en) * 2009-08-03 2017-04-12 霍夫曼-拉罗奇有限公司 Process for the manufacture of pharmaceutically active compounds
US9593099B2 (en) 2009-08-28 2017-03-14 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US10005761B2 (en) 2009-08-28 2018-06-26 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US9850229B2 (en) 2009-08-28 2017-12-26 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US9593100B2 (en) 2009-08-28 2017-03-14 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US10576080B2 (en) 2009-08-28 2020-03-03 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2727918A1 (en) * 2009-08-28 2014-05-07 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
CN102725283A (en) * 2009-08-28 2012-10-10 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
JP2013503186A (en) * 2009-08-28 2013-01-31 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
USRE49556E1 (en) 2009-08-28 2023-06-20 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
EA025222B1 (en) * 2009-08-28 2016-12-30 Новартис Аг Compounds and compositions as protein kinase inhibitors
US10568884B2 (en) 2009-08-28 2020-02-25 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US9314464B2 (en) 2009-08-28 2016-04-19 Novartis Ag Compounds and compositions as protein kinase inhibitors
US8501758B2 (en) 2009-08-28 2013-08-06 Irm Llc Compounds and compositions as protein kinase inhibitors
US9850230B2 (en) 2009-08-28 2017-12-26 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US20230116233A1 (en) * 2009-08-28 2023-04-13 Array Biopharma Inc. Compounds And Compositions As Protein Kinase Inhibitors
CN103896921A (en) * 2009-08-28 2014-07-02 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
JP2014098022A (en) * 2009-08-28 2014-05-29 Irm Llc Compounds and compositions as protein kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP2013504532A (en) * 2009-09-10 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー JAK inhibitors
WO2011042389A2 (en) 2009-10-09 2011-04-14 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles
EP2784073A1 (en) 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides
EP2784072A1 (en) 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides
EP2784070A1 (en) 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides
EP2784071A1 (en) 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8779150B2 (en) 2010-07-21 2014-07-15 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
WO2012010538A3 (en) * 2010-07-21 2013-02-21 F. Hoffmann-La Roche Ag Novel processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
US9556172B2 (en) 2010-07-21 2017-01-31 Hoffman La-Roche Inc. Processes for the manufacture of propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl)-amide
US9150594B2 (en) 2010-07-21 2015-10-06 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
CN103153956A (en) * 2010-07-21 2013-06-12 霍夫曼-拉罗奇有限公司 Novel processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
JP2013537521A (en) * 2010-07-21 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Novel preparation of propane-1-sulfonic acid {3- [5- (4-chloro-phenyl) -1H-pyrrolo [2,3-b] pyridine-3-carbonyl] -2,4-difluoro-phenyl} -amide Method
KR101501856B1 (en) * 2010-07-21 2015-03-11 에프. 호프만-라 로슈 아게 Novel processes for the manufacture of propane-1-sulfonic acid｛3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl｝-amide
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US8877759B2 (en) 2011-04-05 2014-11-04 Vertex Pharnaceuticals Incorporated Aminopyrazines as ATR kinase inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9035053B2 (en) 2011-09-30 2015-05-19 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US10822331B2 (en) 2011-09-30 2020-11-03 Vertex Pharmaceuticals Incorporated Processes for preparing ATR inhibitors
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
US8846686B2 (en) 2011-09-30 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10208027B2 (en) 2011-09-30 2019-02-19 Vertex Pharmaceuticals Incorporated Processes for preparing ATR inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9862709B2 (en) 2011-09-30 2018-01-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
US10258622B2 (en) 2011-11-23 2019-04-16 Array Biopharma Inc. Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
US10561654B2 (en) 2011-11-23 2020-02-18 Array Biopharma Inc. Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US9763941B2 (en) 2011-11-23 2017-09-19 Array Biopharma, Inc. Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US11110086B2 (en) 2012-04-05 2021-09-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US10478430B2 (en) 2012-04-05 2019-11-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9791456B2 (en) 2012-10-04 2017-10-17 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11370798B2 (en) 2012-12-07 2022-06-28 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10787452B2 (en) 2012-12-07 2020-09-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10392391B2 (en) 2012-12-07 2019-08-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9650381B2 (en) 2012-12-07 2017-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9718827B2 (en) 2012-12-07 2017-08-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11117900B2 (en) 2012-12-07 2021-09-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9540362B2 (en) 2013-02-20 2017-01-10 Lg Life Sciences Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11021444B2 (en) 2013-08-21 2021-06-01 Janssen Biopharma, Inc. Antiviral compounds
US11485739B2 (en) 2013-12-06 2022-11-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10815239B2 (en) 2013-12-06 2020-10-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10800781B2 (en) 2014-06-05 2020-10-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10093676B2 (en) 2014-06-05 2018-10-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3615083A4 (en) * 2017-04-28 2021-05-19 Zamboni Chem Solutions Inc. Raf-degrading conjugate compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
EP4344702A3 (en) * 2019-12-20 2024-04-10 Novartis AG Pyrazolyl derivatives useful as anti-cancer agents
WO2021124222A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
US11702409B2 (en) 2019-12-20 2023-07-18 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
EP4237412A4 (en) * 2020-10-30 2024-04-10 Novartis AG New crystalline forms of a kras g12c inhibitor compound
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114181197A (en) * 2022-02-16 2022-03-15 北京康立生医药技术开发有限公司 Preparation method, preparation and purity analysis method of medicine for treating intestinal cancer
CN114181197B (en) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 Preparation method, preparation and purity analysis method of medicine for treating intestinal cancer

Also Published As

Publication number Publication date
UY31260A1 (en) 2009-03-02
TW200911243A (en) 2009-03-16
AP2010005167A0 (en) 2010-02-28
SV2010003472A (en) 2011-03-23
TN2010000052A1 (en) 2011-09-26
MA31574B1 (en) 2010-08-02
CA2695114A1 (en) 2009-02-05
JP4792126B2 (en) 2011-10-12
CR11241A (en) 2010-04-27
PE20090952A1 (en) 2009-07-19
KR20100038119A (en) 2010-04-12
JP2010535189A (en) 2010-11-18
US20090221608A1 (en) 2009-09-03
US7772246B2 (en) 2010-08-10
WO2009016460A8 (en) 2009-10-15
WO2009016460A3 (en) 2009-03-26
CN101815712A (en) 2010-08-25
AU2008281543A1 (en) 2009-02-05
CL2008002255A1 (en) 2009-04-17
DOP2010000047A (en) 2010-04-15
CO6251265A2 (en) 2011-02-21
PA8791801A1 (en) 2009-03-31
EP2183243A2 (en) 2010-05-12
BRPI0815042A2 (en) 2015-02-10
ECSP109922A (en) 2010-03-31
AR067759A1 (en) 2009-10-21
EA201000113A1 (en) 2010-08-30

Similar Documents

Publication Publication Date Title
US7772246B2 (en) Pyrazole compounds as RAF inhibitors
AU2007297212B2 (en) Pyrido (2, 3-D) pyrimidinone compounds and their use as PI3 inhibitors
CA2731368C (en) 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2024353A2 (en) Pyrazole compounds
US20090111805A1 (en) Bicyclic heteroaromatic derivatives useful as anticancer agents
WO2007023382A2 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2008059368A2 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
JP2008540395A (en) Amidoresorcinol compounds
EP2118111A1 (en) 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880109854.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788934

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 201011241

Country of ref document: CR

Ref document number: CR2010-011241

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 583009

Country of ref document: NZ

Ref document number: 2695114

Country of ref document: CA

Ref document number: D2010018

Country of ref document: CU

WWE Wipo information: entry into national phase

Ref document number: 2010010157

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 11675

Country of ref document: GE

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 2010518763

Country of ref document: JP

Ref document number: 203653

Country of ref document: IL

Ref document number: 10010171

Country of ref document: CO

Ref document number: 695/DELNP/2010

Country of ref document: IN

Ref document number: 12010500256

Country of ref document: PH

Ref document number: 201000113

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/001337

Country of ref document: MX

Ref document number: 2008788934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008281543

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20107004409

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008281543

Country of ref document: AU

Date of ref document: 20080721

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010000487

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0815042

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100201